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Abstract 
The formation of embryoid bodies has long been utilized to initiate differentiation of 
embryonic stem cells in vitro. The embryoid body provides an effective means of 
recapitulating early stages during embryogenesis and formation of the three germ 
layers. Current methodology for embryoid formation is extensive but exhibits a lack 
of standardisation and coherence. Here is shown a 3D culure system for controlled 
embryonic stem cell aggregation via a non-cytotoxic cell surface modification and 
cell-cell cross-linking. Embryoid body formation was found to be a complex 
relationship between embryonic stem cell aggregation, proliferation, death, cluster 
agglomeration, extracellular matrix deposition and structural reorganisation. 
Engineered embryoid bodies formed more rapidly and were significantly larger than 
those in control samples. Embryoid body characterisation revealed a layered internal 
structure resulting from poor nutrient and gaseous diffusion and consequent core    ?  ?   suspension culture. Immuno-labelling and PCR 
amplification analysis of Brachyury, Nestin, Gata-4 and Oct-4 showed differentiation 
of mesoderm, ectoderm and endoderm on the embryoid body surface and internal 
undifferentiated cells, respectively. Engineering appeared to enhance mesoderm 
differentiation, a progenitor of the osteogenic lineage. Embryoid bodies in settled 
culture spread outwards to form a plateau of collagen matrix which was later 
mineralized through differentiated osteoblast function. Quantification through 
Alizarin Red stained bone nodules and alkaline phosphatase activity demonstrated 
osteogenic differentiation enhancement within engineered samples. Dex-loaded 
poly-(lactic co-glycolic) acid polymer microparticles were found to be an effective 
method for delivery of osteo-inductive factors to internal undifferentiated embryonic 
  
ii 
stem cells within the embryoid bodies. These findings show that the proposed 3D 
culture system provides reliable and repeatable methodology for the controlled 
formation of embryoid bodies which exhibit enhanced osteogenic differentiation. It 
is hoped that these engineered embryoid bodies could be used to efficiently generate 
homogeneous bone tissue for clinical application. 
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Chapter 1  
1. Introduction 
1.1. Stem Cell Research 
1.1.1. Background Ǯǯ
in 1908 when he postulated the existence of haematopoietic stem (HS) cells. It took 
over 50 years before the first stem cells were discovered (Altman, 1962). Ensuing 
discoveries expanded the field of stem cell research and its potential applications. 
Since the discovery of embryonic stem (ES) cells over 20 years ago, the field has 
generated much promise in regenerative and reparative medicine (Martin, 1981, 
Evans and Kaufman, 1981). ES cells are highly proliferative in vitro and therefore 
provide an ideal abundant and sustainable cell source for tissue engineering (Tsai et 
al., 2000). Researchers endeavour to recapitulate in vivo growth and development of 
ES cells in vitro to better understand the mechanisms involved in their 
differentiation and organogenesis. Their intention is the elucidation of novel 
approaches to the repair or replacement of damaged tissue resulting from disease 
and trauma (Watt and Hogan, 2000, Moon et al., 2006). This would ultimately 
eliminate the need for many of the drugs currently used to maintain failing tissues 
and organs, revolutionizing medicine as we now know it (Keller and Snodgrass, 
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1999). Transplantation would be advanced to the stage where tissues and organs are 
generated according to demand using a combination of differentiated ES cells and 
biomaterial scaffold supports. 
1.1.2. Stem Cell Types and Derivation 
1.1.2.1. Adult Stem Cells 
ES and embryonic germ (EG) cell research is controversial because most resultant 
cell lines are established from the destruction of an embryo. There is no such 
controversy surrounding adult stem (AS) cells. They are derived directly from the 
individual into whom the engineered tissue would be implanted (Ratajczak et al., 
2007). Their isolation is non-destructive and therefore accepted by most people. 
They provide a renewable source of stem cells for ex vivo tissue engineering without 
the hinderance of immune-rejection observed in other stem cell-based therapies 
(Barrileaux et al., 2006). However, as they are genetically identical to the recipient 
they are redundant when repairing tissue damage caused by genetic disorders. 
Unlike ES cells, AS cells do not possess pluripotency. They are multipotent cells 
which can differentiate into any cell type of the tissue from which they are isolated. 
Many AS cells have been discovered from various organs and their related tissues. 
Each type of AS cell carries a prefix referring to its origin tissue, such as 
mesenchymal stem (MS) cells, HS cells, umbilical cord stem (UCS) cells and olfactory 
mucosa stem (OMS) cells (Lee, 2008, Kent et al., 2007, Park et al., 2008c, Murrell et 
al., 2005). This assortment of AS cells has shown regenerative capabilities in tissues 
corresponding to those from which they were derived, including heart, bone, muscle, 
cartilage and liver amongst others (Tateishi et al., 2008, Valenti et al., 2008, 
Bhagavati, 2008, Goessler et al., 2008, Huang, 2007). MS cells specifically, have been 
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utilized for many years to regenerate bone and related tissues, but like other AS cells 
their medical application is restricted (Summer and Fine, 2008). However, some AS 
cells have been shown to exhibit limited plasticity. These special AS cells can 
transdifferentiate to form cells outside the lineage of their origin tissue, i.e. 
pancreatic stem cells forming epithelial cells (Meier et al., 2008, Chim et al., 2008, 
Filip et al., 2005). 
1.1.2.2. Embryonic Carcinoma Cells 
Some of the earliest cells to exhibit true pluripotency were embryonic carcinoma 
(EC) cells, derived from malignant germ cell tumors called teratocarcinomas (Martin, 
1975, Martin, 1980, Lehman et al., 1974, Finch and Ephrussi, 1967). Teratocarinomas 
account for 40% of testicular tumors and can occur in the ovaries of prepubescent 
and teenage girls, although rarely. EC cells are just one of a number of cell types 
derived from these teratocarcinomas, and have been characterised extensively 
(Bluthmann et al., 1983). Recent publications have illustrated the isolation of EC cells 
from embryonic testis and oocytes (Kerr et al., 2008b, Kerr et al., 2008a). Particular 
EC cell lines have been found to contribute to chimeras upon transplantation into 
developing embryos (Brinster, 1974, Andrews, 2002). However, most EC cells do not 
contribute to chimeras, they form clonal teratocarcinomas (Chambers and Smith, 
2004). Epigenetic differences between EC cells and ES cells are thought to confer 
these observed characteristics (Table 1.1) (Bulic-Jakus et al., 2006).  
1.1.2.3. Embryonic Germ Cells 
The existence of EG cells was first reported nearly 20 years ago (Matsui et al., 1991, 
Resnick et al., 1992). Mouse EG cells were isolated directly from a specific part of the 
fetus/embryo called the gonadal ridge, usually 8 weeks following fertilization 
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Table 1.1: Comparison of mouse and human ES, EG and EC cells. 
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(Labosky et al., 1994, McLaren and Durcova-Hills, 2001). Isolation of human EG cells 
came soon after in the late 1990s (Shamblott et al., 1998). EG cells were found to 
originate from primordial germ (PG) cells in the gonadal ridge. During normal 
embryogenesis PG cells give rise to the germ cells, whether that be sperm or egg. EG 
cells have also been isolated from adolescent testicular teratomas (Kimura et al., 
2003, Kimura et al., 2008). This supports current consensus methodology for the 
isolation of EG cells from PG cells. Embryoid bodies (EBs) provide a crude 
recapitulation of in vivo teratomas, which can be cultured in vitro, and from which PG 
cells are isolated. 
EG cells are very similar to ES cells, exhibiting the ability to differentiate into 
multiple cell types. EG cells have also been shown to exhibit normal karyotypes over 
prolonged population doublings (Shamblott et al., 2001). Differences include in vitro 
growth characteristics (Pera et al., 2000), abnormalities in genome imprinting 
(Labosky et al., 1994, Thomson and Odorico, 2000, Onyango et al., 2002), X 
chromosome inactivation (Migeon et al., 2001) and failure to form teratomas in vivo. 
1.1.2.4. Embryonic Stem Cells 
ES cells are isolated from the blastocyst of an early pre-implantation embryo, 
resulting in its destruction (Goumans et al., 1998). However, recent work has shown 
the derivation of ES cell lines without embryo destruction (Klimanskaya et al., 2006). 
The blastocyst is the first definitive developmental structure that is readily 
accessible during embryogenesis (Rathjen et al., 1998). It is composed of a 
microscopic ball of cells which include three individual cellular architectures. The 
first structure is the trophoblast which surrounds the blastocyst and gives rise to all 
extra-embryonic tissues such as the placenta and umbilical cord (Nichols et al., 
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1996). The second is the hollow space within the blastocyst called the blastocoel. The 
third and final structure is the inner cell mass (ICM) which is situated to one side of 
the blastocyst adhered to the trophoblast.  
Cells which constitute the ICM possess pluripotency which is the ability to form all 
three embryonic germ layers including mesoderm, endoderm and ectoderm (Bain et 
al., 1995, Keller, 1995, Bishop et al., 2002, Odorico et al., 2001, Wiles and Johansson, 
1999). The ICM also gives rise to the germ cells, which differentiate and develop into 
oocytes and spermatocytes (Fig 1.1). It is from the ICM that ES cells are derived, 
usually isolated from day 5 to 8 blastocysts prior to gastrulation (Kim et al., 2005, 
Stojkovic et al., 2004, Thomson et al., 1998, Reubinoff et al., 2000, Mitalpova et al., 
2003). 
1.1.2.5. Induced Pluripotent Stem Cells 
Stem cells can be generated via nuclear reprogramming of somatic cells. Induced 
pluripotent stem (iPS) cells were first created in mice via retroviral delivery of four 
defined genes incuding Oct-4, Sox2, Klf4 and c-Myc (Takahashi and Yamanaka, 
2006). These cells are similar to ES cells but exhibit differences in DNA methylation 
and do not contribute to chimeras. Original selection was for Fbx15, however, 
selection for Nanog generated germLine-competent iPS cells; able to contribute to 
chimeras (Okita et al., 2007, Maherali et al., 2007, Wernig et al., 2007).  
Human iPS cells were created using the same four genes as those in mouse 
(Takahashi et al., 2007, Park et al., 2008b, Lowry et al., 2008). Specific methodology 
has been published for their generation through retroviral transfection (Park et al., 
2008a). However, other research groups published work describing the generation 
of human iPS cells using a different combination of genes delivered not by 
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Figure 1.1: ES cell differentiation and germ layer formation. 
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retroviruses, but by lentiviruses. These new human iPS cells were transfected with 
Oct-4, Sox2, NANOG, and LIN28 (Yu et al., 2007). Cutting edge research has generated 
iPS cells without the c-Myc gene. Chimeric mice did not develop cancer when 
implanted with these c-Myc (-/-) iPS cells, demonstrating significant relevance for 
medical application (Nakagawa et al., 2008). 
1.1.3. Embryonic Stem Cells 
1.1.3.1. Definition 
Originally, ES cells were loosely defined as cells which could undergo sustained 
proliferation in vitro, self-renewal and differentiate towards any cell lineage within 
the body. However, other cells fulfil this definition due to observations of 
transdifferentiation in AS cells and the discovery of self renewing EG and EC cells. 
The definition of an ES cell was subsequently updated to incorporate more stringent 
and precise properties that potential ES cells had to exhibit (Bishop et al., 2002). 
ES cells must be derived from the ICM of a blastocyst. They must exhibit and 
maintain a stable diploid karyotype without X-chromosome inactivation during 
unlimited proliferation consisting of symmetrical divisions without differentiation. 
ES cells must be able to differentiate and give rise to all three germ layers and the 
germ line. They should contribute to chimeras and form teratomas upon ectopic 
transplantation in vivo, which resemble in vitro EBs (Nichols et al., 1990, Nagy et al., 
1993, Iannaccone et al., 1994). However, this is not possible when concerned with 
human ES cells. A fully differentiated teratoma should resemble the a developing 
blastula stage embryo, exhibiting a variety of cell types including bone, cartilage, 
skin, heart, gut, hair, brain and muscle (Odorico et al., 2001). 
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1.1.3.2. Identification 
ES cells are isolated from embryos through selection for pluripotency markers which 
reside on the cell surface (Shamblott et al., 2001). ES cell markers include stage 
specific embryonic antigen (SSEA) 3 and SSEA-4 (expressed only on human ES cells), 
Oct-3/4, Sox2, Rex-1 and NANOG (Bielby et al., 2004, Hatano et al., 2005). The 
corresponding ligands of these markers are exploited in efforts to isolate pure ES cell 
cultures. If the isolated ES cells are not pure they can quickly differentiate and also 
potentially cause teratoma formation when ectopically grafted in vivo (Koller et al., 
1995, Burdon et al., 1999). Another distinguishing property of ES cells is de novo 
methylation activity which causes hypomethylation of the embryo genome. 
Hypomethylation may have a direct effect upon genome reformatting in ES cells for 
preparation of the proliferation and differentiation processes that occur during 
embryogenesis (Lei et al., 1996). Other markers which can be used in a negative 
manner are those for differentiation, as opposed to pluripotency. These markers 
select for trophoectoderm, germ layers and germ cells (Ginis et al., 2004). 
Representative markers are listed overleaf (Table 1.2). 
1.1.3.3. Pluripotency 
In vitro proliferation of mouse ES cells currently involves their 2D growth and 
expansion in co-culture with a feeder layer (Nichols et al., 1990, Cheng et al., 1994). 
The feeder layer consists of mouse embryonic fibroblasts (MEFs). The specific 
fibroblast cell line utilized in this study was SNL (STO (SIM (Sandoz Inbred Mice) 
Thioguanine-resistant and Ouabain-resistant) Neo Leukemic). MEFs support mouse 
ES cell growth and maintain pluripotency (Bishop et al., 2002, Boontheekul et al., 
2005). Pluripotency is maintained by the action of a secreted polypeptide called  
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Table 1.2: List of selective markers for trophoectoderm, germ layers and germ cells. 
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leukemia inhibiting factor (LIF) (Piquet-Pellorce et al., 1994, Keller, 1995, Furue et 
al., 2005). LIF acts to suppress differentiation rather than maintain pluripotency 
(Zandstra et al., 2000, Niwa, 2001, Oka et al., 2002). 
LIF functions via heterodimerization of the low-affinity LIF receptor (LIFR) and a 
membrane bound signaling complex gp130 (Starr et al., 1997, Smith, 2001, 
Viswanathan et al., 2002). This heterodimerization causes the transcription of self-
renewal genes within the nuclei of the mouse ES cells. A number of steps involving 
two main signaling molecules called Jaks (non-receptor cytoplasmic protein tyrosine 
kinase) and STATs (SH2 domain-containing signaling molecules) are activated as a 
result of this heterodimerization reaction (Fukada et al., 1996, Niwa et al., 1998, 
Burdon et al., 1999, Matsuda et al., 1999). LIFR and gp130 are receptor complexes 
for a number of other cytokines including LIF, such as ciliary neurotrophic factor 
(CNTF), oncostatin M (OSM) and cardiotrophin-1 (CT-1), each of which has the 
capacity to substitute for LIF and maintain a proliferative state (Thomson et al., 
1995, Yoshida et al., 1996, Dani et al., 1998, Nichols et al., 2001). However, the extent 
to which these alternative factors maintain a proliferative state in mouse ES cells 
varies compared to LIF (Ware et al., 1995, Nichols et al., 1996). A current study 
provided evidence that LIF maintains a proliferative, self-renewing state in mouse ES 
cells in a synergistic manner with Wnt (Ogawa et al., 2006). This finding suggests 
that LIF may not be sufficient for maintaining pluripotency long term alone. 
Alternatives exist for maintenanc of human ES cell culture. 
1.1.3.4. Differentiation 
Although ES cells have been shown to exhibit pluripotency, they have to this day not 
been employed in clinical trials (Deb et al., 2008). This is mainly due to the present 
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lack of knowledge concerning their appropriate and efficient differentiation in vitro 
or in vivo. Current differentiation methodologies are effective but highly inefficient 
(Wiles and Johansson, 1999, Schuldiner et al., 2000). Investigations of ES cell 
cultures that have undergone directed differentiation were found to contain 
contaminating cells of lineages unintentionally induced. These anomalous cells (1) 
lower the efficacy of directed differentiation, (2) illustrate a lack of knowledge 
concerning the factors involved in ES cell differentiation, and (3) demonstrate that 
current engineered tissue is not ready for clinical application in regenerative and 
reparative medicine (Polak and Mantalaris, 2008).  
Once the problems associated with efficient ES cell differentiation have been 
resolved, the potential medical use of ES cells covers a plethora of regenerative and 
reparative applications. The clinical successes in treatment of type I diabetes 
(Voltarelli et al., 2007), autoimmune diseases (Burt et al., 2006, Burt et al., 2002), 
leukemia (Marks, 2008, Sierra et al., 2008) and osteonecrosis (Tauchmanova  et al., 
2002, Kawate et al., 2006) Kawate K. 2006) with human AS cells hints at the 
therapeutic potential of human ES cells. 
1.1.3.5. Feeder Free Culture 
As well as problems with differentiation concerning the advancement of ES cells into 
clinical trials, the use of feeders within in vitro culture poses a similar dilemma. To be 
acceptable for transplantation into the body ES cells must be pure and exhibit 
uniform differentiation. By co-culturing with feeders it is inevitable that some will be 
carried through into clinical transplants. The presence of feeders could trigger an 
immune response which could consequently cause immune-rejection. 
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In response to this dilemma researchers have developed alternative culture 
methodology based on the removal of feeders (Matsubara et al., 2004). Initial feeder 
free culture systems concerning mouse ES cells, simply removed conventional MEF 
feeders and cultured on residual MEF extracellular matrix (ECM) (Klimanskaya et al., 
2005). This removed live MEFs from the culture system but the presence of xeno-
ECM still posed a problem. Matrigel (laminin, collagen IV, heparan-sulphate-
proteoglycan complex) subsequently replaced MEF-derived ECM and has been 
widely used in feeder free culture systems (Navarro-Alvarez et al., 2008). However, 
some studies have published data showing that Matrigel and its individual 
components can actually induce ES cell differentiation (Ma et al., 2008, 
Domoqatskaya et al., 2008, Prokhorova et al., 2008). Another problem was the use of 
conditioned media (CM) from MEFs. Since CM contains unidentified factors essential 
to ES cell maintenance, its removal from the system was not a viable option. Instead, 
MEF-CM was substituted with human fibroblast (HF) CM. This completely resolved 
the problem of xenogeneic material contamination. ES cells were now cultured in a 
xeno-free system on human feeders in HF-CM (Vemuri et al., 2007). However, risks 
still existed with potential genetic disease transmission through the allogeneic HF 
feeder layer, and contamination of engineered tissues with HFs carried over from ES 
cell culture. Current research has developed a culture system based on feeder layers 
from autogeneic HFs (Choo et al., 2008). The latest research has demonstrated a 
human ES cell culture system which is both feeder-free and ECM-free (Bigdeli et al., 
2008). This system however, still employs the use of HF-CM. In future, researchers 
could abrogate the necessity of CM for ES cell culture by replacing it with a 
completely defined media. 
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1.1.4. Ethical Stem Cell Research 
1.1.4.1. Background 
Both derivation and utilization of ES cells are highly regulated and accordingly 
restricted in specific areas by the legal and ethical issues surrounding them. There 
are four primary sources of ES cells including current ES cell lines, cloned embryos, 
aborted embryos and unused in vitro fertilisation (IVF) embryos (Thomson et al., 
1998). Each source has its own regulatory laws and ethical codes, i.e. the law states 
that aborted embryos can only be used for research purposes with the explicit 
consent of the donor and if t ǯ    had no relevance to the ǯl application in stem cell researchǤǮǯǮǯȋȌand 
published in 1994, helped resolve many issues surrounding the derivation of ES cells 
and their application (Meyer, 2000). Mitigation of inhibitory laws and resolution of 
ethical constraints would give researchers freedom to develop new stem cell based 
therapies for regenerative and reparative medicine under effective but not 
restrictive regulation (Griffith and Naughton, 2002). 
1.1.4.2. The Debate 
The use of ES cells has ignited an intense national and international ethical debate 
between government-funded regulatory bodies of stem cell research and pro-life-
groups. The crux of the debate is the Ǯsanctity of lifeǯ. Pro-life groups use this to 
highlight contentious issues surrounding the opportunistic retrieval of ES cells from 
unused IVF embryos. Their argument is that by destroying the embryo you are in fact 
committing murder. To counteract this argument, utilitarians raise the question of 
what constitutes murder. Murder can be interpreted in various ways and the law 
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reflects this. Execution of murderers is legal in the USA, but yet it is still murder. 
Manslaughter verdicts simply make murder a scale of intent. Ethically and legally 
sound benefits arise from murder in the form of available transplants (Robertson, 
2001). The only ethical and legal concern to be addressed in the determination of 
whether someone has committed murder is innocence (Meyer, 2000). A common    Ǯǯ    ǮǯǤ      
interpretation it has no place in the decision-making process concerning ethics. Law 
is essential for issuing guidelines and setting restrictions but is ultimately flawed 
when debating ethical concerns (Chu, 2003). 
1.1.4.3. Definition of a Human 
The ethical controversy surrounding the use of ES cells derived from embryos is 
fundamentally concerned with the question of how to define a human. To commit 
murder, the supposed victim would have to be a human being in the eyes of the law. 
Utilitarians exploit this legal incongruity by arguing that an embryo can not be 
considered a person, as it does not show any indication of a discernable brain and a 
phenotype or ability to express self-consciousness, personality, intellect, will and 
emotion. This may seem at first a strong argument for ES cell research, but 
approaching the same principles from a different perspective changes the entire 
argument on its head. Individuals who suffer Alzheimers, Parkinsons disease or who 
have lost parts of their neural cortex function from stroke are considered no less 
human than they were beforehand. The diminished capacity to express these 
qualities is therefore not a justifiable cause to waver the statutory rights of an 
individual (Chu, 2003). 
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1.1.4 ? ? ?hƚŝůŝƚĂƌŝĂŶŝƐŵ ?ǀƐ ?WƌŽ-Life 
Democracy, a method that governs our country and many others, has great merit 
when decisions are to be made in an honest and fair way. Many people, especially 
utilitarians, support this method. However, public consensus is where democracy 
becomes tainted and fails; the general consensus may not reflect the majority 
decision of a nation, rather the opinion of a powerful and influential minority (Fox, 
1999). Before public consensus can be trusted for its views and opinions to reflect 
the majority decision, numerous factors have to be accounted for, or better yet, 
removed. These include the media, politics, economics, influential personalities and 
most importantly, the way in which the facts are portrayed to the public so that the 
content is highlighted, not the manner of its presentation. The utilitarian view and 
pro-life view should both aim for a balance, not a victory. The arguments are both 
built on the same premise, but each have taken different routes and drawn separate 
conclusions about ES cell research.  
1.1.4.5. Ethical Research Continues 
As a result of this ethical dilemma, progression from laboratory based research to 
clinical trials is tightly regulated (Thomson et al., 1995). The balance between 
benefits of ES cell research and the inherent risks has consequently been thoroughly 
evaluated and is routinely monitored. Despite protests by pro-life groups, stem cell 
research continues because of scientific benefit, commercial demand on 
biotechnology and the demand for new therapeutic strategies to treat patients with 
severe disorders. Ethical concerns should not hinder progress, but provide stem cell 
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1.2. Tissue Engineering 
1.2.1. Background 
Tissue engineering is an interdisciplinary field which combines the principles of 
biology with engineering and medicine (Horch, 2006, Vacanti, 2006). More 
specifically, tissue engineering involves the combination of cells (allogeneic or 
autogeneic), engineered biomaterial scaffolds and biochemical factors for the 
regeneration, repair and replacement of damaged tissue due to disease and trauma 
(Dunn, 2008, Langer and Vacanti, 1993). The field has progressed rapidly over the 
last two decades, and current research approaches involve the use of early 
progenitor cells such as ES cells (Habib et al., 2008). ES cells are expanded in vitro, 
seeded onto a suitable scaffold and implanted in vivo (Handschel et al., 2008b). ES 
cells are differentiated inefficiently in vitro prior to implantation. Alternatively, they 
are differentiated in response to biochemical cues delivered via the scaffold (Inanc et 
al., 2008). 
1.2.2. Biomaterial Scaffolds 
1.2.2.1. Biomimetics  
Biomimetics is the study of models and systems in nature for the generation of 
bioinspired solutions to human problems (Green, 2008). The field of tissue 
engineering uses biomimetics to produce scaffolds which replicate one or more 
advantageous characteristics found in their natural counterparts (Ma, 2008). 
Successful scaffolds provide 3D architecture and mechanical support for engineered 
tissue whilst recapitulating the in vivo microenvironment. Essentially, the scaffold 
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replicates the ECM and therefore influences cell attachment, migration, proliferation, 
differentiation and resultant tissue organization (Shin et al., 2003). The use of 
biomimicry has aided the synthesis of appropriated scaffolds for engineered tissues 
including brain (Panseri et al., 2008, Potter et al., 2008), heart (Radisic et al., 2006), 
liver (Karamuk et al., 1999), blood (Panoskaltsis et al., 2005) and bone (Yang et al., 
2003, Green et al., 2002). 
1.2.2.2. Biocompatibility 
The accepted definition of biocompatibility encompasses two major factors. The 
scaffold should not provoke an immunological nor inflammatory response, whether 
locally or systemically. However, recent studies have found that an inflammatory 
response can be useful for induction of angiogenesis (Levenberg, 2005). Dependent 
on the medical purpose of the implant, the scaffold should exhibit long or short term 
integration eliciting appropriate and beneficial tissue responses. PLA and PGA 
monomeric subunits occur naturally within the body, however they are acidic and 
cause alteration to physiological conditions at the implant site. 
The body can remove lactic acid via the Cori or Krebs cycle (Fig 1.2). Lactic acid 
enters the blood and dissociates to form lactate and a hydrogen ion. The hydrogen 
ions can be removed intracellularly via nicotinamide adenine dinucleotide (NAD+) 
and eventually expelled as H2O. Lactate enters the Cori cycle where it is converted to 
glucose in the liver via gluconeogenesis. Alternatively, blood lactate forms lactic acid 
in the heart and is oxidized to form pyruvic acid via NAD+. The high concentration of 
oxygen stored in the heart cells allows metabolism via the Krebs cycle. 
Glycolic acid undergoes sequential enzymatic reactions in the liver involving 
glycolate oxidase and glycine transaminase to form glycine. Glycine is converted to
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Figure 1.2: Metabolism of lactic acid from scaffold biodegradation, via the Cori and Krebs Cycle. 
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serine and then pyruvate which enters the Krebs cycle (Hollinger, 1983, Xue et al., 
1999). Alternatively, glycine enters the mitochondrial glycine cleavage enzyme 
system (mGCS) where it is eventually expelled via the lungs as CO2 and excreted in 
urine as urea (Fig 1.3) (Hiraga and Kikuchi, 1980, Kikuchi and Hiraga, 1982). 
1.2.2.3. Biodegradability 
Synthetic polymer scaffolds used for in vivo delivery of cells are only a transient step 
in the regeneration of a target tissue. Scaffolds are made from polymers which can be 
readily broken down by the body. The byproducts of degradation should be non-
toxic so as to not damage newly regenerated tissue. Current polymers used as 
scaffolds are degradable polyesters including poly(lactic acid) (PLA) and 
poly(glycolic acid) (PGA) (Freed et al., 1994). These polymers are broken down in 
the body to their monomer subunits, lactic and glycolic acid. The mode of 
degradation is commonly accepted to be non-enzymatic hydrolysis of the ester 
backbone (Anderson and Shive, 1997). However, the action of esterases within the 
body could also have an unsubstantiated effect on polymer degradation. Degradation 
rate differs between PLA and PGA, with PLA degrading the slower of the two. 
Implants are often composites of two or more substances to allow for tailored 
degradation of subsequent scaffolds (Young et al., 2005). One co-polymer is 
poly(lactic co-glycolic acid) (PLGA), which has been routinely employed for the 
production of scaffolds within the field of tissue engineering. However, polymer 
scaffolds and implants do not always need to be biodegradable. Biomaterial implants 
have been utilized for heart valve (Stamm et al., 2004) and hip replacement(Schauss 
et al., 2006). These implants have to be durable and strong enough to withstand the 
physical stresses associated with the replaced body part function, and last the 
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Figure 1.3: Metabolism of glycolic acid from scaffold biodegradation, via the Krebs Cycle. 
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lifetime of the patient. 
1.2.2.4. Biomechanics 
The complexity of regenerating tissues in vivo demands scaffolds capable of 
exhibiting multifactorial properties (Butler et al., 2000). Scaffolds must be capable of 
enduring mechanical and physiological stresses evoked by the body after 
implantation (Ghosh and Ingber, 2007, Semino, 2008). Biomechanical properties of 
potential scaffolds that require consideration include elasticity, thermostability, and 
tensile strength of the constituent polymer(s) (Guan et al., 2004, Lendlein et al., 
1998). 
Scaffold biomechanics can be tailored to aid regeneration, repair or replacement of 
existing in vivo structures, and more importantly their function. Current scaffold 
applications include the replacement of heart valves (Sarraf et al., 2005, Stamm et al., 
2004), blood vessels (Shum-Tim et al., 1999, Shinoka et al., 1998, Shinoka and 
Breuer, 2008), and the repair and regeneration of skin (Blackwood et al., 2008, Cai et 
al., 2005) and bone (Nesti et al., 2008, Duty et al., 2007, Dyson et al., 2007). The 
regeneration of bone places many demands on the mechanical properties of a 
suitable scaffold. These include support of physiological loads (McMahon et al., 
2008), bone remodeling (El Haj et al., 2005), accommodation of physiological strains 
(Howard et al., 2008) and suitability to bone type (Babis and Soucacos, 2005). 
 The method of manufacture is critical when considering what mechanical properties 
resultant scaffolds should exhibit. A range of methods exist including porogen 
deposition/leaching (Liao et al., 2002), liquid-liquid phase separation (Goh and Ooi, 
2008, Budyanto et al., 2008), molecular self assembly (Schneider et al., 2008, Semino, 
2008), supercritical CO2 gas foaming (Barry et al., 2006, Zhu et al., 2008), 
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emulsion/freeze drying (Sultana and Wang, 2008, Uttarwar and Aswath, 2008) 
nanofibre electrospinning (Ngiam et al., 2008, Zhang et al., 2008) and computer 
aided design/manufacture (CAD/CAM) (Park et al., 2008d, Sun et al., 2004). 
1.2.2.5. Cell Organization and Growth 
Polymer scaffolds should exhibit a bioactive surface able to interact with biological 
tissues conducive to cell attachment, spreading and function (Takimoto et al., 2003, 
Sales et al., 2007). The surface can be bioactive due to the biomaterial used to make 
the scaffold, functionalized with a bioactive coating or impregnated with bioactive 
molecules (Murphy and Mooney, 1999, Zhang et al., 2009). However, when treating 
the polymer surface to enhance cellular adhesion, consideration must be invested so 
as to not also enhance bacterial adhesion and colonization (Woo et al., 2002). 
To achieve successful long-term integration in vivo, scaffold porosity must support 
cell migration and vascularization (Bonfield, 2006, Laschke et al., 2008). 3D 
architecture of scaffolds should aid this complex growth and the organization of 
multiple cell types involved in tissue regeneration and organogenesis (Karageorgiou 
and Kaplan, 2005). As the temporary scaffold degrades, cells within and/or cells 
surrounding the scaffold post implantation should proliferate and replace the 3D 
architecture.  
Surface topography of potential scaffolds is also critical to the successful attachment, 
proliferation and survival of cells whether in vivo or in vitro (Cohen and Bano, 1993, 
Engel et al., 2008). Surface topographies have been shown to enhance cell 
attachment and spreading on the micro and even nano-scale. Surface topography and 
chemistry must therefore be considered in unison to ensure successful scaffold 
integration. 
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1.2.2.6. Tissue Support 
Correct growth and development of engineered tissue is dependent on 
environmental cues, both physical and chemical (Quaglia, 2008, Chan and Mooney, 
2008). Implanted scaffolds are designed as a delivery system for essential growth 
factors and hormones critical to cellular proliferation and differentiation. Chemical 
cues are tailored to support the development of functional tissues (Burdick and 
Vunjak-Novakovic, 2008). To date, tissues which have been successfully regenerated, 
either partially or wholly, include cartilage (Park and Na, 2008, Mohan et al., 2008), 
lung (Nichols and Cortiella, 2008), smooth muscle (Baker and Southgate, 2008), bone 
(Basmanav et al., 2008, Cartmell, 2008, Kanczler and Oreffo, 2008), heart (Wissink et 
al., 2000, Huang et al., 2008) and liver (Zhu et al., 2008). 
1.2.3. Cell Types 
1.2.3.1. Autogeneic 
Autogeneic cells are derived from the patient into whom the engineered tissue will 
be implanted. They are genetically identical to the patient and therefore reduce the 
risk of immune-rejection and disease transmission. Cells are isolated and expanded 
in vitro to obtain appropriate numbers for transplantation. These cell cultures are 
delivered back into the patient via a biomaterial scaffold implant. Alternatively, an 
engineered scaffold itself is implanted to provide support, promote angiogenesis and 
recruit adjacent cells to initiate tissue regeneration. Cartilage, skin and bone repair 
are just few examples of the use of autogeneic cells in conjunction with a supporting 
scaffold (Dounchis et al., 2000, He et al., 2007, Menderes et al., 2004). However, there 
are obvious disadvantages to the use of autogeneic cells. Their derivation may cause 
problems at the site of isolation such as chronic pain and infection. Sufficient 
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quantities may not be available, such as skin cells from severe burns victims, or 
harvestable, such as neural cells. In vitro expansion is costly and takes time. Finally, 
autogeneic cells are redundant in the regeneration of damaged tissue caused by 
genetic disease. 
1.2.3.2. Allogeneic 
Allogeneic cells are derived from donors of the same species. The most prevalent 
area in which allogeneic cells have been utilized is skin regeneration. Many studies 
depict the effective application of foreskin cells cultured in vitro for the 
bioengineered substitution of wounded skin (Hirt-Burri et al., 2008, Kellouche et al., 
2007). One advantage of using allogeneic cells is that they can be used to regenerate 
damaged tissue due to genetic disease. The problem of shortages with autogeneic 
cells is significantly reduced when using allogeneic cells. However, the chances of 
disease transmission and immune-rejection are increased. 
1.2.3.3. Xenogeneic 
Xenogeneic cells are isolated from donors of a different species. The use of 
xenogeneic cells bypasses many issues related to the isolation of human cells, but 
raises issues of xenozoonosis (Prabha and Verghese, 2008). Examples of the 
application of xenogeneic cells include the regeneration of liver (Wilson et al., 2006) 
and bone (Xie et al., 2007). However, the biggest demand is not for xenogeneic cells, 
but xenogeneic material such as ECM and decellularized tissue (Badylak, 2004). 
Xenogeneic material has been used extensively in the replacement of heart valves 
using acellular porcine substitutes (Korossis et al., 2002). 
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1.2.3.4. Syngeneic / Isogeneic 
The terms syngeneic and isogeneic pertain to cells that are isolated from genetically 
identical individuals such as twins or donors exhibiting a similar genotype. A typical 
example would be the transplantation of bone marrow from one twin to another, or 
donor tissue which has been matched to the recipient. 
1.2.3.5. Stem Cells 
Numerous types of stem cells exist which were described previously. However, all 
stem cells share similar attributes and are employed due to their ability to 
differentiate into the necessary cell types for regeneration of damaged tissue (Fodor, 
2003, Cedar et al., 2007). Stem cells can be autogeneic or allogeneic in the form of AS 
cells or ES cells respectively. A major problem accompanying stem cell-based 
therapy is their complete and efficient differentiation. A plethora of published 
methodology exists for the directed differentiation of stem cells with varying efficacy 
(Gruen and Grabel, 2006). Stem cells are highly proliferative and without efficient 
differentiation could cause teratoma formation in vivo (Blum and Benvenisty, 2008). 
1.2.3.6. Genetically Engineered 
Cells can be genetically engineered to exhibit phenotypes and characteristics 
advantageous to their application in regenerative medicine. Dependent on their 
intended use they can be engineered to produce vital proteins and growth factors for 
enhanced differentiation of cell types such as chondrocytes (Feng et al., 2008). Other 
cell types include bone mineralising and cardiovascular cells (Phillips and Garcia, 
2008, Phillips et al., 2007, Rosenstrauch et al., 2007). Alternatively, cells can be 
engineered to exhibit increased compatibility for long term integration and survival 
without provoking an immune response. 
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1.2.3.7. Immuno-modulated 
The method of immuno-modulation involves the alteration of a particular cell tyǯ
activity to control immune-response. One approach includes the administration of 
immuno-modulatory factors to improve native cellular responses and tolerance 
levels to implants (O'Neill, 2006, Irvine et al., 2008). The introduction of cells such as 
mesenchymal and neural stem cells has also been shown to exhibit immuno-
modulatory function in hepatic, pancreatic and neural tissues (Parekkadan et al., 
2007, Pluchino and Martino, 2008, Abdi et al., 2008). A combination of immuno-
modulatory factors and immuno-modulated cells can also be used to enhance tissue 
regeneration, i.e. engineered bone (Haisch et al., 2004, Marcu et al., 2007). 
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1.3. Bone Physiology 
1.3.1. Development / Formation 
1.3.1.1. Cartilage 
During embryogenesis large portions of a connective tissue called the mesenchyme 
condense and differentiate to form cartilage in the shape of ensuing bone. Cartilage 
can be broken into three separate types comprising hyaline, elastic and 
fibrocartilage. Hyaline cartilage consists mainy of type II collgen (~40%) and 
proteoglycans. Proteoglycans are glycoproteins covalently attached to 
gylcosaminoglycans (GAGs) such as chondroitin sulfate. Chondroitin sulfate provides 
both structure and organization for collagen fibrils and an overall negative charge 
which promotes electrostatic repulsion and increases matrix integrity and resilience 
to compression (Stuart and Panitch, 2008). Exhibited glycoproteins promote 
matrix/cell interactions and appropriate differentiation. Elastic cartilage is 
composed of chondrocytes surrounded by both type II collagen and elastic fibres of 
which elastin is the major constituent. Elastic cartilage provides support for external 
structures such as the ear and nose and also the epiglottis and can withstand 
repetative bending and flexing. Fibrocartilage is intermediary between hyaline 
cartilage and dense connective tissue, primarily comprising collagen fibres 
(Benjamin and Evans, 1990). Collagen fibres are bundled together in parallel and 
surrounded by fibroblasts. Lacunae, containing chondrocytes, are spread throughout 
the cartilage inbetween the collagen fibres. Collagen fibres form and orientate 
themselves in the direction of stress, and chondrocytes synthesize additional 
collagen fibres. Fibrocartilage aids transfer of load stress between tendons and 
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bones. Most cartilage that acts as a template for bone development is surrounded by 
a dense fibrous tissue called the perichondrium. The perichondrium is composed of 
two layers, the first comprises of fibroblasts spread through a dense collagen matrix. 
The second layer is composed of chondrogenic progenitor cells.  
1.3.1.2. Endochondral Ossification 
The mesenchyme tissue condenses and progenitor cells differentiate to form 
chondrocytes. These chondrocytes begin to secrete and deposit ECM largely 
consisting of type II collagen and GAGs. Chondrocytes trapped within the collagen 
become hypertrophic. They cease to produce type II collagen and begin to secrete 
type X collagen. Hypertrophic chondrocytes adjacent to the perichondrium 
differentiate to form osteoblasts which secrete bone matrix and form the bone collar 
around the template. The cartilage template begins to elongate through interstitial 
growth; hypertrophic chondrocytes continually produce more ECM which pushes 
adjacent cells further apart. The template also widens through appositional growth; 
the chondrogenic layer of the perichondrium secretes additional ECM. Altogether 
this forms the growth plate of endochondral bone (Kronenberg, 2003). The growth 
plate lies in parallel to the direction of extension between the epiphysis (rounded 
end of long bone) and diaphysis (shaft of long bone). At the extending end of the 
growth plate lies the resting zone; chondrogenic progenitor cells that are not 
proliferating. At the opposite end of the proliferative zone reside hypertrophic 
chondrocytes. The proliferating chondrocytes stack into columns separated by 
longitudinal and transverse septa consisting of collagen and proteoglycans (Fig 1.4) 
(Mitchell et al., 1982, Eggli et al., 1985, Gregory et al., 2001). 
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Figure 1.4: Epiphyseal plate (growth plate) of long bone during endochondral ossification. 
Photograph taken from www.kumc.edu. 
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Hypertrophic chondrocytes produce alkaline phosphatase (ALP) and begin to 
mineralize surrounding matrix. These mineralising chondrocytes also secrete 
vascular endothelial growth factor-A (VEGF-A) which chemotactically attracts blood 
vessels and promotes angiogenesis (Dai and Rabie, 2007, Murata et al., 2008). 
Eventually, chondrocytes within the hypertrophic zone undergo programmed cell 
death or apoptosis leaving voids within the ECM called lacunae. Vascularization 
introduces HS cells, osteoclasts and osteoblasts into the hypertrophic zone through 
the lacunae forming the primary ossification centre. HS cells act as progenitor cells 
for bone marrow differentiation within what will eventually become the medullary 
cavity. Osteoclasts completely resorb the transverse septa, hypertrophic and dead 
chondrocytes, and partially resorb longitudinal septa. Osteoblasts replace the ECM 
with osteoid (un-mineralized organic matrix consisting of type I collagen and 
proteins such as osteocalcin (OC), osteopontin (OPN) which binds hydroxyapatite 
(HA), osteonectin (ON), bone sialo-protein (BSP), chondroitin sulphate and GAG 
(Sommerfeldt and Rubin, 2001). Osteoblasts also mineralize osteoid to form the 
primary spongiosa. The primary spongiosa comprises of trabeculae (calcified 
osteoid) which continue to thicken to form the secondary spongiosa. Osteoblasts 
eventually fill the gaps between trabeculae to form compact bone. As they fill in the 
gaps they become encased within the bone and form osteocytes. The perichondrium 
which surrounds compact bone now becomes periosteum. Periosteum consists of 
two layers called the fibrous layer (thick connective tissue and fibroblasts) and the 
cambium layer (osteoblast and chondrocyte progenitor cells). Whilst the periosteum 
provides an outer sheath, the endosteum provides an inner sheath. The endosteum 
comprises a layer of osteoblasts and progenitor cells sandwiched with a layer of 
connective tissue, and lies between the medullary cavity and compact bone. 
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At either end of the bone lies more hyaline cartilage (epiphysis region) which 
undergoes the same process as above and constitutes the secondary ossification 
centre. The diaphysis is separated from the epiphysis by the epiphyseal plate 
(metaphysis or growth plate). In adults, chondrocytes within the epiphyseal plate 
cease mitosis and stop bone elongation. The hypertrophic zone catches up with the 
forefront of the epiphyseal plate and eventually invading osteoblasts mineralize the 
whole tissue fusing the epiphysis and diaphysis to create a complete bone. Articular 
cartilage remains on the peripery of the epiphysis. 
1.3.1.3. Intramembranous Ossification 
Intramembranous ossification is very similar to endochondral ossification but does 
not involve the replacement of hyaline cartilage with bone. Instead, the formation of 
bone comes directly from the condensed mesenchyme. Cells within the condensed 
mesenchyme differentiate to form osteoblasts which begin to secrete osteoid. The 
long type I collagen fibres of the osteoid become mineralized to form bone spicules. 
Bone spicules increase in size and join to form trabeculae. Successive osteoid 
deposition and mineralization by osteoblasts forms concentric rings called lamellae 
which widen the trabeculae. The trabeculae continue to grow until they begin to 
touch one another and form an internal lattice structure. Further deposition and 
mineralization fills in the gaps between trabeculae to form woven bone. Woven bone 
comprises a network of interlacing calcified fibres, also known as nonlamellar bone. 
These fibres are irregular in orientation and are later remodelled into compact bone. 
The areas which remain as a lattice are referred to as primary cancellous or 
trabecular bone. 
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1.3.1.4. Mineralization 
In 1855 a German pathologist named Dr. Rudolf Karl Ludwig Virchow first 
documented the process of mineralization, also known as calcification. He 
documented metastatic calcification of soft tissues during pathologies of the kidney 
such as chronic renal failure. Also now known as calciphylaxis, calcium is 
precipitated into cutaneous tissue forming benign bone nodules. However, it took 
over another 100 years for the mechanism of mineralization to be elucidated. 
It was discovered that extracellular calcium and phosphate concentrations were too 
low for calcium precipitation. This formed the idea of a nucleator to increase the 
concentration at the mineralizing front of the cell membrane (Howell et al., 1968).  It 
was later found that lipids were highly concentrated at the mineralizing front, and 
further investigation identified the presence of matrix vesicles (Wuthier, 1968, Ali et 
al., 1970). These matrix vesicles were found to exhibit intense phosphatase activity 
which regulates lumenal phosphate concentration (Anderson, 2003). Lumenal 
calcium concentration is regulated by calcium binding proteins such as annexin I and 
phosphatidylserine (Nie et al., 1995). The concentration of calcium phosphate within 
the matrix vesicle lumen increases to a level that is permissive to precipitation. 
Calcium phosphate crystals are converted to an intermediary form called octa-
calcium phosphate before final conversion to HA (Sauer and Wuthier, 1988, 
Garimella et al., 2006). The formation of HA is the first of two phases for complete 
mineralization. The first phase ends with the HA crystals piercing the matrix vesicle 
membrane causing it to collapse and release into the extracellular space. The second 
phase involves epitaxial growth of the HA crystals in the extracellular space. Growth 
is radial and culminates in the formation of HA spherules (Tarallo et al., 2008). These 
fuse together at the mineralization front parallel to the longitudinal septa coating the 
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triple helix of type I collagen fibres. This gives bone its characteristic strength, 
resilience to compression and flexibility. 
1.3.2. Types of Bone 
1.3.2.1. Long Bones 
Long bones are characterised by a long diaphysis in comparison to its width. The 
epiphysis is located at either end and the whole bone is surrounded by the 
periosteum. The outermost parts are compact bone and the innermost parts are 
trabecular bone containing red bone marrow within the medullary cavity. The 
centremost part of the medullary cavity contains yellow bone marrow. The bones 
extend via endochondral ossification of the epiphyseal plate. Typical long bones 
include the humerous, radius and ulna of the arm, femur, tibia and fibula of the leg, 
and the metacarpals, metatarsals and phalanges of the hands and feet. 
1.3.2.2. Short Bones 
Short bones are characterised by their length and width being similar and resulting 
in a cube shape. These bones are predominantly made of trabecular bone with a thin 
crust of compact bone. Consequently, short bones are more susceptible to fracture 
than long bones. Carpal and tarsal bones of the wrist and ankle are examples of short 
bones. 
1.3.2.3. Flat Bones 
Flat bones are characterised by two broad layers of compact bone sandwiched either 
side of a thin layer of trabecular bone filled with red bone marrow. Their function is 
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to provide either shielding or larger surface area for muscle attachment. Typical 
examples include the skull, sternum, ribs, pelvis and scapula. 
1.3.2.4. Irregular Bones 
Irregular bones include the occipital, parietal, frontal, nasal, temporal, vomer, 
maxilla, echmoid, sphenoid, zygomatic and lacrimal bones of the skull, sacrum 
(triangular bone of the pelvis), hyoid (located in the neck and supports the root of 
the tongue), palatine (roof of the mouth), mandible (jawbone) and vertebrae. These 
are characterised by their lack of similarity to any long, short or flat bone within the 
body. Their function is the support or protection of organs and nerves such as the 
brain and spinal cord. They comprise predominantly of trabecular bone with a thin 
crust of compact bone. 
1.3.2.5. Sesamoid Bones 
Sesamoid bones are typically located within tendons spanning a joint. Examples 
include the patella and pisiform (pea shaped bone in the wrist). They are primarily 
composed of trabecular bone with a thin layer of compact bone. They act to hold the 
tendon away from the joint and enhance the mechanical action of the tendon. By 
holding the tendon at an increased angle to the joint, the force exerted by muscles 
through the tendon is also increased.  
1.3.3. Bone Structure 
1.3.3.1. Compact Bone 
Compact bone, also known as cortical bone, accounts for ~80% of the weight of a 
human skeleton and gives bones their characteristic white, smooth and solid 
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appearance. Initial bone formation involves deposition and random orientation of 
mineralized collagen fibres. Cortical bone exhibits a highly ordered structure called 
the Haversian system which comprises predominantly of closely packed osteons. 
Osteons lie in parallel to one another along the length of the diaphysis. Each osteon 
comprises a central cavity called the Haversian canal, in which resides the artery and 
vein supplying blood to the bone. This is surrounded by concentric rings of compact 
bone called lamellae. Each lamella comprises of mineralized type I collagen fibres 
that are in parallel to one another along the length of the osteon in various 
orientations (Weiner et al., 1999). X-ray diffraction and electron microscopy studies 
of the osteon structure have found that mineralized collagen fibres lie in parallel 
within a single lamella, and within a 90° difference in adjacent lamellae (Ascenzi and 
Bonucci, 1976, Ascenzi et al., 1978). This has led to the discovery of three structural Ǯǯȋ	 ?Ǥ ?Ȍ(Martin and 
Ishida, 1989). This plywood structure confers the characteristic strength of cortical 
bone. Within each lamella lie osteocytes encased in lacunae, thought to have 
mechano-sensory function. Osteocytes signal to one another and dispose of wastes 
via cytoplasmic extensions termed dendrite termini. These occupy channels called 
canaliculi which transect lamellae linking to the Haversian canal (Blumer et al., 
2008)Ǥ         ǯ
canals. The space between osteons is filled with interstitial lamellae. Osteoclast 
function also creates resorption cavities. Fig 1.5 illustrates the structure of cortical 
bone. 
1.3.3.2. Trabecular Bone 
Also known as spongy or cancellous bone, trabecular bone accounts for the 
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Figure 1.5: Structure of compact and trabecular bone. Photograph taken from 
www.archive.nyu.edu. Individual images are adapted from wikipedia. 
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remaining 20% of the weight of a complete adult human skeleton. Trabecular bone 
lies within bones surrounded by cortical bone. Unlike cortical bone, trabecular bone 
is oriented irregularly and exhibits reduced strength and increased porosity. It 
comprises an irregular lattice structure of flat and rod shaped trabeculae. This 
reduces weight of the bone and allows space for blood vessels and bone marrow. The 
lattice structure acts like braces in a building, helping to distribute load along the 
bone to be supported by cortical bone. Trabeculae can also realign to support 
changes in stress. Canaliculi transect trabeculae connecting lacunae and blood 
vessels. Fig 1.5 illustrates the structure of trabecular bone. 
1.3.3.3. Cells of the Bone 
Osteoblasts 
Osteoblasts are mature bone forming cells, characteristically cuboid in shape and are 
thought of as complex fibroblasts. They originate from differentiated from 
multipotent MS cells within the periosteum (Duque et al., 2008). These same 
progenitor cells give rise to both adipocytes and chondrocytes (Muruganandan et al., 
2008, Choi et al., 2008b). Osteoblasts are located on the surface of bone where they 
form a thick layer alongside their progenitor cells which block osteoclast activity at 
the same location. Osteoblasts produce osteoid which is regulated by fibroblast 
growth factor (FGF) and insulin-like growth factor (IGF) I and II. IGF-I and IGF-II 
which inhibit the expression of collagenase and thus aid type I collagen synthesis 
(Wang et al., 2008). Other factors that control osteoblast differentiation and activity 
include Runx2, also known as osteoblast specific factor-2 (OSF-2) or core binding 
factor alpha 1 (Cbfa1), bone morphogenetic proteins (BMPs), transforming growth 
factor-Ⱦ ȋTGF-Ⱦ) and platelet derived growth factor (PDGF) (Lavery et al., 2008). 
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Runx2 also directly inhibits differentiation of adipocytes and chondrocytes. 
Overexpression of another factor called osterix was found to increase osteoblast 
proliferation, ALP activity and bone nodule formation (Tai et al., 2004). Osterix was 
found to be important in bone formation when osterix (-/-) mice were discovered not 
to exhibit osteoblasts (Nakashima et al., 2002). 
Osteoclasts 
Osteoclasts originate from differentiated HS cells within the bone marrow. 
Progenitor cells differentiate towards mononuclear pre-fusion osteoclasts which 
then fuse to form characteristic giant multinucleated osteoclasts (MacDonald et al., 
1987, Jimi et al., 1999). They are located in resorption pits or Howships lacunae 
where they produce a localised acidic environment conducive to bone de-
mineralization (Boyde et al., 1990). Osteoclastogenesis requires macrophage colony-
stimulating factor (M-	ȌËȾȋȌ
(RANKL). RANK is a member of the tumor necrosis family (TNF) and activates   ËȾ ȋ	- ËȾȌǤ Osteoblasts positively regulate development and 
activation of osteoclasts through exhibiting RANKL (Schoppet et al., 2002). Another 
TNF member is osteoprotegrin (OPG) also known as osteoclast inhibiting factor 
(OCIF). OPG is produced by osteoblasts and binds RANKL inhibiting 
osteoclastogenesis (Drugarin et al., 2003). 
Osteoclasts are recruited to the bone by VEGF-A or M-CSF (Niida et al., 1999). 
Osteoclasts attach to the bone via specific adhesion structures called podosomes 
located at sealing zones (Lakkakorpi and Vaananen, 1991). Podosomes specifically 
attach to OPN and type I collagen through expression of numerous integrins 
(Helfritch et al., 1992, Horton et al., 1995). Once attached, osteoclasts become 
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polarised with membrane adjacent to the bone becoming convoluted and forming a Ǯ ǯǤ       an H+ pump 
called vacuolar ATPase, matrix metalloproteases (MMPs), tartrate-resistant acid 
phophatase (TRAP) and hydrolytic enzymes such as cathepsin K. The acidic 
environment solubilizes mineralized calcium. MMPs are a family of endopeptidases 
which are important in bone resorption. For example, MMP-9 is a gelatinase and 
MMP-13 (-/-) mice show decreased numbers of osteoclasts. TRAP is involved in the 
de-phosphorylation of OPN which enables osteoclast migration. Cathepsin K is a 
collagenolytic cysteine protease secreted from membrane vesicles called lysosomes. 
As a result of these secretions bone is de-mineralized, degraded and finally 
phagocytosed by osteoclasts. 
Osteocytes 
Osteocytes are formed when osteoblasts become trapped within the mineralized 
osteoid they secrete. When osteoblasts become osteocytes they exhibit increased 
expression of dentin matrix protein 1 (Dmp1), matrix extracellular 
phosphogylcoprotein (Mepe) in complex with osteoblast/osteoclast factor 45 
(OF45), and Phex. These factors control phosphate metabolism through regulation of 
the phosphaturic factor FGF23 (Bonewald, 2006). Osteocytes are mitotically arrested 
and smaller than osteoblasts exhibiting minimal endoplasmic reticulum and reduced 
golgi apparatus. They have many functions including bone formation, matrix 
maintenance and calcium homeostasis. They also have a mechano-sensory function 
involved in sensing and transducing signals from stress and loading. Osteocytes are 
located within lacunae and exhibit dendrite termini which occupy canaliculi. 
Through these dendrite termini osteocytes communicate with one another and 
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osteoblasts via formation of transient gap junctions (Doty, 1981). This 
communication is thought to regulate bone remodelling in response to stress and 
loading. Dendrite termini growth is regulated by a lipid growth factor called 
lysophosphatidic acid (LPA) (Karagiosis and Karin, 2007). Although osteocytes are 
thought of as trapped osteoblasts, they are actually mobile. Green fluorescent protein 
(GFP) labelled osteocytes have been found to move along canaliculi (Kalajzic et al., 
2004, Veno, 2006). A final function termed osteocytic osteolysis involves the 
destruction of surrounding mineralized matrix within osteocyte-containing lacunae 
(Belanger, 1969). Osteocytic osteolysis is a rapid and transient mechanism involved 
in mineral homeostasis, not bone remodelling (Cullinane, 2002). 
1.3.4. Bone Function 
1.3.4.1. Movement 
Bones provide solid structures for muscles and tendons to attach to. Muscles, 
tendons and bones function together to generate and transfer forces which allow 
movement of the whole body or individual parts. The human skeleton provides 
support for the body and enables movement through 3D space. Bones are specific to 
the type of movement they accommodate. For example, the femoral head of the 
femur and the acetabulum of the pelvis fit like a ball and socket allowing flexion, 
extension, abduction, adduction, medial or lateral rotation and circumduction 
motions. 
1.3.4.2. Protection and Shape 
An important function of bone is the protection of soft tissues and organs. Bones 
provide strong shielding against impacting forces, but also exhibit a certain degree of 
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flexibility. The skull, spine, scapula, ilium, patella, carpals and tarsals protect the 
brain, spinal cord, shoulder, urogenital system, knee joint, wrist and ankle, 
respectively. The ribs and sternum provide protective casing for the heart, lungs, 
stomach, liver, pancreas, spleen and major blood vessels. Bones are specially adapted 
to their protective function. For example, the shoulder covers a large area and 
accordingly, the scapula is large and flat so as to provide maximum protection of the 
joint. The skeleton also acts as internal scaffolding, supporting the weight of the 
body. It provides anatomical shape and 3D spacing for internal organs. 
1.3.4.3. Blood 
Within bone lies both red and yellow bone marrow, the difference being ~50% red 
marrow is converted to yellow marrow in adults and contains mainly adipocytes. 
The bones of infants only contain red marrow. Red marrow contains HS cells which 
undergo haematopoiesis to form the three major cell types of blood; erythroid, 
lymphoid and myeloid cells. These cells include erythrocytes, thrombocytes, 
platelets, mast cells, neutrophils, eosinophils, basophils, macrophages, 
megakaryocytes, T and B lymphocytes and natural killer cells. Some HS cells within 
the bone marrow remain in a multipotent state. These provide a cell source for 
future proliferation and differentiation. 
1.3.4.4. Detoxification 
It has been known for many years that heavy metals such as lead and cadmium are 
adsorbed and stored within bones (Wiechula et al., 2008). This has marked 
toxicological effects on the Haversian remodelling system (Anderson and Danylchuk, 
1977, Anderson and Danylchuk, 1978). Consequently, a significant amount of blood 
lead is prevented from adsorption into vital organs such as the liver and heart. Their 
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storage within bone is transient and they can be gradually excreted in the urine. This 
is a slow process and increases the chance of physiological damage. Diseases and 
conditions which affect bone can mobilize lead and other heavy metals, 
reintroducing them into the blood (Silbergeld et al., 1993, Silbergeld et al., 1988).  
1.3.4.5. Mineral Storage 
Bones act as a reservoir of essential minerals for biological processes and cellular 
function. There are two types of stored minerals called macro and micro-minerals. 
Macro-minerals (bulk elements) include calcium, iron, magnesium, phosphorus, 
potassium and sodium. Micro-minerals (trace elements) include boron, chromium, 
copper, iodine, manganese, selenium and zinc. Storage within bone helps reduce 
toxic levels occurring within the blood. 
1.3.4.6. Acid-Alkali Balance 
Blood can accommodate changes in pH via acceptance of H+ ions through plasma 
cells, circulating bicarbonate, phosphate in erythrocytes and haemoglobin. Muscles 
can also help to buffer changes in pH. However, the major buffering capacity of the 
body lies within bones. Bones balance pH by releasing or adsorbing H+ ion acceptors 
in the form of carbonates. Sodium carbonate is first to be released from bone. 
Calcium carbonate is released over longer periods. Further available carbonate is 
located within HA crystals of mineralized osteoid. 
1.3.4.7. Sound Transduction 
The smallest bones in the human body are located within the middle ear and 
transduce vibrational signals from the tympanic membrane (eardrum) to the 
fenestra ovalis of the cochlea. These bones are called the ossicles and include the 
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malleus (hammer), incus (anvil) and stapes (stirrup). The ossicles function together 
as a leveraging system to intensify the force of airborne sound vibrations collected at 
the eardrum. The purpose of intensifying the vibrations is to efficiently transduce 
airborne sounds into the fluid of the cochlea. Imagine being underwater and 
someone is talking to you. Their voice is muffled because the water does not 
transduce vibrational signals as well as air. The signal has to be intensified to travel 
through the water. 
1.3.4.8. Modulatory Adaptation 
Natural bone homeostasis through osteoclast/osteoblast function remodels bone 
shape and density. Collagen fibres are successively realigned and deposited in an 
orientation parallel to the direction of stress exerted on the bone. Continuous 
remodelling enables structural adaptation to environmental changes. Bone structure 
is altered according to the forces exerted upon it. For example, professional tennis 
players exhibit thicker and denser bones in their playing arm. Professional runners 
and cyclists would have femurs more dense than average. 
1.3.5. Bone Injury and Repair 
1.3.5.1. Reactive Stage 
Upon bone fracture, blood vessels are broken filling the site of injury with 
extravascular blood cells. Blood vessels then constrict to stem the flow. Within hours 
to days a hematoma forms to clot the site of injury. Cells within the hematoma 
degenerate and die. Prostaglandins chemotactically attract the infiltration of 
inflammatory cells and fibroblasts. Primary nutrients and oxygen supply are 
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provided by exposed cancellous bone and surrounding muscle. Vascularization and 
ECM deposition by fibroblasts forms granulation tissue. 
1.3.5.2. Reparative Stage 
The periosteum generates chondrocytes which migrate into the granulation tissue 
and begin depositing hyaline cartilage. Chondrocytes and invading osteoblasts 
introduced through newly formed blood vessels mineralize the hyaline cartilage to 
form a fracture callus. The callus is soft and provides minimum support to the 
fracture site for the first 4 to 6 weeks. Osteoblasts convert deposited hyaline 
cartilage to osteoid which later becomes calcified forming woven bone. Trabeculae 
within woven bone consist of irregularly orientated mineralized collagen fibres. 
Woven bone affords stability to the fracture until osteoblasts replace it with lamellar 
bone. The lamellar bone is in the form of trabecular bone strengthening the fractured 
bone enough to begin supporting compressive forces.  
1.3.5.3. Remodeling Stage 
Complete healing of the fractured bone occurs during the remodelling stage. Bone 
homeostasis remodels the bone to its original shape. Trabecular bone is converted to 
cortical bone according to mechanical stresses. Bone is deposited where it is needed 
and adsorbed from where it is not. The fractured bone is usually completely healed 
in 3 to 6 months. 
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1.3.6. Bone Damage 
1.3.6.1. Fracture 
During life bones experience a multitude of forces, some of which may cause trauma 
in the form of fracture. Bone fractures are classified using the orthopaedic trauma 
association (OTA) classification system (Marsh et al., 2007). The OTA classification 
system comprises five parts for accurate identification of fractured bone (Table 1.3). 
Bone fractures can be simple or complicated and require detailed definition in order 
to assess the best treatment. Fractures are classified by the bone in which they 
reside, location on the bone, whether it is simple or multi-fragmentary, geometry and 
bone functionality. 
1.3.6.2. Disease/Disorder 
A plethora of diseases and disorders exist which can cause bone damage. Certain 
infections such as syphilis and periodontitis cause erosion and loss of bone matrix. 
Other bone infections (osteomyelitis) can lead to osteonecrosis via constriction or 
blockage of blood capillaries to the bone causing hypoxia and eventual necrosis. 
Numerous disorders involve an imbalance in bone homeostasis resulting in the 
gaining or reduction and hardening or softening of the bone mass. These disorders 
include osteoporosis, osteopetrosis, osteomalacia and rickets. Other disorders such   ǡ    Ǯ  ǯǡ   
plate and cause bones to be easily broken. Osteoarthritis causes bone damage as a 
result of wearing within joints due to loss of cartilage. There are also many types of 
bone cancer such as osteosarcoma which cause varying degrees of bone damage. 
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Table 1.3: The OTA classification system and common bone fractures. 
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1.3.6.3. Surgery 
Birth defects such as cleft lip and palate, clubfoot, arthrogryposis multiplex 
congenital (locked joints) and hip dysplasia require corrective surgery in which 
bones are surgically dissected and realigned. Scoliosis (curved spine) is commonly 
associated with conditions such as spina bifida and cerebral palsy. It is corrected by 
use of rods to fuse the spine in place, which are drilled directly into the spine. This 
again employs deliberate surgical damage to the bone. Elective or cosmetic surgeries 
cause damage to bone to improve aesthetics of the body and face. For example, 
malarplasty and rhinoplasty involve alteration of the cheek, jaw, chin and nose. 
Individuals who suffer from achondroplasia or dwarfism electively undergo bone 
lengthening surgery. 
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1.4. Engineered Aggregation 
1.4.1. Background 
Much research has been focussed on the control of ES cell differentiation to produce 
homogeneous cell cultures for therapeutic applications (Curtis and Riehle, 2001, 
Fodor, 2003, Cedar et al., 2007, Raikwar et al., 2006). However, advances in the 
efficiency of directing differentiation and producing desired cell types suitable for 
clinical application have been somewhat troublesome (Gruen and Grabel, 2006). ES 
cells are often differentiated in a series of steps involving both physical and chemical 
cues. One of the foremost steps is the production of cell clusters or aggregates known 
as EBs (Dang et al., 2002, Hwang et al., 2006a, Schuldiner et al., 2000). EBs provide a 
crude but effective method of recapitulating natural 3D interaction and proliferation 
of ES cells in vitro. All three germ layers have been identified within these structures 
(Fok and Zandstra, 2005, Itskovitz-Eldor et al., 2000, Ling and Neben, 1997, Wiles 
and Johansson, 1999). The benefit of including the EB step has been published 
repeatedly, whether its effect had been direct or indirect (Wenger et al., 2004, Abe et 
al., 1996, Bagchi et al., 2006). However, studies have also shown that ES cells can be 
effectively differentiated without prior EB formation (Hwang et al., 2008b, Hwang et 
al., 2008a). 
Although the use of EBs to control ES cell differentiation has become accepted 
practice, consensus methodology for their generation remains elusive. Many 
methods exist for the generation of EBs, each having its own advantages and 
disadvantages with respect to aggregation efficiency (Carpenedo et al., 2007, 
Gerecht-Nir et al., 2004, Ng et al., 2005, Dang et al., 2002). The variation between EB 
formation methods results in variable ES cell differentiation (Koike et al., 2007, 
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Kurosawa, 2007). Table 1.4 illustrates the variety EB formation methods and 
associated cell types. Consequently, it is hypothesized that control of EB formation 
may also control differentiation of constituent ES cells and enable generation of 
homogeneous cultures (Ungrin et al., 2008, Raikwar et al., 2006, Karp et al., 2007). 
The first step would be to collate current knowledge and produce standardised 
methodology wherein EB formation, ES cell differentiation, process scalability and 
cost effectiveness could be assessed (Placzek et al., 2009). 
1.4.2. In Vitro Culture 
1.4.2.1. 2D Culture 
ES cells are maintained in vitro through 2D culture. 2D culture involves the 
proliferation of ES cells in a monolayer under defined conditions (Ying et al., 2008, 
Amit, 2007). The main purpose of 2D culture is cell expansion whilst maintaining ES 
cell pluripotency (Trish et al., 2006). The monolayer format minimizes ES cell-ES cell 
contact and interaction, which consequently reduces intercellular signalling. 
Monolayer culture enables sufficient spatial orientation of proliferating ES cells so 
that the majority are exposed to the defined exogenous conditions. Defined 
conditions such as temperature, humidity and media composition are adapted to 
mimic the in vivo environment and reduce the chance of differentiation during 
continuous culture. 
1.4.2.2. 3D Culture 
ES cells are usually allowed to proliferate in 3D culture for the purpose of initiating 
differentiation. As previously stated, ES cells are suspended in culture media to allow 
EB formation. It is thought that the increased ES cell-ES cell contact and decreased 
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Table 1.4: List of aggregation methods currently used in ES cell research. 
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exposure to pluripotency maintenance factors such as LIF in mouse and basic FGF 
(bFGF) in human, promotes adequate intercellular signalling to induce 
differentiation (Parekkadan et al., 2008). However, differentiation is random with 
the appearance of many cell types. Elucidation of the mechanisms involved in cell-
cell signalling and control of 3D culture would greatly benefit our understanding of 
differentiation pathways. 
1.4.2.3. Co-culture 
Co-culture involves in vitro proliferation and/or differentiation of ES cells with one 
or multiple other cell types. ES cell culture remains far from ideal. Most ES cells are 
cultured on feeder cells or in CM since feeder cells produce unidentified factors 
important to pluripotency maintenance (Amit et al., 2003). Alternatively, ES cells are 
cultured with a second cell type to provide differentiation cues. For example, ES cell 
co-culture with endothelial cells, hepatic cells, periodontal ligament fibroblasts and 
visceral endodermal cells have induced neurogenesis, chondrogenesis, osteogenesis 
and cardiomyogenesis, respectively (Lai et al., 2008, Lee et al., 2008a, Inanc et al., 
2007). 
1.4.3. Natural Aggregation 
1.4.3.1. Tissue Organization 
Many factors influence natural aggregation and growth of ES cells and their 
subsequent differentiation. It is well established that normal cell function is directly 
correlated with tissue organization and the 3D intercellular orientation of 
constituent cells (Roskelley et al., 1995). Atypical tissue structures and cell 
morphologies may lead to abnormal cell growth and tumorigenicity (Weaver et al., 
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1997, Wang et al., 1998). 3D orientation is dictated by both cell-cell and cell-ECM 
interaction. Fibroblasts are responsible for the production of large amounts of 
connective tissue. In vitro studies have found fibroblast ECM exhibits morphology 
akin to that observed in vivo, and that it stimulates cell migration and proliferation 
(Cukierman et al., 2001). Analyzing cell-cell and cell-ECM interactions in more 
natural 3D settings offers a relevant paradigm of natural cell aggregation and tissue 
development in living systems (Yamada and Clark, 2002). 
1.4.3.2. Cadherins 
In vitro, cells naturally coalesce to form aggregates after ~3 to 5 days of removing 
proliferation maintenance factors (Itskovitz-Eldor et al., 2000). Homotypic cell-cell 
adhesion is largely mediated through cadherins. For example, cells expressing 
epithelial cadherins (E-cadherins) only bind other cells expressing E-cadherins. This 
enables alike cells to adhere to one another and form tissues during development. 
Cadherins are a class of transmembrane protein responsible for cell-cell adhesions 
(Pokutta and Weis, 2007). Cadherins bind intracellular anchorage proteins called 
catenins ȋ Ƚ  Ⱦ-catenin) which bind to actin filaments of the 
cytoskeleton, effectively anchoring one cell to another (Hartsock and Nelson, 2008). 
In the epithelium, these complexes form adherens junctions which occur as bands or 
spots between cells (Ko et al., 2001). The action of cadherins is dependent on calcium 
ion signaling due to their extracellular calcium binding domain (Courjean et al., 
2008). 
1.4.3.3. Integrins 
Integrins are proteins which have a single transmembrane helical domain. They are 
involved mainly in cell-ECM adhesion and signal transduction. The helix is composed 
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of two chains called  Ƚ  Ⱦ , each of which has numerous types 
(Schneider and Engelman, 2004). The combination of these two subunits dictates the 
binding capacity of integrins. Ligands of integrins include collagen, fibronectin, 
laminin and vitronectin (Reyes et al., 2008). They form adhesion complexes through     ǡ   Ƚ-actin (Ziegler et 
al., 2008, Bois et al., 2006). Through the recruitment and action of 
phosphotransferases (kinases) integrins anchor the actin cytoskeleton to the 
surrounding ECM. These adhesion complexes provide important signals pertaining 
to the surrounding environment. Signal transduction from integrin binding is critical 
for cell attachment, migration, differentiation or apoptosis (Arnaout et al., 2007). 
1.4.4. Engineered Aggregation 
1.4.4.1. Surface Modification 
Surface modification creates reactive residues on the ES cell surface that can be used 
to control 3D aggregation. The surface of an ES cell naturally exhibits a 
monosaccharide called sialic acid (Martin et al., 2005, Schwarzkopf et al., 2002). 
These residues are biochemically altered by a periodate oxidation step to exhibit 
reactive aldehyde groups (De Bank et al., 2003). These groups are then biotinylated 
through reaction with biotin hydrazide. Biotin molecules are subsequently cross-
linked with a protein called avidin (Yarema et al., 1998, Jacobs et al., 2000). Surface 
modification enables the construction of a controlled model for investigation of cell-
cell interaction, EB formation and subsequent differentiation. 
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1.4.4.2. Control of Aggregation  
The system provides many levels of manipulation, applicable in different ways for 
control over ES cell aggregation and subsequent EB formation (Kellam et al., 2003). 
Aggregation kinetics including formation process, size, rate of development and 
differentiation pathway can be fine-tuned by the adjustment of factors such as initial 
cell seeding density, avidin concentration, degree of biotinylation and addition of 
environmental cues at specific concentrations and at different stages. Initial cell 
seeding density has a direct effect upon differentiation. Inter-EB agglomeration has 
been shown to have effects on ES cell proliferation and differentiation (Gerecht-Nir 
et al., 2004, Dang et al., 2004). However, this method provides a solution to the 
problem by inhibiting EB-EB interaction with the addition of biotin-poly-ethylene 
gylcol (PEG). Biotin-PEG coats the surface of an engineered EB and blocks adhesion 
to other engineered EBs through non-adhesion of PEG molecules. 
1.4.4.3. Microparticle Incorporation 
As previously stated, biomaterial scaffolds have been used for the purpose of 
delivering cell cultures in vivo whilst providing growth factors and surface 
topography conducive to morphogenesis (Drury and Mooney, 2003, Lutolf and 
Hubbell, 2005, Levenberg et al., 2003). Previously scaffolds have been large 
structures for the purpose of space filling in vivo. However, scaffolds can also be in 
the form of individual microparticles which incorporate within the EB structure. 
Microparticles still provide surface for cell attachment and proliferation but act more 
as a delivery system for growth factors during degradation (Weber et al., 2002, Awad 
et al., 2004). Efficient delivery of growth factors and other environmental cues 
directly to differentiating ES cells within the EB structure is essential for eventual 
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tissue formation and vascularization (Dawson and Oreffo, 2008, Shamblott et al., 
2001, Balakrishnan and Jayakrishnan, 2005, Boontheekul et al., 2005). The 
hypothesis is that microparticles would deliver growth factors directly to internal ES 
cells. This would abate the problem of only exposing the EB surface to inductive 
factors, and aid uniform differentiation throughout the EB structure. 
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1.5. Aims and Objectives 
The main aim of this study was to characterize ES cell aggregation and subsequent 
EB formation using a chemically engineered 3D culture system (De Bank et al., 2003). 
The hypothesis that control of early ES cell aggregation via surface modification may 
provide control over downstream ES cell differentiation was also investigated with 
respect to osteogenic differentiation. Specific objectives of this study included: 
1. Assess ES cell viability after surface modification 
2. Investigate aggregation kinetics 
3. Characterize physical properties 
4. Determine differentiation potential 
5. Investigate osteogenic potential 
6. Generate microparticle incorporated EBs 
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Chapter 2  
2. Methods and Materials 
 
All chemicals were obtained from Sigma-Aldrich Ltd (Poole U.K.) unless stated 
otherwise.  
 
2.1. Mammalian Cell Culture 
2.1.1. Culture Media 
2.1.1.1. SNL Fibroblast Media 
SNL fibroblasts were cultured in a standard culture media (SCM) containing ǯ    ȋȌ ȋǡ  ǤǤȌǡ  ? ? ? 	
Calves Serum (FCS), 1% Penicillin/Streptomycin (Pen/Strep) (Invitrogen), 2mM L- ? ? ?ɊȾ-ȋȾ-Mercap). DMEM acts a buffered liquid-
culture support for in vitro proliferation of cells. The main ingredients are glucose 
(energy source), L-glutamine (essential amino acid), and N-2-hydroxy-
ethylpiperazone-N-2-ethanesulfonic acid (HEPES) (buffer). FCS was added to supply 
nucleotides and other various factors required for proliferation. Pen/Strep was 
added to minimize risk of bacterial infection. Additional L-glutamine was added to 
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cope with the rate of cell growth. Ⱦ-Mercap acts as a reducing agent to control the 
detrimental effects of harmful metabolites produced as byproducts of cell 
proliferation. SCM was made fresh every 1 to 2 months. 
2.1.1.2. Embryonic Stem Cell Media 
ES cells were cultured in SCM supplemented with 500units/mL LIF (Chemicon, 
Hampshire U.K.). LIF was added to the culture media as a maintenance factor of ES 
cell pluripotency. ES cell media (ESM) was made fresh every month. 
2.1.1.3. Aggregation Media 
Initial aggregation of engineered and control ES cells in mass suspension, was 
carried out in aggregation media (AM) (DMEM, 1% FCS, 2mM L-glutamine and 1% 
Pen/Strep). DMEM acts as a support, L-glutamine is an essential amino acid and 
Pen/Strep reduces risk of bacterial infection. The reduced FCS minimized ES cell 
proliferation to allow for maximum aggregation immediately after seeding. 
2.1.1.4. Cryopreservation Media 
Stock aliquots of both SNL fibroblasts and ES cells were prepared and frozen in 
cryopreservation media (CPM) (DMEM, 20% FCS and 10% dimethyl-sulfoxide 
(DMSO)). DMSO is a polar aprotic solvent which exhibits hydrogen bonding and can 
stabilize ions in solution. It is routinely used as a cryoprotectant as it minimizes the 
formation of damaging ice crystals intracellularly and extracellularly. During 
freezing, water molecules move into the extracellular space, reducing water content 
and risk of ice crystal formation intracellularly. DMSO hydrogen bonds to the cells 
displacing water molecules, reducing risk of ice crystal formation extracellularly. 
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2.1.2. Culture Apparatus and Reagents 
2.1.2.1. Equipment 
Mammalian cell culture was performed in a sterile environment in a Class II cabinet 
(Envair, Lancashire U.K.) fitted with high efficiency particulate air (HEPA) filters. Air 
is drawn into the cabinet to protect the user from the samples. This is then circulated 
under the internal working area and passed through a HEPA filter before being 
directed on top of the working area to protect the samples. Dispensable lab-ware 
utilized for routine cell culture included plugged serological pipettes (Fisher, 
Leicestershire U.K.), T25cm3 and T75cm3 flasks (Nunc, Fisher, Leicestershire U.K.), 
syringes (Becton Dickinson (BD) Biosciences, Oxford U.K.), 15mL and 50mL tubes 
(BD Falcon, Oxford U.K.), 30mL universals and 7mL bijouxs (Sterilin, Caerphilly U.K.), 
sterile glass Pasteur pipettes (Costar, Fisher), 1.5mL Eppendorfs (Sarstedt Ltd., 
Leicestershire U.K.), 100mL beakers (Scientific Laboratory Supplies (SLS), 
Nottingham U.K.), cell scrapers (Fisher), cryovials (Fisher), pipette tips (SLS) and 
weighing boats (SLS). A lab coat and sterile nitrile gloves (SLS) were worn 
throughout to protect work from contamination and waste plastic-ware was 
disposed of in autoclave bags (SLS). Sterilization of reagents was either by filtration 
using 0.22µm filters (Sartorius, Epsom U.K.) or by autoclaving using a Prestige 
Medical 20100 autoclave (SLS). All cell cultures were kept in a Sanyo incubator 
(Gaithersburg U.S.A.) at 37°C and 5% CO2 in a humidified atmosphere.  
2.1.2.2. Chemicals 
All used and/or contaminated plastic-ware was disinfected by overnight immersion 
in diluted trigene (SLS) before incineration. 70% ethanol in dH2O was used to 
sterilize the working area within the Class II cabinet and any items prior to their 
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transfer into the cabinet to reduce risk of contamination. 
Trypsin/ethylenediaminetetraacetic acid (EDTA) was used to break cell-cell 
adherens junctions, cell-matrix adhesions and aid cell detachment from plastic-ware.  
Trypsin is a serine protease which predominantly targets and cleaves peptide chains 
at the carboxyl-terminus of amino acids lysine and arginine, except when either has 
an adjacent proline towards the amino-terminus. Specificity is imparted by an 
aspartate residue (Asp 189) which is located in the S1 catalytic pocket. EDTA is a 
chelating agent that binds metal ions via four carboxylate and two amine groups. It is 
used in conjunction with trypsin in cell culture to bind calcium and prevent 
formation of adherens junctions between cells. 
2.1.2.3. Buffers 
Buffers regularly used in cell culture, engineering and assays included phosphate 
buffered saline (PBS) (1 tablet per 100mL dH2O), biotinylation buffer (0.1% FCS in 
PBS, pH 6.5 with HCl), avidin buffer (0.1% FCS in PBS, pH 7.0), papain buffer (0.1M 
dibasic sodium phosphate, 0.005M cysteine hydrochloride and 0.005M EDTA in 
dH2O, pH 6.5), and Hoescht buffer (0.01M Trizma base, 0.01M EDTA and 0.1M 
sodium chloride (VWR International, Poole U.K.)). 
2.1.3. Cell Types 
2.1.3.1. Embryonic Stem Cells 
Mouse ES cells were a kind gift from Miss Magdalen Self, Wolfson Centre for Stem 
Cells, Tissue Engineering and Modelling (STEM), Division of Drug Delivery and 
Tissue Engineering, Centre for Biomolecular Sciences, University of Nottingham, U.K. 
The ES cell line was originally derived from mouse columnar epiblast epithelium 
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(CEE). It is unknown when the ES cells were first isolated and therefore, the passage 
number was also unknown.  However, they are a well characterized and 
immortalized stem cell line. Their differentiated and undifferentiated states have 
both been shown in this and previous studies. All ES cells utilized in experimentation 
were between passages 1-30 post receipt. 
2.1.3.2. SNL Fibroblasts 
The SNL fibroblasts were again, a kind gift from Miss Magdalen Self. It is unknown 
how many passages the SNLs had been through prior to receipt. However, they are a 
well established feeder layer for in vitro support of ES cell proliferation and 
pluripotency maintenance. They were used between 1-50 passages post receipt. 
2.1.3. In Vitro Proliferation and Maintenance 
2.1.3.1. SNL Fibroblast Culture 
SNL fibroblasts were proliferated in a SCM. Cultures were incubated at 37°C and 5% 
CO2 in a humidified atmosphere in T75cm3 flasks. Flasks were incubated under 
stationary conditions until cell cultures were ~80-90% confluent. Confluency was 
judged by eye on a compact inverted microscope (Olympus CKX-31). 
Once confluent, media was carefully aspirated using a sterile glass Pasteur pipette, 
cultures were washed twice with 5mL room temperature PBS and treated with 2mL 
trypsin/EDTA. Cells were treated with trypsin/EDTA for no longer than 5mins at 
room temperature to minimize cell damage and gently agitated. Once the cells had 
fully detached from the flask surface, the suspension was transferred to a 15mL 
Falcon tube. The suspension was repeatedly pipetted to disperse cell clumps before 
the addition of 3mL SCM to inactivate the trypsin/EDTA. Specifically, FCS within SCM 
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causes inactivation through competition; FCS provides more proteins for the trypsin 
to target. Suspensions were centrifuged for 5mins at 1000rpm in a Mistral 1000 
centrifuge (MSE, London U.K.). Supernatant was then aspirated, carefully avoiding 
the cell pellet.  
Pellets were suspended in 4mL SCM and passaged in a typical ratio of 1:4. 9mL SCM 
was added to each of 4 x T75cm2 flasks before the cell suspension was added, 1mL to 
each. SNLs were cultured for ~3 to 4 days until confluent, prior to subsequent 
passage. Passage ratio was adjusted as required to accommodate time taken to reach 
confluency. Media was changed when the phenol indicator turned yellow or every 2 
to 3 days. 
2.1.3.2. Embryonic Stem Cell Culture 
ES cells were proliferated in ESM. ES cells were cultured in T25cm2 flasks on a feeder 
layer of mitotically inactivated SNL fibroblasts (mSNLs) under stationary conditions 
at 37°C and 5% CO2 in a humidified atmosphere until ~80% confluent or until 
individual colonies were about to touch one another. Confluency was judged by eye 
on a compact inverted microscope. 
Media was carefully aspirated once confluent and cultures were washed twice with 
5mL PBS. Subsequently, cultures were treated at room temperature for 5mins with 
2mL trypsin/EDTA. Cultures were gently agitated until gaps appeared in the 
confluent layer indicating detachment of ES cells from the feeder layer. The cell 
suspension was then transferred to a 15mL Falcon tube. The suspension was 
pipetted gently to disperse any cell clumps before the addition of 3mL ESM to 
inactivate the trypsin/EDTA. Cell suspensions were centrifuged for 5mins at 
1000rpm and supernatant was then aspirated.  
Chapter 2                                 Methods and Materials 
 
64 
 
Pellets were suspended in ESM and passaged in a typical ratio of 1:5. SCM media was 
aspirated from 5 x T25cm2 flasks of mSNLs and replaced with 4mL ESM.  The cell 
pellet was suspended in 5mL ESM and distributed evenly between the 5 flasks. 
Cultures were incubated at 37°C and 5% CO2 in a humidified atmosphere for 2 days 
under stationary conditions prior to subsequent passage.  
Media was changed when the phenol red indicator began to turn yellow; ~1 to 2 
days, dependent on confluency. Passage ratio was adjusted as required to 
accommodate time taken to reach confluency. Cellular morphology was monitored 
over passage number for visual alterations. If changes were observed, fresh cells 
were reanimated and old cultures disposed of. 
2.1.3.3. Cryopreservation and Reanimation 
Confluent cells, either SNL fibroblasts or ES cells were washed twice in 5mL room 
temperature PBS and treated with 2mL trypsin/EDTA. After cell detachment, 
suspensions were transferred to a 15mL Falcon tube, trypsin inactivated with 3mL 
CPM and centrifuged for 5mins at 1000rpm. Supernatant was aspirated and cells 
suspended in CPM. Cells were subsequently seeded in 1mL suspensions of CPM in 
cryovials and placed in a polystyrene box. This was then stored at -80°C where cells 
were slowly frozen at a rate of 1°C per hour. This allows time for DMSO to displace 
water molecules. Once cooled to -80°C, cryovials were transferred to liquid nitrogen 
(-196°C to -210°C) for long term storage. 
Cells were reanimated by immediate transfer from liquid nitrogen storage to 37°C. 
Once thawed, the suspensions were quickly centrifuged and supernatant was 
aspirated. Cells were suspended in appropriate media pre-heated to 37°C and seeded 
into T75cm2 flask for SNL fibroblasts and T25cm2 flasks for ES cells. Cells reanimated 
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at varying rates, usually ranging between 1 week for ES cells and 2 weeks for SNL 
fibroblasts. 
2.1.4. Mitotic Inactivation 
2.1.4.1. SNL Fibroblast Inactivation 
Confluent cultures of SNL fibroblasts were treated with a 10mL solution of 
0.01mg/mL mitomycin C (MMC) and incubated for 2hrs at 37°C and 5% CO2 in a 
humidified atmosphere. MMC solution was then removed and cultures were washed 
with 2 x 10mL PBS. Cultures were treated with 2mL trypsin/EDTA at room 
temperature and gently agitated. After the confluent cell layer dissociated from the 
flask, the cell suspension was transferred to a 15mL Falcon tube. 3mL SCM was 
added to the tube to inactivate the trypsin/EDTA before the suspension was 
centrifuged for 5mins at 1000rpm. Supernatant was aspirated and the pellet 
suspended in 2mL SCM.  
MMC is isolated from Streptomyces lavendulae and is a potent deoxyribonucleic acid 
(DNA) cross-linker. It prevents DNA replication and halts treated cells in G1 phase of 
the cell cycle. Cells are consequently mitotically inactivated. 
2.1.4.2. Cell Number Quantification 
10µl of a cell suspension was seeded into an improved neubauer hemocytometer and 
viewed under an inverted light microscope. The hemocytometer displayed a 5 by 5 
square grid. All cells within the 4 corner and central squares were counted. Only cells 
which were positioned fully within the square and those which were situated on two 
sides of each square were counted (Fig 2.1). Cell concentration was calculated by the 
following equation; 
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Figure 2.1: Diagrammatic representation of a cell count using an improved neubauer 
hemocytometer. ES cells are trypsinized to ensure full dissociation into single cell suspensions. 
10µl aliquots are carefully loaded onto the hemocytometer on either side so that the aliquot in 
trapped between the hemocytometer and cover slip. The reference grid is composed of a 5 by 5 
square grid, and each of the 25 squares is further separated into a 4 by 4 square grid. All cells 
within the four corners and central squares of the 5 by 5 square grid are counted and an average 
calculated. Specifically, all cells lying completely within each and those overlapping two of the 
four sides are included. Dilution factor of the loaded suspension and the inherent dilution factor 
of the hemocytometer are then used to calculate ES cell number within the original suspension. 
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A x B x C x D = number of cells/mL 
A = number of cells counted in all 5 squares 
B = 5 (number of cells in the 25 square grid)  
C = 100 (inherent dilution factor of the hemocytometer) 
D = 100 (dilution factor of the volume added) 
2.1.4.3. Feeder Layer Preparation 
T25cm2 flasks were prepared for mSNL culture via incubation at room temperature 
with 2-3mL 0.1% bovine gelatin in PBS for 20-30mins. Excess gelatin was aspirated 
and replaced with 5mL SCM. mSNLs were seeded into the flasks at 8 x 104 cells/mL 
(1.6 x 104 cells/cm2). The appropriate volume of cell suspension required to seed at 8 
x 104 cells/mL was calculated as follows; 
(A / B) x C = volume (µl) 
A = 8 x 104 cells/mL (desired cell concentration) 
B = number of cells/mL (cell suspension concentration) 
C = 1000 (conversion factor from mL to µl) 
The correct volume of cell suspension was then added to each flask and gently mixed 
to ensure homogeneity. Flasks were incubated overnight to allow adhesion of the 
mSNL fibroblasts to the flask surface prior to their use for ES cell culture. MMC 
solution was used at 37°C, and mSNL coated T25cm2 flasks were replenished every 2 
weeks due to cell death and detachment from the flask. 
Gelatin is the subunit of denatured collagen whose natural structure is a left-handed 
helix composed of three hydrogen bonded gelatin strands (tropocollagen). Gelatin 
can be extracted by either acidic, alkali or neutral treatment of tropocollagen. Bovine 
collagen is complex and contains chemical cross-linkages such as covalent bonding 
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between tropocollagen fibrils. Alkali treatment is used to break these bonds and 
denature bovine collagen producing type-B gelatin (alkali extracted). Gelatin has a 
highly repetitive structure consisting of three amino acid subunits. The amino acid 
sequence of the basic subunit is Gly-X-Hyp or Gly-Pro-Y, where X and Y can be any 
amino acid. Gelatin is soluble in dH2O and forms a hydro-colloidal mixture which is 
used to coat the polystyrene flasks. Gelatin adsorbs to the polystyrene flasks 
providing a base layer which binds integrins on the cell surface. 
2.1.4.4. Embryonic Stem Cell Inactivation 
ES cells were inactivated with a solution of 0.01mg/mL MMC and incubated for 2hrs 
at 37°C and 5% CO2 in a humidified atmosphere. MMC solution was removed with 2 x 
5mL PBS washes at room temperature prior to experimentation, i.e. aggregate 
formation. 
 
2.2. Engineered Embryonic Stem Cells 
2.2.1. Sodium Periodate Oxidation 
Confluent ES cell cultures were washed twice with 5mL room temperature PBS, after 
removal of ESM. Cultures were then treated with 2mL trypsin/EDTA and agitated 
gently until breaks appeared in the monolayer. 3mL AM was added to inactivate the 
trypsin/EDTA and then cell suspensions were transferred to 15mL Falcon tubes and 
centrifuged for 5mins at 1000rpm. Supernatant was aspirated and the pellet 
suspended in 5mL PBS. The cell suspension was centrifuged again, supernatant 
aspirated and the pellet suspended in 5mL 1mM sodium periodate solution (sodium 
periodate powder in PBS). Cell suspensions were incubated for 15mins at 4°C in the 
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dark with agitation after 5mins. Sodium periodate solution was used at 4°C and 
made fresh every week. 
Sodium periodate is used to target the terminal vicinal diol groups of cell surface 
saccharides. The target saccharide was sialic acid. Loss of the terminal carbon atom 
creates a non-native reactive aldehyde group. The reaction is carried out at 4°C to 
minimize intracellular uptake of the exogenous sodium periodate by slowing 
membrane transport. This oxidation reaction is also exothermic and the cool 
environment is required to dispel the released heat energy. Heat can also cause 
decomposition of sodium periodate to form sodium iodate and oxygen, altering the 
oxidation kinetics. The reaction is carried out in the dark as light can cause oxidation, 
introducing an uncontrolled variable which reduces reproducibility of the 
modification. Light can cause photoactivation of periodate to form reactive 
intermediaries that act over a range of pH (Tang and Weavers, 2007). Dark 
conditions minimize the generation of these intermediaries, reducing the risk of cell 
damage via organic degradation by iodine radicals. 
2.2.2. Embryonic Stem Cell Biotinylation 
Sodium periodate-treated ES cells were removed from incubation at 4°C and 
centrifuged for 5mins at 1000rpm. Sodium periodate solution was aspirated and the 
pellet suspended in 5mL biotin buffer. Cell suspensions were centrifuged again and 
suspended in 5mL 5mM biotin hydrazide solution (lyophilized biotin hydrazide 
powder in biotin buffer) then incubated for 30mins at 37°C. During incubation cell 
suspensions were under constant rotational agitation on a Stuart Roller Mixer SRT6 
(Scientific Laboratories Supplies, Nottingham U.K.). Biotin hydrazide solution was 
used at room temperature and made fresh every week. 
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The reactive aldehydes are joined with biotin groups via a hydrazone linkage. The 
hydrazide group of biotin hydrazide replaces the oxygen atom of the aldehyde. The 
reaction is carried out at 37°C to simply speed up the whole procedure and minimize 
stress to the cells before being placed back in culture. 
2.2.3. Control Embryonic Stem Cells 
Control ES cells were processed identically to engineered ES cells, except that all 
chemical washes were replaced with PBS washes. Two controls were employed, (1) 
non-engineered ES cells without avidin supplementation, and (2) non-engineered ES 
cells with avidin supplementation (to assess any non-specific binding of avidin). 
 
2.3. Mass Suspension 
Both engineered and control ES cell suspensions were centrifuged for 5mins at 
1000rpm after incubation with biotin hydrazide solution. Supernatant was aspirated 
and pellets were suspended in 5mL avidin buffer, then centrifuged. Pellets were 
suspended in AM and cell concentration was calculated using an improved neubauer 
hemocytometer as previously stated. ES cells were then seeded into non-tissue-
culture treated 6 well plates (Falcon) in AM supplemented with 10µg/mL avidin 
(lyophilized avidin powder from chicken egg white in PBS). All suspensions were 
2mL final volume (Fig 2.2). Avidin incorporation study employed avidin-FITC 
conjugate (buffered aqueous solution). 
Avidin is a 66-69kDa tetrameric protein composed of four identical subunits, each of 
which can bind covalently to biotin. Due to the size of the ES cells, only two subunits 
of an individual avidin molecule bind the biotin groups attached to the cell surface. 
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Figure 2.2: Chemically engineered ES cell aggregation (De Bank et al., 2003). Engineering is based 
on modification of surface glycoforms. ES cells are treated with 1mM NaIO4 for 10mins at 4°C in 
the dark. NaIO4 is an oxidizing agent which specifically targets the vicinal diol of sialic acid 
residues which is invariably the terminal or penultimate sugar residue in most glycoforms. NaIO4 
treatment creates a non-native reactive aldehyde group. ES cells are then treated with 5mM 
biotin hydrazide which results in the ES cell surface becoming effectively biotinylated via a 
hydrazone bond between biotin hydrazide and the reactive aldehyde groups. Biotinylated ES cells 
are then cross-linked with exogenously added avidin, exploiting the known binding affinity of 
avidin for biotin. 
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Seeding densities used were 0.05, 0.1, 0.25, 0.5, 0.75 and 1 x 106 cells/mL. Plates 
were incubated for 6hrs at 37°C and 5% CO2 in a humidified atmosphere and 
constant agitation using a gyrotwister 3D-shaker (Labnet International Inc., Dorset, 
U.K.) set between 0 and 30rpm. After 6hrs incubation, FCS concentration was 
increased to 10% and suspensions placed under stationary conditions. Aggregation 
was allowed for up to 9 days and media was changed every 2 to 3 days with SCM pre-
warmed to room temperature. FCS concentration was kept at 1% for the first 6hrs to 
encourage aggregation between ES cells with minimum proliferation. 
 
2.4. Trypan Blue 
EBs were fully dissociated with trypsin/EDTA, centrifuged and suspended in SCM. 
Before cell counting, an aliquot of the cell suspension was mixed with trypan blue in 
equal volumes, i.e. 20µl of each. 10µl was then added to the haemocytometer and a 
cell count was carried out as stated previously. However, cells which stained blue 
were not included as these cells were dead. This was repeated prior to all 
experiments to ensure that cell concentrations were calculated for live cells only. 
Trypan blue is a derivative of toluidine (an isomeric derivative of toluene) which is 
capable of entering cells without intact membranes such as necrotic cells and cells 
undergoing apoptosis. These cells therefore appear blue under a microscope. Live 
cells have intact membranes which trypan blue cannot permeate. 
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2.5. Alamar Blue Assay 
After 2hrs incubation with 0.01% MMC solution, ES cell cultures were washed twice 
with 5mL PBS to thoroughly remove the MMC. PBS was then aspirated and 1mL 
Alamar Blue working solution (Alamar Blue diluted 1:10 in HBSS (Hanks Balanced 
Salts Solution)) was added to the cultures. Cultures were incubated at 37°C and 5% 
CO2 in a  ?Ǥ ? ? ?Ɋ 
a 96 well plate (Nunc) and absorbance was read at 570nm using a KC4 plate reader 
(Labtech International, East Sussex U.K.). 
Alamar Blue has previously been identified as resazurin (7-hydroxy-3H-phenoxazin-
3-one 10-oxide). Resazurin is normally used for testing spoilage of milk, indicated by 
a colour change. The removal of oxygen and formation of reducing agents during 
cellular proliferation are thought to cause the reduction of resazurin (blue and non-
fluorescent) to resorufin (pink and fluorescent) (O'Brien et al., 2000). However, 
continued reduction generates hydroresorufin, which is not coloured and non-
fluorescent. This hints at a possible draw back of using Alamar Blue as a proliferation 
assay in long term cultures. Alamar Blue was specifically used to give continuous 
measurement of ES cell viability over MMC concentration. Rather than showing 
whether the cells were alive or dead due to increasing MMC concentration, Alamar 
Blue assay allowed identification of a graded response. 
 
2.6. Live/Dead
 ?
 Stain 
ES cells/EBs were incubated at 37°C and 5% CO2 in a humidified atmosphere for 1hr 
in Live/Dead ? solution ( ?Ɋ     ?Ɋ  -1 in SCM). 
Samples were then allowed to settle or they were centrifuged briefly at 200rpm for 
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30secs before being washed with 2mL PBS. PBS suspended samples were imaged at 
excitation/emission 495/515nm for calcein AM and 495/635nm for ethidium 
homodimer-1 using fluorescence microscopy. Samples were viewed on an inverted- ȋ   ?Ȍǡ      Ǯǯ 
software. Live/Dead ? solution was either prepared fresh each time, or used within 1 
freeze-thaw cycle. Live/Dead ? solution was pre-heated to 37°C to avoid cold 
shocking the samples. 
Calcein AM is the acetomethoxy derivate of calcein, also known as fluorescein 
complex. It is membrane permeable and enters both living and dead cells. However, 
only living cells have functional esterases which remove the acetomethoxy group. 
Once removed, the calcein chelates intracellular calcium ions to give bright green 
fluorescence. Ethidium homodimer-1 is a membrane-impermeable red fluorescent 
dye. The dye intercalates with DNA, highlighting dead cells under U.V. light. 
 
2.7. Microscopy 
2.7.1. Light Microscopy 
During aggregation EBs were measured by phase contrast microscopy on a stereo-
microscope (Nikon Eclipse TS100) at 10x magnification. Photographs were taken 
using an attached imaging screen with built in software (Nikon Digital Sight DS-L1). 
2.7.2. Fluorescence Microscopy 
Fluorescently immuno-labelled EB sections were viewed using an inverted-
microscope (Nikon Eclipse 90i). Photographs were captured using a Hamamatsu ǮǯǤ 
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2.8. Scanning Electron Microscopy 
2.8.1. Preparation for SEM 
EBs were transferred to 15mL Falcon tubes and allowed to settle for 20mins at room 
temperature. Medium was aspirated and the EBs suspended in 5mL PBS. After 
settling again the EBs were suspended and fixed overnight at 4°C in 3% 
glutaraldehyde. EBs were allowed to settle and then suspended in 1% osmium 
tetroxide (TAAB, Berkshire U.K.) for 2hrs at room temperature. These were then 
washed in 5mL dH2O and allowed to settle. After washing they were dehydrated 
through a series of ethanol washes (25%, 50%, 70%, 90%, 95% in dH2O, and 100% 
ethanol) each lasting 2-5mins. Once dehydrated, EBs were chemically dried twice 
with 5mL hexa-methyldisilazane (HMDS) for 5mins at room temperature. HMDS was 
removed and EBs were allowed to air dry overnight in an externally vented fume 
hood. 
Glutaraldehyde is a fixative which in its monomeric form exhibits two aldehyde 
groups, each of which can bind the amino groups on proteins. Consequently, 
glutaraldehyde cross-links intracellular proteins quickly killing the cells. Osmium 
tetroxide cross-links and stabilizes all cell and organelle membrane lipids. It binds 
the double bonds found in lipoproteins depositing heavy metal in the cell 
membranes. Membrane deposited osmium also enhances bulk conductivity of the 
biological samples which increases image contrast by reducing localized electrostatic 
build up of electrons fired from the scanning electron microscopy (SEM) tungsten 
element. HMDS consists of ammonia substituted with two trimethylsilyl groups. It 
readily displaces the organic solvent ethanol allowing for removal by evaporation. ǡ       Ǯ  ǯ  
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terminates at a methyl group. Methyl groups are relatively inert and do not easily 
attach to each other or other molecules (Nation, 1983). Excess HMDS evaporates and 
leaves behind thinly-coated EBs that are prevented from adhering to one another. 
2.8.2 SEM Imaging 
Desiccated EBs were carefully removed from the Falcon tubes and adhered to carbon 
discs (Agar Scientific Ltd., Essex U.K.) mounted on aluminium stubs (Agar). These 
were gold-coated using a Balzers SCD 030 gold sputter coater (Balzers Union Ltd., 
Leichtenstein) for 3mins under argon atmosphere. Coated EBs were then imaged 
using a JEOL 6060L scanning electron microscope (JEOL Ltd., Hertfordshire U.K.). 
Images were initially taken at 12kV, and later at 14kV dependent on higher 
resolution images. Magnification was balanced with working distance from element 
to reduce the voltage required for imaging and hence, ionization of the sample. 
Repeat gold sputtering was applied to EBs imaged at 14kV for long periods as 
ionization build up reduced contrast resolution. 
Gold sputtering involves the thin-layer deposition of ionized gold atoms on a target 
sample. Gold is electron dense, thus providing a source of secondary electrons for 
SEM imaging (Ludwig et al., 1976). Biological samples are carbon based and poor 
emitters of secondary electrons. Secondary electrons collide with surrounding 
electrons creating a detectable electrical current. Gold also enhances conductivity of 
the biological samples. Sputtering was carried out in an argon atmosphere due the 
inert property of argon and that argon can be easily ionized to create conductive 
plasma for transmission of gold ions. 
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2.9. Histology 
2.9.1. Paraffin Embedding 
EB suspensions were transferred to 15mL Falcon tubes and allowed to settle for 
20mins at room temperature. The media was aspirated and the EBs carefully 
suspended in 5mL PBS. After settling, PBS was aspirated and EBs were suspended 
and fixed in 5mL 10% formalin (formaldehyde in dH2O) for 20mins at room 
temperature. After a second wash with 5mL PBS the EBs were allowed to settle for 
20mins and then they were suspended in a solution of 3% (w/v) agarose (low gelling 
temperature). EBs were carefully positioned adjacent to one another, opposed to 
evenly distributed throughout the gel suspension. The agarose was allowed to gel 
and then cooled to 4°C for 30-60mins. Using a Fireboy Bunsen burner (INTEGRA 
Biosciences AG, Zurich Switzerland) to heat a scalpel blade, the cone tip of the Falcon 
tube holding the gel suspended EBs was carefully removed. A syringe needle was 
used to remove the gel cone from the Falcon tube tip. A second scalpel blade at room 
temperature was used to slice the gel cone in half. Sliced gel halves were placed in a 
histology cassette and stored in 10% formalin before being processed at the     ǯ   ȋǡ  ǤǤȌ
where the EBs were finally embedded in paraffin wax. 
Formalin is formaldehyde in aqueous solution and causes fixation of biological 
tissues through covalent bonding and cross-linking of proteins to each other and the 
cytoskeleton. All intracellular biochemical reactions are stopped immediately upon 
exposure to the formalin, effectively killing the cell and preventing decay. The cross-
links also provide rigidity, preventing structural collapse of the cells. Agarose is one 
of two polysaccharides which make agar, the other (more complex) polysaccharide 
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being agaropectin. It consists of a galactose-based backbone exhibiting far less 
complex side chains as those of agaropectin. Due to this low degree of chemical 
complexity and neutral charge, agarose provides an ideal support for suspension of 
cells. Agarose also exhibits reduced risk of biochemical interaction with cell proteins. 
3% agarose has sufficient pore size to trap cells in a stationary position once cooled 
and allowed to gel. Paraffin wax helps to harden and secure the EBs in a stationary 
position ready for sectioning. 
2.9.2. Microtome Sectioning 
Once embedded, EBs were sectioned on a Leica RM2165 microtome (Leica 
Microsystems Ltd., Buckinghamshire U.K.). The section diameter was set to 4µm. 
Successive sections were collected as a ribbon and carefully placed into a water-bath 
set approximately at 60°C. When ribbons became shredded, the blade was either 
cleaned with UltraClear (TAAB) or replaced. If the ribbon continued to shred, the 
paraffin block was removed and placed on ice to cool for 10-15mins. The ribbon was 
carefully separated into individual sections with ice cold forceps and tweezers. 
Sections were adhered to SuperFrost® Plus glass slides (Laboratory Sales Ltd., 
Rochdale U.K.) and excess water was gently dabbed off. These slides were dried 
using a Hearson hot-bed set at 60°C for 30-60mins. Sections were allowed to cool to 
room temperature and stored under dark and dry conditions. 
SuperFrost® Plus glass slides are treated to exhibit a permanently positive surface. 
This electrostatically attracts formalin-fixed tissue sections and binds them through 
covalent bonding. 
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2.10. Haematoxylin and Eosin Stain 
Sections were placed in a glass holder and washed twice in a bath of xylene for 3mins 
to de-wax. Sections were rehydrated through a series of ethanol washes (100%, 
90%, 70% and 50% in dH2O) and a final rinse in dH2O, each for 2-3mins. Once 
hydrated, sections were treated with enough Mayers haematoxylin to cover the 
sample for 5-10mins at room temperature then washed with dH2O. Sections were   ǯ   ȋ ? ?     ?Ǥ ? ? ? 
bicarbonate in dH2O) and partially dehydrated through 50%, 70% and 90% ethanol 
in dH2O washes, 2-3mins each. After being dipped in alcoholic 1% eosin (eosin in 
ethanol), dehydration was completed with a 2-3min wash of 100% ethanol and a 
final wash in xylene. Stained sections were left to air dry on a hot-bed for 30-60mins 
and mounted with DPX. Sections were stored in a cool, dark and dry place. 
Xylene is essentially a mix of three dimethyl benzene isomers including ortho, meta 
and para-xylene. It acts as a solvent for the removal of paraffin wax. Haematoxylin is 
a compound derived from logwood trees which binds and stains basophilic 
structures within biological sections. Basophilic structures include the nucleus and 
ribosomes which contain nucleic acid. Once oxidized, haematoxylin forms haematein 
which has a deep blue/purple colour. Haematein binds nuclear histones in 
chromatin, specifically lysine residues, and exhibits a blue colour as a result of 
metallic ion mordant formation through linkage to iron and aluminium salts. The 
linkage creates insoluble aluminium hydroxide (mordant) in the alkaline conditions ǯǤ
process called blueing. Eosin is a compound which stains eosinophilic structures 
within biological samples such as collagen and the cytoplasm. It is used as a counter-
stain in conjunction with haematoxylin. Eosin is a mixture of two derivates resulting 
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from the chemical reaction between bromine and fluorescein; eosin Y (tetrabromo) 
and eosin B (dibromo dinitro). Alcoholic eosin is used to give a deeper red stain, 
opposed to the pink colour in non-alcoholic eosin. DPX contains a plastic resin 
dissolved in xylene supplemented with di-N-butyl phthalate as a plasticizer for 
dissolved resin flexibility. It acts as a transparent shield to protect the stained 
biological sections during imaging and storage. 
 
2.11. Immuno-Histochemistry 
2.11.1. Citrate Buffer 
Citrate buffer was prepared by mixing equimolar sodium citrate and citric acid 
solutions (41mL to 9mL, respectively), diluting with dH2O to 100mL and adjusting 
the pH to 6.0. Both sodium citrate and citric acid solutions were 0.1M in dH2O with 
0.05% Tween 20 and adjusted to pH 6.0. All solutions were stored at 4°C. 
Tween 20 is a polysorbate surfactant used to solubilize and create holes in the cell 
membrane. It is a polyoxyethylene derivative of sorbitan monolaurate.  
2.11.2. Section Preparation 
Sections were washed in xylene twice for 5mins to de-wax, hydrated in 100% 
ethanol twice for 3mins, 95% and 80% ethanol in dH2O twice for 1min, all 
sequentially. After a final wash in dH2O for 1min, sections were immersed in citrate 
buffer pre-heated to 95-100°C for 20-40mins for antigen retrieval. Sections were 
then allowed to cool at room temperature for 20mins. 
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2.11.3. Antibody Labelling 
2.11.3.1. Blocking Solution 
Once cooled, sections were loaded into a slide holder and rinsed with PBS containing 
0.1% Tween 20. Sections were then washed and incubated with 100µl 0.1% Triton 
X-100 and 1% bovine serum albumin (BSA) in PBS (PBT) for 30mins at room 
temperature. After 3 x 5 min washes with 100µl 0.1% BSA in PBS (PBA), 100µl 
blocking solution (10% donkey serum in PBS) was added for 30mins at room 
temperature. 
Triton X-100 is a nonionic surfactant which causes cell membrane permeabilization. 
BSA is a serum albumin protein that is used as a stabilizer and for its lack of 
biochemical interaction during the labelling procedure. 
2.11.3.2. Primary Antibody 
Blocking solution was rinsed away with 3 x PBA washes, 5mins each. Sections were 
incubated for 1hr at room temperature with 100µl primary antibody (1:50 dilution 
in PBA). Alternatively, if target epitopes were internal markers, samples were 
incubated at 4°C overnight. A list of the primary antibodies used is shown overleaf 
(Table 2.1). 
2.11.3.3. Secondary Antibody 
Primary antibody solution was washed away with 3 x 100µl PBA rinses, 5mins each. 
Sections were incubated at room temperature with 100µl fluorescently-labelled 
secondary antibody (1:250 dilution in PBA) for 1hr in the dark (Table 2.1). Sections 
were rinsed with 3 x 5min washes of 100µl PBA. Finally, sections were washed for 
10mins in PBS before being removed from the slide holder. Before the sections began
Chapter 2                                 Methods and Materials 
 
82 
 
 
Table 2.1: List of primary antibodies and corresponding fluorescently-conjugated secondary 
antibodies. 
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to air dry     Ǯ®  ǯ ȋ 
Ltd., Peterborough U.K.) and incubated overnight at 4°C in the dark. Fluorescence 
images were taken on a Leica DMIRE2 inverted microscope using the appropriate 
filters. Stained sections were stored at 4°C in the dark. 
Vectashield® preserves fluorescence by scavenging free radicals produced upon 
exposure to U.V. light. DAPI is a fluorescent stain that binds strongly to DNA via 
intercalation in the minor groove of the helical structure. Its excitation and emission 
wavelengths are 358nm and 461nm respective. 
 
2.12. Hoescht Assay 
2.12.1. Papain Digestion 
Cells were collected in 15mL Falcon tubes and centrifuged for 5mins at 1000rpm. 
Pellets were suspended in 0.5-1mL papain solution (1.06mg/mL papain powder in 
papain buffer) pre-heated to 60°C. Papain solution was pre-heated to 60°C to dissolve 
papain powder prior to addition of cells. Cells were rigorously mixed by pipetting in 
papain solution prior to overnight incubation in a Grant waterbath (JB4 mid-sized 
16litre, Cambridgeshire U.K.) set at 60°C. 
Papain is derived from Carica papaya and the latex of its tree. Papain is a cysteine 
protease which has two structural domains and a cleft in between which hosts the 
active site. The active site consists of three amino acid residues including Cys-25, 
His-159 and Asp-158. Papain function involves deprotonation of Cys-25 by His-159 
which is spatially orientated by Asp-158. Cys-25 then nucleophilically attacks the 
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carbonyl carbon of peptides. Over a prolonged period papain completely digests ECM 
and lyses cells. 
2.12.2. DNA Quantification ǡ ? ?Ɋ digested sample solution was mixed with 0.5mL Hoescht 
buffer and 0.75mL of Hoescht working solution (Hoescht stock solution in Hoescht 
buffer, 1:2000). Hoescht stock solution was made by mixing 1mg/mL bis-benzimide 
with single-Ǥ  ? ? ?Ɋ  mixture was then transferred to a 96 
well plate and fluorescence was read at excitation/emission 360nm/460nm using a 
KC4 plate reader. All solutions and samples were kept under minimal light 
conditions throughout. 
Bis-benzimide is a fluorescent dye which intercalates with DNA and can be used to 
quantify DNA content from plotting a standard emission-to-content curve. Two bis-
benzimides are regularly used including Hoescht 33258 (pentahydrate) and Hoescht 
33342 (trihydrate). The difference between them is an additional ethyl group on 
Hoescht 33342 making it more lipophilic. 
 
2.13. Osteo-Induction 
EB suspensions were transferred to 15mL Falcon tubes and allowed to settle. 
Alternatively, suspensions were centrifuged briefly at 200rpm to pellet the EBs. 
Media was removed and EBs were suspended in either osteo-inductive media 
(DMEM, 15% FCS, 1% L-glutamine, 1% PȀǡ  ? ? ? ? Ⱦ-ǡ  ? ?Ɋ
d ȋȌǡ  ? ?ɊȀmL ascorbate-2- ȋȌǡ   ? ? Ⱦ-
glycerophosphate (BGP)) or control media (no Dex or BGP). EBs suspensions were 
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then transferred to tissue-culture treated 6 well plates, pre-coated with 0.1% gelatin 
for 30-60mins at room temperature. Plates were incubated at 37°C and 5% CO2 in a 
humidified atmosphere for 3-4 days before changing media to allow time for EBs to 
adhere. Cultures were grown for 4 weeks and media was changed every 2-3 days 
with fresh osteo-inductive and control media pre-heated to 37°C. Dex, Asc and BGP 
were freshly added to stock culture media every week. 
Dex is a synthetic member of the glucocorticoid class of steroid hormones. The 
mechanism and signaling involved in dex-induced osteogenic differentiation is not 
fully understood. However, its ability to induce osteoblast differentiation has been 
reported extensively (Zalman et al., 1979, Bellows et al., 1987, Bellows et al., 1990, 
Grigoriadis et al., 1988). Bone nodule formation occurs initially through secretion of 
ECM followed by the deposition of calcium phosphate crystals by osteoblasts. Asc 
induces ECM secretion including collagen and GAG deposition (Poliard et al., 1993, 
Choi et al., 2008a). GAG is a chain of repeating disaccharide subunits which are 
unbranched. It is important in fibrous connective tissue and can covalently bond to 
proteins to form proteoglycans which are constituents of bone matrix. Asc has also 
been found to maintain the proliferative capacity of stem cells (Choi et al., 2008a). 
BGP is an organic phosphate added to induce mineralization of the collagen matrix 
through calcium phosphate deposition (Garimella et al., 2006). It serves as an 
inorganic phosphate reservoir once hydrolyzed by acid phosphatase (AP) (Fratzl-
Zelman et al., 1998, Lee et al., 1992, Ecarot-Charrier et al., 1983, Chang et al., 2000). 
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2.14. Alizarin Red Stain 
Cultures were washed in 3mL PBS, fixed in 1mL 10% formalin for 20-30mins at 
room temperature and washed twice in 2mL dH2O. Cultures were treated with 1mL 
Alizarin Red solution (2% w/v Alizarin Red powder in dH2O) for 5-10mins at room 
temperature under continuous agitation. Alizarin Red solution was removed and 
cultures were washed repeatedly with dH2O until no further colour leached out. 
Images were taken under wet conditions (in dH2O) using the Nikon Eclipse TS100 
stereo-microscope described previously. Plates were then desiccated and stored in 
the dark. 
Alizarin Red is a derivative of anthracene (three fused benzene rings) which exhibits 
two hydroxyl groups at positions 7 and 8, and two ketone side chains at positions 9 
and 10 on the central ring. Originally extracted from the root of the madder plant, 
synthetic Alizarin Red is used today to stain calcium deposition in bone nodules 
formed by osteoblast function. Specifically, Alizarin Red chelates with calcium 
phosphate crystals deposited in the ECM to give a bright red/orange colour. 
 
2.15. Alkaline Phosphatase Assay 
Cell cultures were washed with 37°C PBS to remove traces of culture media. Alkaline 
phosphatase (ALP) substrate, p-nitrophenyl phosphate (PNPP) disodium salt 
hexahydrate in 0.2M Tris buffer, was prepared in dH2O at a concentration of 
1mg/mL. 1mL aliquots were transferred to each well containing cell cultures. 
Samples were then incubated at 37°C and 5% CO2 in a humidified atmosphere for a 
maximum of 15mins until solution began to turn yellow. Incubation time was equal 
for all samples. Reactions were stopped upon addition of 100µl 3M NaOH after 
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removal from cell cultures. 300µl aliquots were transferred to a 96 well plate in 
triplicate per well and absorbance was measured at 405nm using a KC4 plate reader. 
Averages were taken of the triplicate readings after deducting a blank measurement 
of fresh PNPP solution. All readings were then equalized for DNA content of 1 x 106 
cells using accompanying Hoescht data. 
PNPP is a non-proteinaceous, non-specific substrate used for the detection of acid 
and ALPs. ALP acts as a catalyst for PNPP hydrolysis which forms p-nitrophenol. P-
nitrophenol is a chromogenic product which has a yellow appearance with an 
absorbance at 405nm. Absorbance readings therefore give indirect measurement of 
ALP activity within the cell cultures. 
 
2.16. Alcian Blue Stain 
Cell cultures were washed with room temperature PBS and then fixed with 95% 
methanol solution in dH2O at room temperature for 1hr. Samples were washed with 
dH2O and then incubated with 1mL Alcian Blue solution (1% Alcian Blue powder in 
3% glacial acetic acid) at 4°C for a maximum of 10mins. Alcian Blue solution was 
then removed and cultures were washed with dH2O repeatedly until no further dye 
leached out. Samples were then imaged using the Nikon Eclipse TS100 
stereomicroscope and Nikon DS-L1 imaging system at 10x magnification. 
Alcian Blue is a cationic phthalocyanine dye which contains a central copper atom 
giving it a blue appearance. It electrostatically binds to the negatively charged 
regions of GAGs. 
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2.17. Polymerase Chain Reaction 
2.17.1. Primer Design 
Go to www.ensembl.org and in the drop down menu choose the desired animal 
model, i.e. mus musculusǤ            ǯ
ǯǤǮǯǤ  Ǯ  ?ǯǤ
either side of the break between the two exons and keeping all the preset parameters ǮǯǤǮǯ
both primer sequences match (± 1). Check the primer sequences using the online Ǯǯ gram found on the website, www.ncbi.nlm.nih.gov. Simply paste the 
sequence in, choose the correct genome for comparison, i.e. mouse, and click on ǮǯǤ           ? ? ? ?    
gene. If there is another gene which has matched 100%, then refer back to the results   Ǯ  ?ǯ      Ǥ 	          ǯ ǯ  
www.basic.northwestern.edu/biotools/oligocalc.htmL. Paste in the sequence and   Ǯ -ǯǤ     ǡ   
choose another set of primer sequences. Once the sequences have been chosen and 
verified they were ordered from www.ecom.mwgdna.com.  
Primers are tailored oligonucleotides of specific base sequence complimentary to the 
target cDNA. Their purpose is to provide a starting position either side of a target 
gene for polymerase to transcribe the encompassed cDNA derived from mRNA.  
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2.17.2. RNA Isolation and Purification 
Ribonucleic acid (RNA) was extracted using the protocol supplied in the RNeasy mini 
kit handbook (Qiagen, West Sussex U.K.). Samples were lysed in 300µl RLT lysis 
solution and stored at -80°C. Once thawed, the solution was transferred to an RNeasy 
mini spin column and the volume doubled with 70% ethanol. The columns were 
spun in a centrifuge (Spectrafuge 24D, Labnet) at 9400rpm (800g) for 15-30secs. 
The waste liquid in the collection tube was removed. 700µl of RPE buffer 
(supplemented with ethanol) was added and the columns centrifuged again. The 
collection tubes were emptied, 500µl of RW1 buffer was added and the columns 
centrifuged for 15-30secs. After a second wash with RW1 buffer the columns were 
centrifuged for 2mins. Collection tubes were replaced and the columns centrifuged 
for 1min to ensure all liquid was collected. Columns were transferred to Eppendorf 
tubes and 30-50µl RNase free water was added. The columns were centrifuged for 
1min before adding another 30-50µl and centrifuging again. RNA solutions were kept 
on ice throughout and frozen at -80°C.  
2.17.3. cDNA Reverse Transcription 
RNA solutions were thawed and their concentration measured on a NanoDrop® 
spectrophotometer (ND-1000, Labtech) at 260nm. The RNA solutions were reverse 
transcribed to form stable cDNA for polymerase chain reaction (PCR) amplification. 
The total volume for reverse transcription was 40µl. Maximum volume of RNA 
solution added to the reaction was up to 28µl (dependent on RNA concentration and 
made up to volume with RNase free water). The reaction required 1µg RNA. Oligo-dT    ? ?     ȋ ? ?Ȁ ?Ȍǡ   Ǯ ǯ    ? ? ?Ǥ  Ǯ ǯ   ? ?  
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(RT) buffer, 2µl deoxyribonucleotide triphosphates (dNTPs) (1mM), 0.5µl RNase 
inhibitor (20ng/µl) and 0.5µl RT (20ng/µl). 1µg of RNA was made to a volume of 
28µl with RNase free water and transferred to a 0.2mL thin walled PCR tube 
(STARLAB, Milton Keynes U.K.). The tubes are thin walled to minimize insulation and 
aid heat transfer. 1µl of stock oligo-dT primers was added to the tubes and 
centrifuged at 5000rpm for a pulse-spin in a microfuge (Sigma 1-14, SLS). Tubes 
were transferred to a PCR machine (Px2 Thermal Cycler, Thermo Scientific, Surrey 
U.K.) and heated to 65°C for 10mins. This denatures any secondary structures to 
expose the RNA sequence to oligo-Ǥ ? ? ?Ǯǯ s added to each tube and the tubes were pulse-spun. The tubes were 
transferred back into the PCR machine and heated for 2hrs at 55°C then 10mins at 
85°C. Reverse transcriptase binds the oligo-dT primers and reverse transcribes the 
RNA sequence to form cDNA. The high temperature spent at 85°C denatures the 
reverse transcriptase and ceases cDNA synthesis. Resultant cDNA transcripts were 
stored at -20°C. 
2.17.4. PCR Amplification 
cDNA transcripts were subsequently used as templates for PCR amplification of 
targeted markers. Two PCR Ǯmaster mixesǯ    combined with a 
cDNA template in a thin walled PCR tube. PCR Ǯmaster mix 1ǯ consisted of 0.2mM 
dNTPs, 0.5µM forward primer, 0.5µM reverse primer and RNase free water. Total 
volume was made to 20µl per sample. PCR Ǯmaster mix 2ǯ consisted of 0.25µl Taq 
polymerase, 5µl of 10x PCR buffer and 19.75µl RNase free water, per sample. 20µl 
PCR Ǯmaster mix 1ǯ and 25µl PCR Ǯmaster mix 2ǯ were added together in a thin walled 
PCR tube. 5µl of the cDNA transcript was added and the tubes were pulse-spun. The 
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reaction solutions were loaded into a PCR machine and run on an appropriate 
amplification program. The PCR amplification programs included an initial 
denaturation step at 94°C for 5mins before a cycling step including denaturation and 
annealing, and a final extension phase. The exact cycling step was dependent on the 
primer pair being used (Table 2.2). The last step involved a final extension at 72°C 
for 10mins. The cycling step involves 30secs at 94°C to denature the cDNA 
transcripts breaking double strand DNA (dsDNA) into single strand DNA (ssDNA). 
The temperature then decreased according to the annealing temperature of the 
primer pair for 30secs. Once the primers had annealed to their targets, Taq 
polymerase bound the primers and transcribed the cDNA during the extension phase 
at 72°C for 1min. These three steps were repeated 30-35 times to amplify the DNA to 
a detectable level. Amplified DNA transcripts were stored at -20°C. 
2.17.5. Gel Electrophoresis 
A 2% (w/v) agarose gel was prepared by mixing 1.5g multipurpose agarose (agarose 
MP) (Roche, Hertfordshire U.K.) in 75mL Tris-Borate-EDTA (TBE) buffer. The 
solution was mixed in a glass 200mL Duran bottle (SLS) and heated in a microwave 
on full power for 1min to dissolve the agarose MP. The solution was heated for 
another 15secs and then supplemented with 0.5µg/mL ethidium bromide. The 
solution was poured into a mould holding two combs, each with 20 prongs, and 
allowed to set for 20mins at room temperature. Once set the gels were placed in a gel 
electrophoresis tank (Fisher) and submerged in TBE buffer. Additional ethidium 
bromide (~0.1µg/mL) was added to the buffer to counteract leaching from the gel. 
The combs were removed and 10µl PCR amplified DNA was loaded per sample per 
well, once mixed with 5µl of gel loading solution. The lid was placed on the gel 
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Table 2.2: Primer pair sequences, corresponding annealing temperatures and optimized cycle 
number. 
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electrophoresis tank and connected to a power 300 - gel electrophoresis power 
supply (Fisher) then run for ~20 to 30mins at 100volts. 
Gel loading buffer contained 0.05% (w/v) bromophenol blue, 40% (w/v) sucrose, 
0.1M EDTA pH 8.0 and 0.5% (w/v) sodium lauryl sulphate (SLS). Bromophenol blue 
acts as a visible colour indicator to track samples during electrophoresis. Sucrose 
makes the solution dense and therefore enables the solution to sink into the well 
rather than diffusing in the buffer. EDTA denatures any contaminating enzymes and 
SLS dissociates any potential DNA-protein complexes and also imparts a negative 
charge on the DNA surface. The negative charge is essential for the electrical current 
to pull the sample through the gel.  
2.17.6. Gel Imaging 
Once finished, the tanks were drained of TBE buffer and the gels dabbed dry of 
excess liquid. The gels were imaged in a Fujifilm intelligent dark box using Fujifilm 
LAS-1000 imager (Bedfordshire U.K.) and Win TV2000 (Hauppage, London U.K.) 
software. The gels were illuminated with ultra violet (U.V.) light which excited 
ethidium bromide intercalated with DNA, therefore highlighting the sample bands. 
Advanced image data analyzer (AIDA) 2D densiometry software v3.28.001 (Raytest 
Inc., Sheffield U.K.) was used to convert the images into a usable format such as 
bitmap. The density of triplicate bands were quantified using ImageJ version 1.35i 
(NIH, USA). These measurements were normalised to the corresponding GAPDH 
value of that sample and expressed as a mean ± standard deviation. Waste gels were 
disposed of in toxic waste due to the ethidium bromide content. 
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2.18. May-Grünwald and Giemsa Stain 
After ES cells had attached to the microparticle surface and spread out, samples were 
removed from culture media, washed in room temperature PBS and fixed with 4% 
(w/v) paraformaldehyde in PBS for 30mins at room temperature. Samples were 
washed with PBS to remove fixative solution and incubated in 0.1% (v/v) Triton X-
100 in PBS for 15mins at room temperature to permeabilize the cell membrane. 
After another wash in PBS samples were incubated at room temperature in 0.25% 
(w/v) May-Grünwald solution in methanol for 15mins to stain the cell cytoplasm. 
After a wash in PBS, samples were incubated at room temperature in 0.4% (w/v) 
Giemsa solution in methanol for 20mins to stain the cell nucleus. Samples were then 
washed twice in dH2O and left to air dry overnight. Samples were imaged using light 
microscopy. 
Paraformaldehyde is formed by polymerising formaldehyde molecules to make a 
chain. It cross-links amino groups within biological samples effectively sterilising 
and fixing the tissue protecting it from decay and structural collapse. May-Grünwald 
stain is a solution of methylene blue eosinate in methyl alcohol. Giemsa stain is a 
solution of methylene azure eosinate in methyl alcohol. Azure of methylene is the 
oxidized version of methylene blue. Methylene blue/azure of methylene cations 
(basic dye) mix with eosin Y anions (acid dye) to form a salt. The salt is dissolved in 
methyl alcohol as an inactive solution. Contact with acidic or basic water causes 
colouring of the solutions via redox reactions. The cell cytoplasm and nucleus are 
stained with a pink and blue colour, respectively.  
 
Chapter 2                                 Methods and Materials 
 
95 
 
2.19. Statistical Analysis 
EB populations did not follow a Gaussian distribution as determined by a 
Kolmogorov Smirnov test, and were subsequently analyzed using non-parametric 
methods. Significant variation among means within individual samples was assessed 
by one-way ANOVA, specifically a Kruskal Wallis test. Significant difference between 
the means of any two individual data sets within the same sample was determined 
by Dunns multiple comparison test. Significance between two data sets from 
different samples was assessed by a Mann Whitney U test. Significance is depicted as 
*** P  ?0.001, ȗȗ ? ?Ǥ ? ?, * P  ?0.05. 
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Chapter 3  
3. Results 
Aggregation Kinetics 
3.1. Introduction 
Much methodology currently exists with regards to EB formation encompassing a 
range of techniques (Kurosawa, 2007, Carpenedo et al., 2007). Each technique affects 
various properties of resultant EBs including size, stability, viability and density, but 
more importantly constituent ES cell differentiation. Previous studies have portrayed 
a direct link between the aggregation method and downstream ES cell differentiation 
(Ng et al., 2005, Burridge et al., 2007, Kim et al., 2007a, Gerecht-Nir et al., 2004). 
Consequently, research is now being heavily invested in the elucidation of how EB 
formation exhibits control over ES cell differentiation. However, due to a lack of 
standardized methodology, comparison between studies is convoluted and difficult 
to decipher. We hypothesize that by controlling early ES cell-ES cell interaction and 
aggregation, ES cell differentiation within resultant EBs can be efficiently and 
effectively directed towards desired cell types. The controlled generation of specific 
cell types in potentially homogeneous populations is a crucial step in the 
advancement of ES cell research from the laboratory to clinical application (Karlsson 
et al., 2008, Zweigerdt et al., 2003). Controlled ES cell-ES cell interaction could allow 
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for more detailed investigation of variables affecting EB formation and ES cell 
differentiation which may have previously not been identified or quantified. These 
variables include constitutive ES cell number, cell-cell attachment and signalling, 
resultant EB size, number and density, and aggregation time prior to the addition of 
exogenous biochemical cues (Koike et al., 2007, Dang et al., 2004). Here is shown 
how a non-cytotoxic modification to the cell surface which is then biotinylated and 
cross-linked with avidin, provides control over ES cell-ES cell aggregation and 
subsequent EB formation. This proposed methodology is reliable, repeatable and 
robust, and has the potential to be expanded to an industrial scale.  
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3.2. Methods and Materials 
3.2.1. Engineered Aggregation and Avidin 
The effect of avidin concentration on EB formation and incorporation within the EB 
structure was investigated. Both engineered and control ES cells were seeded into 
mass suspension over a range of densities (5 x 104 to 1 x 106 cells/mL). Suspensions 
were then rotated for 6hrs at 15rpm with 5, 10, 20, 50 and 80µg/mL exogenously 
added avidin. Control samples were rotated without avidin. ES cell suspensions were 
cultured for 24hrs prior to EB measurements. Avidin incorporation was visualised by 
fluorescence microscopy looking for avidin-FITC. Duplicate ES cell suspensions over 
the same seeding density range were rotated for 6hrs at 15rpm and incubated for 
48hrs with 10µg/mL avidin-FITC conjugate. After 24 and 48hrs incubation, EBs were 
washed thoroughly with room temperature PBS to remove any unbound avidin-FITC 
from suspension, and imaged at ex/em of 495/515nm on a stereo-microscope 
(Nikon SMZ1500) with Nikon Digital Sight DS-L1. 
3.2.2. Particle Sizing System 
To investigate the effect of rotation speed on ES cell aggregation and EB formation, 
both engineered and control ES cells were seeded into mass suspension and rotated 
at 5, 10, 15, 20, 25 and 30rpm for the first 6hrs of 24hrs incubation. Control samples 
were left stationary for the first 6hrs. Rotation was applied only for the first 6hrs to 
encourage cell-cell interactions and aggregation of individual EBs. Observations 
revealed that suspensions rotated beyond 6hrs began to show inter-EB adhesion. 
After incubation, EB formation was quantified by high throughput analysis afforded 
by Particle Sizing System (PSS) analysis. 
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After aggregation, the whole sample suspension was carefully transferred to a 15mL 
Falcon tube so as to minimize EB disruption and fragmentation. The suspension was 
kept at room temperature whilst remaining suspensions were transferred. 
Suspensions were made to a volume of 10mL with PBS. The glass holding vial of a  ȋ ?  ? ? ? PAT, PSS.NICOMP, California U.S.A.) was washed 
through with 50mL aliquots of dH2Ǥ      ?  ? Ȁ
dH2O was allowed to drain until the last few millilitres so as to not allow air bubbles 
to enter the measuring chamber. A 50mL aliquot of PBS (inclusive of 2mL SCM) was 
poured into the glass holding vial and analyzed using accompanying software 
(CW780md Version 1.55). Measurements provided blank controls to be subtracted 
from sample measurements. Individual sample suspensions were subsequently 
poured into the glass holding vial, one at a time. The volume was made to 50mL with 
PBS and gently stirred for 10secs then analyzed. Between each sample suspension 
the glass holding vial was washed through continuously with dH2O until the PSS  ? ?ȀǤ 
3.2.3. Mitomycin C Toxicity 
To investigate the toxicity of MMC, ES cells were incubated for 2hrs with a range of 
MMC concentrations (0.001, 0.005, 0.01, 0.05 and 0.1mg/mL). ES cell viability was 
assessed by Alamar Blue assay (Chapter 2). ES cells incubated with 0.001, 0.01 and 
0.1mg/mL were seeded onto a SNL feeder layer in SCM for continuous culture. After 
1hr and 60hrs incubation, ES cells were imaged for colony formation and ES cell Ȁ ?ȋ ?ȌǤ 
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3.2.4. Embryoid Body Formation 
Engineered and control ES cells were seeded at 0.05, 0.1, 0.25, 0.5, 0.75 and 1 x 106 
cells/mL in mass suspension and rotated between 0 and 30rpm for the first 6hrs of a 
24hr period. Only data from the lowest (5 x 104 cells/mL) and highest (1 x 106 
cells/mL) seeding densities is shown, highlighting major differences with relation to 
initial seeding density. After every 4hrs, ES cell suspensions were photographed to 
assess EB formation. EBs were observed in both engineered and control suspensions 
after 6hrs rotation. All subsequent experiments involved an initial rotational period 
of 6hrs. To assess EB formation further and surface cell morphology, EBs after 1, 3 
and 5 days incubation were imaged using SEM (Chapter 2). 
3.2.5. Embryoid Body Quantification 
A 0.25cm square grid was printed onto an acetate sheet. Discs were cut from the 
sheet to match the well size of a 6 well plate (2cm diameter circle) and externally 
adhered in identical orientations prior to seeding of ES cell suspensions. Three 
squares spanning the well in a diagonal line were marked on each grid in the same 
locations. 
ES cell suspensions were seeded into 6 well plates and cultured for a period of 9 
days. At each time point plates were removed from incubation, gently agitated to 
homogenize EB suspensions and viewed using a Nikon Eclipse TS100 microscope at 
10x magnification. All EBs observed within the three squares were counted and 
measured using the attached imaging screen and Nikon Digital Sight DS-L1 imaging 
software. EB diameter was measured between the sides closest to one another 
across the EB centre to reduce the error of measuring two connected EBs. An 
average of EB number and diameter was calculated for all EBs falling within the 
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three sample squares. Plates were then placed back into incubation ready for the 
next time point. EBs were counted and measured over time and seeding density in 
both engineered and control ES cell samples. Duplicate samples using mitotically 
inactivated ES cells were also measured using this method. 
Initial aggregation formed randomly orientated ES cell clusters which later 
reorganized to form compact EBs. Compac        ?
40µm. Consequently, ES cell clusters with a diameter < 40µm were not included 
within EB measurements. Previous studies have also encountered the issue of when 
to call an ES cell aggregate and EB, and have defined an EB as having a diameter  ?
40µm and ES cell aggregates with diameter < 40µm defined as primitive EBs 
(Carpenedo et al., 2007). 
3.2.6. Aggregation and Cell Populations 
3.2.6.1. Numbers of Cells in Sample Suspension 
Multiple samples were prepared to provide one per time point. At each time point EB 
suspensions were transferred to a 15mL Falcon tube and centrifuged for 5mins at 
1000rpm. Supernatant was removed and pellets were suspended in 5mL PBS. 
Suspensions were centrifuged a second time and the DNA content of the pellets was 
assessed by Hoescht assay. Cell number was calculated from fluorescence readings 
using a standard curve (Fig 3.1). 
3.2.6.2. Numbers of Cells within Embryoid Bodies 
Suspensions were washed through a 40µm cell strainer (Falcon) with 5mL PBS. 
Flow-through was collected in a 50mL Falcon tube and centrifuged for 5mins at 
1000rpm. Supernatant was removed and the DNA content of resultant pellets was 
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Figure 3.1: Standard curve of fluorescence against cell number using Hoescht assay. ES cells were 
trypsinized from continuous culture flasks into suspension and cell number quantified by 
haemocytometer-based cell count. 250, 500, 1000, 1250, 2500 and 5000 x 10
3
 cells were treated 
with papain solution at 60°C overnight and DNA content was quantified the following day by 
Hoescht assay. The experiment was repeated in triplicate and each experiment consisted of 3 
fluorescence measurements; n = 9. Error bars = S.E.M. 
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assessed by Hoescht assay. Fluorescence readings were converted to cell numbers 
using a standard curve (Fig 3.1). Cells and clusters smaller than 40µm were washed 
through the filter leaving behind EBs. Ǯells within the whole sampleǯ minus Ǯells 
washed through the filterǯ gave a representative number of cells within EBs. 
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3.3. Results: Critical Factors 
3.3.1. Avidin Cross-linker 
3.3.1.1. Avidin Incorporation 
Avidin-FITC was clearly visibly spread throughout the structure of both engineered 
and control EBs, indicated by fluorescence when observed under an epi-fluorescent 
microscope (Fig 3.2). Fluorescence within engineered EBs was speckled and not 
uniformly distributed (Figs 3.2A and C). Conversely, fluorescence within control EBs 
did appear uniformly distributed (Figs 3.2B and D). Samples incubated for 48hrs 
exhibited greater amounts of fluorescence than those incubated for 24hrs. 
Engineered EBs within Figs 3.2E and G, cultured without avidin-FITC conjugate, were 
smaller in size than equivalent control EBs in Figs 3.2F and H. The lack of 
fluorescence observed in Figs 3.2E, F, G and H revealed that EBs themselves did not 
auto-fluoresce. Therefore, any fluorescence observed was due solely to exogenous 
avidin-FITC conjugate.  
3.3.1.2. Avidin Concentration 
Engineered EBs were significantly ȋ  ?  ?Ǥ ? ? ?Ȍlarger in size than corresponding 
control EBs at 5 x 104 cells/mL and 1 x 106 cells/mL over a range of avidin 
concentrations (Figs 3.3A and B). Interestingly, similar sized EBs were observed at 
low avidin concentration of 5µg/mL as what were observed at high avidin 
concentration of 80µg/mL. Engineered EBs were significantly ȋ ? ?Ǥ ? ? ?Ȍsmaller in 
size without exogenous avidin at low seeding density (Fig 3.3A) demonstrating the 
importance of avidin for engineered ES cell aggregation, and that natural aggregation 
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Figure 3.2: Avidin-FITC conjugate incorporation within engineered and control EBs. Engineered (A, 
C, E and G) and control ES cells (B, D, F and H) were rotated at 15rpm for the first 6hrs of a 24hr 
(A, E, B and F) and 48hr (C, G, D and H) incubation period. Both engineered and control EBs were 
incubated in SCM supplemented with 10µg/mL avidin-FITC conjugate (A to D) or SCM without 
avidin-FITC conjugate (E to H). All images were of ES cells seeded at 1 x 10
6
 cells/mL. Both 
brightfield and fluorescence (ex/em - 495/515nm) images were taken at each time point. Scale 
bar measures 500µm.  
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Figure 3.3: ES cell aggregation and EB formation over a range of avidin concentrations. 
Engineered and control 2 ES cells were seeded into mass suspension in SCM supplemented with 
exogenous avidin over a range of concentrations (0 to 80µg/mL) at 5 x 10
4
 cells/mL (A and C) and 
1 x 10
6
 cells/mL (B and D). Suspensions were then rotated at 15rpm for the first 6hrs of a 
stationary 24hr incubation period. Suspensions were subsequently sampled and analyzed for 
average EB diameter (A and B) and EB number (C and D). Engineered and control 1 ES cells were 
also incubated without exogenous avidin, shown in all graphs at 0µg/mL. When calculating mean 
EB number, n = 9. When calculating mean EB diameter, n ranges from 16 to 49 (5 x 10
4
 cells/mL) 
and n ranges from 140 to 415 (1 x 10
6
 cells/mL).  ? ? ?WA? ? ? ? ? ? ? ? ?WA? ? ? ? ? ? ?WA? ? ? ? ? ?ƌƌŽƌďĂƌƐA?
S.E.M. 
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may be temporarily hindered by engineering. However, engineered ES cells without 
exogenous avidin at 1 x 106 cells/mL aggregated to form EBs of equivalent size to 
those with exogenous avidin (Fig 3.3B). Avidin concentration had no effect on 
control 2 EB diameters at either seeding density. No significant differences were 
observed between different control EBs cultured with and without avidin (Fig 3.3A 
and B). Avidin concentration also had no significant effect on engineered ES cell 
aggregation at low seeding density. However, at 1 x 106 cells/mL engineered EBs 
were significantly ȋ  ?  ?Ǥ ? ? ?Ȍ      ?  ? ? ?ȀmL, 
indicating a potential threshold concentration of avidin required to efficiently 
aggregate 1 x 106 cells/mL (Fig 3.3B). 
EB numbers were significantly ȋ  ?  ?Ǥ ? ? ?Ȍreduced at 5 x 104 cells/mL, concurrent 
with the idea of more ES cells available for aggregation more EBs can be formed (Fig 
3.3C). Significantly ȋ  ?  ?Ǥ ? ?Ȍmore control EBs were observed at both seeding 
densities. Avidin concentration had no significant effect on EB number in both 
engineered and control samples. However, there was a significant ȋ  ?  ?Ǥ ? ?Ȍ
decrease in engineered EB number at 1 x 106 cells/mL  ?
50µg/mL (Fig 3.3D). 
3.3.2. Rotation Speed 
Engineered and control ES cells were seeded at 5 x 104 and 1 x 106 cells/mL (Figs 
3.4A and B, respective) and either left stationary or rotated for 6hrs at 5 to 30rpm 
with increasing increments of 5. After 6hrs of rotation the suspensions were left 
stationary overnight and analyzed using PSS. Greater numbers of EBs were observed 
at 1 x 106 cells/mL over all rotation speeds investigated until speed reached 30rpm. 
At 30rpm individual EBs adhered to one another and resulted in mass agglomeration  
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Figure 3.4: Effect of rotation speed on ES cell aggregation. ES cells were seeded at 5 x 10
4
 cells/mL 
(A) and 1 x 10
6
 cells/mL (B) into mass suspension, rotated between 0 and 30rpm for 6hrs and 
incubated for 24hrs to establish EB formation. EB suspensions were washed with PBS and 
analyzed using PSS to calculate average EB number. Cultures rotated at 30rpm resulted in mass 
agglomeration of ES cells and EBs (C) and were therefore not analyzed by PSS. Images were taken 
of cultures seeded at 1 x 10
6
 cells/mL. Experiments were repeated in triplicate and each 
experiment consisted of 3 duplicate suspensions; n = 9. Error bars = S.E.M. 
Chapter 3                       Results: Aggregation Kinetics 
 
109 
(Fig 3.4C). Both engineered and control EBs appeared to follow the same trend over 
rotation speed. Suspensions rotated at 15rpm formed the greatest number of EBs  ? ? ? ?Ǥ1 x 106 cells/mL engineered ES cells formed significantly ȋ ? ?Ǥ ? ?Ȍ less EBs than control ES cells (Fig 3.4B).  
3.3.3. Mitomycin C Concentration 
A range of MMC concentrations from 0.001 to 0.1% were investigated and their 
effect on sustained ES cell culture assessed. Confluent ES cells were removed from 
feeder layers and treated with MMC solution for 2hrs prior to re-seeding. Increasing 
MMC concentration directly resulted in decreased ES cell viability (Fig 3.5J). At the 
lowest concentration of 0.001%, ES cells continued to proliferate and form colonies 
(Figs 3.5A and D). At the highest concentration of 0.1%, most ES cells had detached 
from the feeder layer and floated into a single cell suspension, indicative of cell death 
(Figs 3.5C and F). ES cells treated with 0.01% MMC solution neither proliferated nor 
detached from the feeder layer (Figs 3.5B and E). Figs 3.5G to I revealed remaining 
cells adhered to the feeder layer were viable. The green fluorescence in Fig 3.5I was 
possibly due to the underlying SNL feeder layer with only a few remaining viable ES 
cells. 
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Figure 3.5: Effect of MMC concentration on ES cell viability. ES cells were incubated at 37°C and 
5% CO2 in a humidified atmosphere with a range of MMC concentrations (0.001, 0.005, 0.01, 0.05 
and 0.1µg/mL) for 2hrs. Cell viability was assessed by metabolic activity via Alamar Blue assay (J). 
ES cells from duplicate cultures were passaged after MMC treatment onto fresh SNL feeder layers 
and cultured for up to 60hrs. Efficient mitotic inactivation was assessed by absence of colony 
formation (A to F). Viability of ES cells adhered to the feeder layer was also assessed by 
>ŝǀĞ ?ĞĂĚ ?ƐƚĂŝŶ ?'ƚŽ/ ? ? n =9. Error bars = S.E.M. 
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3.4. Results: Aggregation 
3.4.1. Embryoid Body Formation 
3.4.1.1. Aggregation Time 
Engineered and control ES cells were both seeded over a range of densities. Fig 3.6A 
shows images of ES cell suspensions seeded at 5 x 104 cells/mL. ES cells were seeded 
into suspension and rotated at 15rpm continuously for 12hrs. At 1hr both 
engineered and control samples appeared as single cell suspensions, and at 12hrs 
both had formed large EBs (Fig 3.6A). Engineered ES cells had aggregated to form 
initial EBs resembling loose clusters after just 4hrs of incubation which later 
appeared as tightly packed structures after 8hrs. Control ES cells began to show 
signs of aggregation after 8hrs and tightly packed structures resembling EBs after 
12hrs. 
3.4.1.2. Cell Morphology 
Engineered ES cells were seeded at 5 x 104 and 1 x 106 cells/mL and allowed to 
aggregate for 5 days in SCM. Resultant EBs were removed from suspension and 
processed for SEM imaging after 1, 3 and 5 days (Fig 3.6B). ES cells seeded at 5 x 104 
cells/mL after 1 day formed randomly orientated ES cell aggregates. These early 
aggregates resembled loose clusters of ES cells rather than tightly packed cell 
structures. They also exhibited a rough and uneven surface morphology. ES cell 
aggregates seeded at 1 x 106 cells/mL after 1 day appeared as tightly packed cell 
clusters exhibiting a smooth and uniform surface morphology. After 5 days of 
aggregation, ES cells at both seeding densities had formed tightly packed EBs similar 
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Figure 3.6: Effect of engineering on ES cell aggregation and EB formation. Engineered and control 
ES cells were seeded into mass suspension at 5 x 10
5
 cells/mL and continuously rotated for 12hrs. 
Brightfield images were taken of the suspensions every 4hrs (A). Scale bars in Fig A measure 
100µm. Engineered and control 1 ES cells were seeded into mass suspension at 5 x 10
4
 and 1 x 10
6
 
cells/mL, rotated at 15rpm for 6hrs and cultured for 5 days. EB surface morphology was analyzed 
by SEM after 1, 3 and 5 days aggregation (B). 
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in surface morphology. EBs at 1 x 106 cells/mL after 1 day of aggregation resembled 
EBs seeded at 5 x104 cells/mL after 5 days of aggregation. This indicated an 
acceleration of ES cell aggregation with increased seeding density. Minimal 
difference was observed between engineered and control samples, indicating that 
engineering merely accelerates EB formation rather than altering the mode of 
aggregation. 
3.4.2. Effect of Engineering on Embryonic Stem Cell Aggregation 
Fig 3.7 shows ES cell aggregation over 9 days of aggregation at 5 x 104 cells/mL and 1 
x 106 cells/mL. Engineered ES cells formed EBs with significantly ȋ ? ?Ǥ ? ? ?Ȍlarger 
diameter than control EBs at 5 x 104 cells/mL (Fig 3.7A). EBs continued to increase 
in diameter over time indicating cell proliferation and sustained aggregation. Control 
EBs at 5 x 104 cells/mL did not significantly increase in diameter over 9 days of 
culture. At 1 x 106 cells/mL the difference between engineered and control EB 
diameters was insignificant (Fig 3.7B). Consequently, the positive effect of 
engineering on ES cell aggregation was lost with increasing seeding density. Fig 3.7B 
depicted a significant ȋ  ?  ?Ǥ ? ? ?Ȍincrease in both engineered and control EB 
diameters at 1 x 106 cells/mL. Therefore, at 1 x 106 cells/mL engineered and control 
EBs exhibited continued ES cell proliferation and aggregation. 
3.4.3. Effect of Mitotic Inactivation on Embryoid Body Formation 
Engineered ES cells formed EBs of a significantly ȋ  ?  ?Ǥ ? ?Ȍ larger diameter than 
control ES cells at 5 x 104 cells/mL (Fig 3.8A). This was concurrent with findings in 
Fig 3.7 indicating mitotic inactivation did not detrimentally affect the ability of ES 
cells to be engineered. However, EB augmentation via engineering was not observed 
when ES cells were seeded at 1 x 106 cells/mL (Fig 3.8B). Both engineered and 
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Figure 3.7: Effect of engineering on ES cell aggregation and resultant EB diameter and number. 
Engineered and control ES cells were seeded into mass suspension at 5 x 10
4
 cells/mL (A and C) 
and 1 x 10
6
 cells/mL (B and D) in SCM with or without avidin supplementation of 10µg/mL. Cell 
suspensions were rotated ay 15rpm for 6hrs then cultured  for a period of 9 days at 37°C and 5% 
CO2 in a humidified atmosphere. Mean EB diameter (A and B) and number (C and D) were 
calculated after 1, 3, 5, 7 and 9 days of aggregation. Experiments were repeated in triplicate, and 
in each experiment all EBs within 3 representative areas were quantified. When calculating mean 
EB number, n = 3. When calculating mean EB diameter, n ranged from 9 to 19 (5 x10
4
 cells/mL) 
and 79 to 288 (1 x 10
6
 cells/mL).  ? ? ?WA䜀  ? ? ? ? ? ? ? ?WA? ? ? ? ? ? ?WA?0.05. Error bars = S.E.M. 
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Figure 3.8: Effect of engineering on MMC treated ES cell aggregation and resultant EBs. 
Engineered and control ES cells were treated with 0.01% MMC solution for 2hrs prior to seeding 
into mass suspension at 5 x 10
4
 cells/mL (A and C) and 1 x 10
6
 cells/ mL (B and D). ES cell 
suspensions were rotated at 15rpm for 6hrs prior to 9 days incubation at 37°C and 5% CO2 in a 
humidified atmosphere in SCM with or without avidin supplementation of 10µg/mL. Mean EB 
diameter (A and B) and number (C and D) were calculated after 1, 3, 5, 7 and 9 days aggregation. 
Experiments were repeated in triplicate. When calculating mean EB number, n = 3. When 
calculating mean EB diameter, n ranged from 11 to 32 (5 x 10
4
 cells/mL) and 68 to 181 (1 x 10
6
 
cells/mL).  ? ? ?WA䜀  ? ? ? ? ? ? ? ?WA䜀  ? ? ? ? ? ?WA?0.05. Error bars = S.E.M. 
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control EBs exhibited a significant ȋ  ?  ?Ǥ ? ? ?Ȍdecrease in diameter over 9 days of 
incubation. Engineered EBs maintained a significant ȋ  ?  ?Ǥ ? ? ?Ȍdifference in 
diameter to control EBs over the 9 days of culture. EB number increased significantly 
 ?WA? ? ? ? ? ? ?as their diameter decreased, at both 5 x 104 and 1 x 106 cells/mL (Figs 
3.8C and D). No significant difference in EB number between engineered and control 
EBs was observed. 
3.4.4. Effect of Engineering on Cell Populations 
3.4.4.1. Cells in Suspension 
Figs 3.9A and B show the number of cells in suspension over 9 days of culture in both 
engineered and control samples seeded at 5 x 104 cells/mL and 1 x 106 cells/mL, 
respectively. There was a significant ȋ  ?  ?Ǥ ? ? ?Ȍdecrease in the number of cells in 
suspension over the 9 day culture period at 5 x 104 cells/mL (Fig 3.9A). The number 
of cells in suspension at 1 x 106 cells/mL showed no significant change during 9 days 
of culture. The number of engineered cells in suspension was significantly ȋ  ?
0.001) less than the numbers of control cells at 5 x 104 cells/mL. However, the 
number of engineered cells in suspension showed no significant difference to the 
number of control cells in suspension after 5 days of culture (Fig 3.9A). There was no 
significant difference between the numbers of engineered and control cells in 
suspension over the 9 day culture period at 1 x 106 cells/mL (Fig 3.9B). 
3.4.4.2. Cells Constituting Embryoid Bodies 
At 5 x 104 cells/mL, the number of cells constituting engineered EBs was significantly ȋ  ?  ?Ǥ ? ? ?Ȍgreater than the number of cells constituting control EBs (Fig 3.9C). 
Therefore, engineered EBs consisted of more cells than control EBs indicating 
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Figure 3.9: Effect of engineering on cell populations during aggregation. ES cells were seeded into 
mass suspension at 5 x 10
4
 cells/mL (A and C) and 1 x 10
6
 cells/mL (B and D). Cell suspensions 
were rotated at 15rpm for 6hrs prior to 9 days in culture at 37°C and 5% CO2 in a humidified 
atmosphere. After 1, 3, 5, 7 and 9 days, suspensions were filtered through a 40µm sieve. Cell 
numbers washed through the sieve were quantified by Hoescht assay, representing the 
proportion of cells not constituting EBs (A and B). Duplicate samples were also analyzed after 1, 3, 
5, 7 and 9 days without prior filtering; cell numbers were quantified by Hoescht assay. Flow-
through cell numbers were subtracted from total suspension cell numbers to give constituent cell 
number within EBs (C and D). Experiments were performed in triplicate and each experiment 
consisted of 3 repeat measurements. n = 9.  ? ? ?WA?  ? ? ? ? ? ?  ? ?WA?  ? ? ? ? ?  ?WA? 0.05. Error bars = 
S.E.M. 
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enhanced cell- cell interaction and aggregation at 5 x 104 cells/mL. No significant 
difference was observed between the numbers of engineered and control cells in 
samples seeded at 1 x 106 cells/mL (Fig 3.9D). The number of cells in suspension in 
both engineered and control samples at 5 x 104 and 1 x 106 cells/mL significantly (P  ? ?Ǥ ? ? ?Ȍdecreased between 1 and 9 days of culture. 
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3.5. Discussion 
Ever since ES cells and their pluripotency were first discovered researchers have 
endeavoured to control their differentiation using a plethora of in vitro methodology. 
However, directed differentiation remains highly inefficient with the formation of 
contaminating cell types resulting in heterogeneous populations. A general 
consensus between studies is the use of EB formation for ES cell differentiation 
(Hamazaki et al., 2004). An EB comprises ES cells which adhere to one another to 
form a 3D cluster. ES cells then produce ECM which stabilizes and cements the 3D 
structure. Close proximity between ES cells causes differentiation, along with 
exogenously added growth factors (Mohr et al., 2006). However, there is currently a 
distinct lack of standardisation for EB formation (Kurosawa, 2007). It has been 
repeatedly documented that methodology used to produce EBs has a direct effect on 
ES cell differentiation and consequently on their potential clinical application (Fig 
1.4) (Rathjen et al., 1998). This lack of standardisation and consequent variability in 
ES cell differentiation makes comparison between studies immensely difficult. Here 
is proposed a simple, repeatable and reliable chemical process involving cell surface 
engineering and intercellular cross-linking, for the efficient production of EBs using 
the mass suspension method (De Bank et al., 2007, De Bank et al., 2003). 
3.5.1. Investigation of Critical Factors 
Prior to investigating the effect of chemical modification on ES cell aggregation and 
EB formation in mass suspension, certain variables were analysis tested. These 
variables included avidin concentration, rotation speed and MMC concentration. 
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3.5.1.1. Avidin Concentration and Embryoid Body Formation 
ES cells were incubated with avidin-FITC conjugate to investigate avidin 
incorporation (Fig 3.2). Avidin was incorporated within the EB structure. However, 
fluorescence was speckled within engineered EBs and uniform within control EBs. 
Speckled fluorescence was most likely the result of accumulated avidin-FITC 
conjugate specifically located at ES cell-ES cell cross-links within the engineered EB 
structure. Alternatively, speckling could simply have been due to cell dense regions 
(Fig 3.2A). The uniform fluorescence observed in control EB samples was indicative 
of non-specific binding of avidin and/or physical entrapment between ES cells and 
ECM (Fig 3.2B). Similar observations were made after 48hrs incubation between 
engineered and control samples (Figs 3.2C and D, respectively). Fluorescence was 
still observed showing persistence of avidin-FitC within the EB. 
To investigate the effect of avidin on ES cell aggregation, engineered and control ES 
cells were incubated with varying concentrations ranging from 0 to 80µg/mL (Fig 
3.3). Control ES cells incubated with and without avidin formed EBs of equal 
diameter, at 5 x 104 and 1 x 106 cells/mL (Figs 3.3A and B). Increasing the 
concentration of exogenous avidin therefore had no significant effect on control EB 
diameter, indicating non-specific binding of avidin. Engineered ES cells formed 
significantly ȋ  ?  ?Ǥ ? ? ?Ȍlarger EBs than control samples at 5 x 104 cells/mL, but 
showed no significant difference over avidin concentration (Fig 3.3A). This shows 
the importance of engineering, since large EBs can be produced with minimal levels 
of exogenous avidin. However, without avidin engineered ES cells formed 
significantly ȋ  ?  ?Ǥ ? ? ?Ȍsmaller EBs than control samples. Engineering may 
therefore have had a negative or inhibitory effect on natural ES cell adhesion. If so, 
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engineering provides precise control over EB formation as ES cell-ES cell interaction 
can only occur upon addition of exogenous avidin.  
At 1 x 106 cells/mL, engineered ES cells formed EBs of equal diameter whether 
incubated with or without exogenous avidin (Fig 3.3B). The fact that engineered ES 
cells formed EBs without exogenous avidin demonstrated that they could still 
aggregate through natural adhesion. High ES cell density increased the occurrence of 
ES cell-ES cell collisions and subsequent interactions within the given suspension 
volume generating EBs of equivalent diameter to those incubated with avidin. 
Engineered EBs significantly ȋ  ?  ?Ǥ ? ? ?Ȍincreased in diameter when avidin   ?  ? ? ?ȀmL (Fig 3.3B). At this concentration there may have 
been a sufficient amount of avidin in ratio to engineered ES cells to cause measurable 
enhancement of ES cell-ES cell interaction and adhesion. Alternatively, the high 
concentration of avidin may have enabled or enhanced EB agglomeration. EB 
agglomeration is discussed later, but the increase in EB diameter correlated with a 
significant ȋ  ?  ?Ǥ ? ? ?Ȍdecrease in EB number at 1 x 106 cells/mL (Fig 3.3D). The 
same increase in EB diameter and decrease in EB number was not observed at 5 x 
104 cells/mL (Figs 3.3A and C). 10µg/mL avidin was chosen as the ideal working 
concentration for all subsequent experiments. 
3.5.1.2. Rotation Speed and Embryoid Body Formation 
The second variable which required analysis was rotation speed. To investigate the 
effect of rotation on ES cell aggregation, a range of speeds were investigated in 
comparison to stationary culture. Suspensions rotated at 15rpm generated the most  ? ? ? ?ȋ	 ?Ǥ ?ȌǤ5 x 104 cells/mL engineered ES cell 
suspensions rotated at 15rpm generated more EBs than control ES cell suspensions. 
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 ? ? ?-ES cell interaction 
and EB formation. Above 15rpm rotation became too vigorous and disrupted ES cell-
ES cell interactions. Also, increased kinetic energy could have caused inter-EB 
collisions resulting in EB fragmentation into < 40µm diameter ES cell clusters. 
However, this seems unlikely since increasing the rotation speed to 30rpm generated 
EBs which had mass agglomerated in both engineered and control samples (Fig 
3.4C). 
There was a significant ȋ  ?  ?Ǥ ? ? ?Ȍdecrease in both engineered and control EBs 
formed in stationary cultures. However, EBs still formed demonstrating that rotation 
was not essential to, but enhanced EB formation. Engineered EBs showed no 
significant difference in diameter to control EBs without rotation. It is difficult to say 
whether EBs in stationary culture resulted from ES cell aggregation alone or simply 
proliferation and adhesion between daughter cells. 15rpm was chosen as the 
optimum rotation speed for all subsequent experiments. 
3.5.1.3. Mitomycin C Concentration and Embryonic Stem Cell Viability 
A third variable that required analysis was MMC concentration. A series of 
concentrations were investigated ranging from 0.001 to 0.1%. After 60mins 
incubation in Alamar Blue solution, ES cell metabolic activity was found to decrease 
with increasing MMC concentration (Fig 3.5J). However, ES cells remained viable, so 
prolonged culture after MMC treatment was investigated. After 60hrs incubation ES 
cells had proliferated to form distinct colonies, showing that ES cells were not 
mitotically inactivated after treatment with 0.001% MMC (Fig 3.5D). ES cells treated 
with 0.1% MMC solution did not form colonies due to cytotoxic effects and cell death. 
Few ES cells remained adhered to the feeder layer as many had dissociated and 
Chapter 3                       Results: Aggregation Kinetics 
 
123 
floated into suspension (Fig 3.5F). ES cells treated with 0.01% MMC were viable and 
mitotically inactivated, as indicated by attached ES cells but absence of colony 
formation (Fig 3.5E). 
3.5.2. Embryonic Stem Cell Aggregation 
3.5.2.1. Embryoid Body Formation 
To investigate EB formation the first step was to assess rotation time required to 
initiate ES cell aggregation (Fig 3.6). Evidently, engineered ES cells formed 
aggregates after only 4hrs, demonstrating accelerated aggregation (Fig 3.6A). 
Control ES cells formed aggregates after 8hrs incubation, taking up to twice as long. 
After 12hrs incubation both engineered and control aggregates appeared to have 
formed dense, compacted EB structures. This may be the result of simple 
restructuring and/or constituent ES cell proliferation. Consequently, initial rotation 
phase was defined as 6hrs. 
Aggregation occurs through the random collisions of ES cells in suspension which 
result in ES cell-ES cell interaction and adhesion. These collisions produce small 
loosely packed clusters of ES cells, which initially exhibited a rough surface 
morphology and uneven structure after 1 day at 5 x 104 cells/mL (Fig 3.6B) (Song et 
al., 2003). After 5 days, aggregation had progressed and tightly packed EB structures 
emerged exhibiting a smoother surface morphology and an organized spherical 
composition. It appeared that ES cells at 5 x 104 cells/mL aggregated rapidly and 
formed randomly oriented branched structures. These structures reorganized after 5 
days into a less chaotic spherical orientation, possibly through compaction. The 
smooth surface morphology could be the effect of strained adhesion between surface 
ES cells. Surface ES cells encase central ES cells which continually proliferate 
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increasing the size of the core exponentially compared to the surface. This would 
have the effect of stretching the surface making it appear smooth. Alternatively, the 
smooth morphology was the result of spontaneous differentiation of surface ES cells. 
Surface cell morphology resembled cells of the primitive endoderm, found to occur 
in other studies (Fok and Zandstra, 2005). 
EBs at 1 x 106 cells/mL exhibited a spherical composition and smooth surface 
morphology after just 1 day (Fig 3.6B). This may have been due to the elevated 
number of ES cells in suspension which increased the chance of ES cell-ES cell 
collisions, enabling accelerated EB formation. Similarity between engineered and 
control 1 samples merely indicated that engineered ES cells aggregated in an 
accelerated fashion, rather than a different mode of aggregation. However, 
engineered EBs did show signs of advanced compaction after 3 days at 5 x104 
cells/mL compared to control 1 EBs (Fig 3.6B). It is therefore possible that analysis 
or surface morphology over shorter time intervals may help resolve differences 
between engineered and control EBs. Similar results were observed in control 2 
samples (data not shown). 
3.5.2.2. Engineered Embryonic Stem Cell Aggregation 
Engineered ES cells formed EBs of a s ȋ  ? 0.001) larger diameter than 
control EBs at 5 x 104 cells/mL (Fig 3.7A). Engineered EBs continued to increase in 
diameter over time demonstrating that enhancement was not lost even though 
natural membrane renewal would have been active (Mahmutefendic et al., 2007, De 
Bank et al., 2007). This is to be expected as membrane recycling would not be able to 
break the avidin/biotin bond and internalize the modified sugar residues. However, 
enhancement was not observed at 1 x 106 cells/mL where engineered EBs were not 
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significantly larger than control EBs (Fig 3.7B). This could be due to the increased 
number of ES cells within the same volume. More ES cells would mean two things, 
increased chance of ES cell-ES cell collisions, and a reduced ratio of avidin to 
engineered ES cells. Therefore, limited avidin would reduce the size of engineered 
EBs, and increased collisions would enhance the size of control EBs. Also, engineered 
EBs may have been reduced in size due to inter-EB collisions and EB fragmentation 
before ES cell clumps had time to restructure and exhibit a stable spherical 
conformation (Sachlos and Auguste, 2008, Carpenedo et al., 2007).  
Both engineered and control EBs increased in diameter over time at 1 x 106 cells/mL 
but not at 5 x 104 cells/mL. At 1 x 106 cells/mL more ES cells were available for 
aggregation which resulted in increased ES cell-ES cell collisions and interactions, 
adhesion and resultant EB growth. The increase in EB diameter over time indicated 
that the population of single ES cells in suspension at 1 x 106 cells/mL were 
inexhaustible. At 5 x 104 cells/mL, aggregation may have exhausted the limited 
number of available ES cells within 1 day, after which further aggregation became 
restricted or ceased. The lack of significant increase in diameter over time in control 
EBs indicated that ES cell proliferation contributed minimally to EB growth; 
constituent ES cells were actively proliferating but the EB was not significantly 
increasing in diameter. 
There were no significant differences between the numbers of engineered and 
control EBs at 5 x 104 and 1 x 106 cells/mL (Figs 3.7C and D). This was concurrent 
with engineered and control EBs being of similar diameter at 1 x 106 cells/mL. 
However, at 5 x 104 cells/mL engine    ȋ  ? 0.001) larger 
than control EBs (Fig 3.7A). If available ES cells in suspension were exhausted after 
24hrs and the numbers of EBs were similar between samples, then logically, 
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engineered EBs should have been of similar diameter to control EBs. Engineered EBs 
may be larger in diameter due to internal structure and orientation of constituent ES 
cells (Karbanova and Morkry, 2002). Alternatively, the set number of ES cells within 
control samples generated a population of ES cell clusters with diameters measuring 
< 40µm. The number of ES cells tied up in these clusters may have accounted for the 
difference between engineered and control EB diameters and numbers. The number 
of EBs did not increase over time at 5 x 104 cells/mL, indicating there was no 
generation of new EBs. The hypothetical ES cell clusters with diameter < 40µm 
should have increased the number of control EBs over time as they themselves grew. 
However, as described earlier, proliferation rate of constituent ES cells over 9 days 
was insufficient to significantly increase EB diameter. Therefore, these clusters were 
still below the measurable diameter threshold of 40µm. ES clusters were not 
regarded as EBs due to a diameter < 40µm. Aggregates of ES cells have previously 
been identified as EBs when nucleated and cell dense (observed to occur in EBs with  ? ? ?µm) (Bauwens et al., 2008, Zandstra et al., 1994, Chen et al., 2008). 
In fact, the number of engineered and control EBs at 5 x 104 and 1 x 106 cells/mL 
significantly (P  ? 0.001) decreased over time (Figs 3.7C and D). A decrease in EB 
number can mean one of two things; EB fragmentation, which is unlikely since EBs 
increased in diameter, or EB agglomeration (Fig 3.10). EB agglomeration occurs 
when two individual EBs come into close proximity through chance collisions and 
interact. As with single ES cell-ES cell interactions, EB-EB interactions result in 
temporary adhesion. As constituent ES cells migrate and re-structure the two EBs 
begin to merge together (Carpenedo et al., 2007). Over time the two EBs become one 
larger EB via cohesion. EB agglomeration therefore raised problems concerning 
investigation of individual EB development. Growth of individual EBs was masked by 
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Figure 3.10: Inter-EB collision, cohesion and eventual agglomeration in mass suspension. 
Individual EBs free floating in mass suspension randomly collide with adjacent EBs resulting in 
inter-EB adhesion. Adhered EBs slowly reorganize during further cell proliferation and aggregation 
exhibiting a merged appearance. Eventually the two individual EBs are no longer distinguishable 
and exhibit a smooth spherical individual EB morphology. EB agglomeration results in decreased 
EB numbers and increased EB diameters. 
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EB cohesion interactions, and inter-EB signalling interfered with differentiation of ES 
cells within individual EBs. Studies have emerged described EB formation 
specifically targeted at minimizing EB agglomeration such as physical separation of 
EBs in separate compartments (Karp et al., 2007, Burridge et al., 2007, Moeller et al., 
2008). However, EB agglomeration required a high number of EBs to have a 
significant effect on EB diameter and number measurements. Also, EB agglomeration 
was only observed when ES cell suspensions were rotated at 30rpm, and 
suspensions in Fig 3.7 were rotated at 15rpm. Since suspensions were stationary 
after the first 6hrs, it is unlikely that resultant EBs had sufficient kinetic energy to 
move around compared to rotated suspensions. Therefore, the observed decrease in 
EB number appeared to have been the result of fragmentation or dissociation due to 
cell death. The fact that EB diameter continued to increase even though EB number 
decreased was probably due to the fact that EB fragments or dissociated EBs were 
amalgamated into surviving EBs. Alternatively, the residual EB components were 
themselves < 40µm in diameter and thus not included within measurements, 
maintaining the average diameter. Consequently, this would leave measurements of 
thriving EBs unaffected. The increase also indicated that the population of single ES 
cells in suspension were not exhausted after 24hrs. Engineered EBs increased in size 
due to enhanced aggregation at 5 x 104 cells/mL (Fig 3.7A). Control EBs may have 
increased in size, but not at a measurable rate over the aggregation time period 
investigated, at 5 x 104 cells/mL. The increase in EB diameter at 1 x 106 cells/mL 
would therefore be an outcome of increased ES cell-ES cell interactions. 
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3.5.2.3. Aggregation of Mitotically Inactivated Embryonic Stem Cells 
EB formation is the consequence of chance collisions between ES cells in suspension 
and resultant aggregation. However, EB growth is the result of continued ES cell 
aggregation and constituent ES cell proliferation. To investigate EB formation and 
growth as a direct result of ES cell aggregation, ES cell proliferation was removed. ES 
cells were mitotically inactivated with 0.01% MMC prior to engineering. Engineered    ȋ  ? 0.05) larger in diameter than control EBs at 5 x 104 
cells/mL (Fig 3.8A). Since ES cells were non-proliferative this showed that ES cell 
proliferation played a minor role, if any, in EB growth. At 1 x 106 cells/mL 
enhancement was no longer observed. This was most likely due to the same reasons 
stated previously for aggregation of proliferating ES cells; avidin became a limiting 
factor as ES cell number increased and increased chance collisions accelerated 
control EB formation. 
Evidently, engineered aggregation was not detrimentally affected by mitotic 
inactivation. However, EBs significantly ȋ ? 0.001) decreased in diameter over time 
in both engineered and control suspensions despite change in seeding density (Figs 
3.8A and B). Mitotically inactivated ES cells have a shorter lifespan than proliferating 
ES cells, accelerating constituent ES cell death. Consequently, dead ES cells would 
have separated causing the EB diameter to become diminished. Engineering simply 
provided a stronger interaction between ES cells than natural adhesion which only 
slowed observed EB dissociation.  
Proliferation may not have contributed largely to EB growth but it appears that it 
had a major role to play in EB stability. Upon ES cell-ES cell collision a temporary 
bond is formed. This temporary bond becomes long term adhesion upon ECM 
production and deposition. Mitotically inactivated ES cells produce reduced amounts 
Chapter 3                       Results: Aggregation Kinetics 
 
130 
of ECM (Occleston et al., 1997). Therefore, the lack of ECM required to bind ES cells 
together long term could explain the observed decrease in EB diameter (Figs 3.8A 
and B). The number of EBs in s  ȋ  ? 0.001) increased over 
time at 5 x 104 and 1 x 106 cells/mL. This increase correlated with the observed 
decrease in EB diameter (Figs 3.8C and D). However, dissociation due to cell death 
would cause diminished EB diameter and an increase of single cells in suspension, 
not an increase in EB number. The most likely cause of increased EB number was 
fragmentation. EBs would have been structurally weak due to mitotic inactivation. 
This instability on top of cell death would have made EBs become easily fragmented 
as a result of any significant movement applied to the suspension, such as when 
cultures were measured. There was no significant difference between EB numbers in 
engineered and control samples regardless of seeding density. Once membrane 
recycling removed the surface modification, engineered EBs would have been 
expected to dissociate completely. However, engineered EB number remained 
equivalent to control samples, possibly indicating some degree of natural adhesion. 
Similar trends were observed during aggregation of proliferative ES cells. This 
illustrated that engineering is possibly a temporary step for the formation of EBs and 
not persistent during their growth. 
3.5.2.4. Cell Number and Embryoid Body Formation 
As previously mentioned EBs increase in diameter largely due to the aggregation of 
additional ES cells during growth (Cormier et al., 2006). Therefore, as both 
engineered and control EBs increased in diameter over time it would be expected 
that constituent cell number increased as a function of cell aggregation and 
proliferation (Figs 3.7A and B). However, the number of cells within both engineered 
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and control EBs significantly ȋ ? ?Ǥ ? ? ?) decreased over time at 5 x 104 and 1 x 106 
cells/mL (Figs 3.9C and D). The decreased constituent cell number was most likely 
the result of natural cell death in combination with core necrosis (Wartenberg et al., 
1998, Carpenedo et al., 2007, Boyd et al., 1984, Conley et al., 2005, Kurosawa, 2007), 
discussed in Chapter 4. Increase in EB diameter was therefore not simply the result 
of ES cell aggregation. 3D conformation of constituent cells may also have had a 
direct effect on EB diameter. Initial aggregation of ES cells formed loosely packed 
clusters which later reorganized to form compact EBs (Enmon et al., 2001). It was 
possible that restructuring did not involve compaction. Cell aggregation caused cell-
cell adhesion in a random spatial orientation and cell proliferation may have filled in 
the gaps. This would explain why cell proliferation has minimal effect on EB growth, 
since gap filling would not increase overall EB diameter. Even though constituent cell 
number decreased, remaining cells within the EB maintained 3D structure. 
Continuous aggregation of additional cells increased the diameter. Alternatively, 
ECM production and deposition from constituent cells would have acted to fill in the 
gaps. Therefore EB diameter becomes a function of cell aggregation, proliferation 
and ECM production. ECM deposition would maintain existing EB diameter whilst 
aggregation of additional cells would increase the diameter. The decrease in 
constituent cell number could have been the result of internal cells becoming 
trapped within ECM. Trapped ES cells may have undergone apoptosis or necrosis, 
either of which would cause a decrease in constituent cell number (Abe et al., 1996). 
The decrease in constituent cell number appeared to occur more rapidly at 1 x 106 
cells/mL (Fig 3.9D). This would be concurrent with the hypothesized aggregation 
system described above. A greater number of cells in suspension available for 
aggregation would have caused an increase in the number of cells within EBs 
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becoming trapped in deposited ECM. Therefore, more cells would become necrotic 
and decrease the overall constituent cell number (Kurosawa, 2007). 
At 5 x 104 cells/mL the number of constituent cells within engineered EBs was 
significantly ȋ  ? 0.001) greater than control EBs (Fig 3.9C). This showed that the 
diameter was directly related to the number of constituent cells. Engineering 
enhanced aggregation between ES cells and increased EB size without affecting EB 
number (Fig 3.7C). The difference in number of constituent cells within engineered 
and control EBs was insignificant at 1 x 106 cells/mL (Fig 3.9D). This was expected 
since there was also no significant difference in EB diameter (Fig 3.7D). 
EB formation and growth depends on the availability of additional cells in 
surrounding suspension. As aggregation progresses, the set number of available cells 
seeded into suspension would be expected to decrease. At 5 x 104 cells/mL the 
number of single cells in suspension gradually decreased over time supporting this 
idea. However, cells were continuously proliferating and increasing available 
numbers. The fact that the number still decreased showed that aggregation rate 
outweighed proliferation rate. At 1 x 106 cells/mL the number of single cells in 
suspension showed no significant change over time even though aggregation 
continued. It was possible that at 1 x 106 cells/mL proliferation rate exceeded 
aggregation rate and thus provided an inexhaustible supply of additional cells. 
Alternatively, the high number of cells in suspension could have been due to the 
hypothesized cell death and diminishing EB number observed at 1 x 106 cells/mL. 
Also, the higher the proportion of cells per given volume, the faster the nutrient 
supply is utilized. Consequently, cells may have died rapidly from starvation 
maintaining a high single cell population in suspension. However, trypan blue stains 
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revealed that the majority of cells were still alive. A minority had taken up the stain, 
thus cell death played a minor role in the population of single cells in suspension.  
A possible explanation for the lack of a significant change in suspended cell number 
was that the data collected did not represent the true single cell population. EB 
suspensions were washed through a < 40µm sieve and a Hoescht assay quantified 
the DNA content of flow-through cells. Initial ES cell clusters and true individual ES 
cells were not distinguishable using this technique. Ultimately, true single ES cells in 
suspension may have decreased in number over time due to aggregation. Most cells 
at 1 x 106 cells/mL would have formed EBs due to increased chance collisions. 
However, many cells would have collided with adjacent cells to form small cell 
clusters with a < 40µm diameter. Some cell clusters would have continued to 
accumulate additional cells and eventually form EBs (Kim et al., 2007b, Come et al., 
2008, Cormier et al., 2006).  EBs would also have grown through amalgamation of 
adjacent cell clusters. Remaining cells clusters that had escaped amalgamation would 
have slowly increased in diameter mainly due to cell proliferation since single cell 
availability for aggregation would have been limited. Since the contribution of cell 
proliferation to EB diameter was insignificant over the time period investigated, cell 
clusters may have remained < 40µm in diameter adding to the true population of 
single cells. 
The number of engineered cells in suspension was significantly ȋ ? ?Ǥ ? ? ?) less than 
control samples for the first 5 days of aggregation at 5 x 104 cells/mL (Fig 3.9A). This 
was concurrent with engineered EBs being significantly ȋ  ?  ?Ǥ ? ? ?) larger than 
control EBs (Fig 3.7A). Larger EBs required more ES cells to form causing the 
observed decrease in overall ES cell number in suspension. However, by day 7 
engineered samples contained a similar number of single cells in suspension to 
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control samples. Initially, engineered aggregation enhanced ES cell-ES cell 
interaction and adhesion which rapidly decreased available cells in suspension. 
However, the surface modification was removed over time and further aggregation 
slowed to the same rate of control samples. It was possible that control aggregation 
took 7 days to accumulate as many single cells from suspension as what engineered 
aggregation accumulated in only 5 days. At 1 x 106 cells/mL the difference between 
engineered and control samples was insignificant (Fig 3.9B). This was simply 
because at 1 x 106 cells/mL engineered cells did not exhibit enhanced aggregation. 
Therefore, the number of cells from single cell populations in suspension which 
aggregated to form EBs was the same in both engineered and control samples. 
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3.6. Conclusions 
In summary, engineering provided influence over ES cell-ES cell interaction, 
adhesion and subsequent EB formation. Engineered EBs were both significantly ȋ ?
0.001) larger and more stable than control EBs. Interestingly, enhancement due to 
engineering was only observed at 5 x 104 cells/mL. EB number reflected the average 
diameter of both engineered and control EBs, such that EB number decreased as EB 
diameter increased. Consequently, the relationship illustrated that ES cell 
aggregation may not have been responsible for initial ES cell clusters, but continued 
EB growth and development was dependent to an extent on cluster-cluster 
interactions. Engineered EBs were composed of a significantly ȋ  ?  ?Ǥ ? ? ?) higher 
number of cells than control EBs showing cell number was directly related to EB 
diameter. However, over time constituent cell number decreased whilst diameter 
increased or remained unchanged. Structural arrangement of constituent cells 
therefore played a major role in determining EB diameter, able to counter potential 
detrimental effects of decreasing cell number as a result of apoptosis/necrosis. EB 
formation was found to be a complex relationship between ES cell aggregation, 
proliferation, death, cluster agglomeration, and ECM deposition. 
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Chapter 4  
4. Results 
Embryoid Body Characterization 
4.1. Introduction 
For many years ES cells have been cultured via EB formation to induce and 
sometimes control differentiation (Itskovitz-Eldor et al., 2000, Bratt-Leal et al., 2009, 
Mansergh et al., 2009). Numerous aggregation methods have generated a variety of 
results with previous studies having repeatedly documented a direct relationship 
between EB formation method and resultant ES cell differentiation (Mogi et al., 2009, 
Dang et al., 2004, Chen et al., 2008). For example, EBs formed individually in 
separate wells with and without centrifugation have exhibited enhanced 
cardiomyogenesis (Burridge et al., 2007, Kurosawa, 2007). Alternatively, EBs formed 
through 3D hydrogel culture have exhibited enhanced chondrogenesis, adipogenesis 
and osteogenesis (Kanczler and Oreffo, 2008, Hwang et al., 2008a, Rohani et al., 
2008, Hillel et al., 2009). EBs formed by hanging drop have exhibited enhanced 
neurogenesis (Kuo et al., 2003), hepatogenesis (Takashimizu et al., 2009) and 
vasculogenesis (Kim et al., 2008) (Table 1.4). 
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This high degree of variability impedes our understanding of how the EB confers 
control and influence over ES cell differentiation. Due to a lack of standardization fro 
EB formation, inherent mechanisms during ES cell aggregation and resultant EB 
characteristics which affect differentiation are difficult to decipher and remain 
convoluted. One possible solution would be to standardize aggregation methodology. 
An ideal standardized method should provide control over aspects of EB formation 
known to affect ES cell differentiation, such as size, number, growth, morphology and 
density. However, we first need to understand how and why these particular 
parameters of EB formation cause differentiation towards specific cell types. 
Chapter 3 has described a novel aggregation method for EB formation. Here is shown 
a detailed characterization of resultant engineered EBs in comparison to control EBs, 
identifying key aspects of the EB affected by aggregation method and affecting 
differentiation. 
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4.2. Methods and Materials 
4.2.1. Embryoid Body Cell Density 
At each time point EB sections were processed through haematoxylin and eosin stain 
described in Chapter 2. Cross sections were photographed at 10x magnification using 
the Nikon Eclipse TS100 and attached Nikon Digital Sight DS-L1 imaging system. 
50µm by 50µm squares were positioned on top of EB cross-section images in similar 
locations (Fig 4.1). Three squares were positioned over the centre and three more 
around the surface. Squares were positioned at equal distances from one another 
where possible. ES cell nuclei within each square were counted and an average 
taken. As with haemocytometer based counts, only ES cell nuclei lying within the 
squares or those overlapping two of the four sides were included in the count. This is 
because two of the sides would constitute a side of an adjacent square. Since square 
measurements were 50µm width, 50µm depth and 4µm height, the number of ES cell 
nuclei counted were in a total volume of 10,000µm3. EB cross-section images showed 
a clear structural difference between the surface and the core. As a result, two 
separate sets of squares were used to evaluate ES cell density within the EB core and 
at the EB surface. Three individual EB cross-section images were used to calculate an 
average core and surface ES cell density measurement. 
4.2.2. Embryoid Body Necrosis 
At each time point during the 9 day period of aggregation, duplicate EB samples were 
removed from culture and washed through a 40µm cell strainer. Single ES cells and 
ES cell clusters were rinsed through the cell strainer with 5mL room temperature 
PBS. Flow through was collected in a 50mL Falcon tube and discarded. EBs were 
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Figure 4.1: Measuring cell density using EB cross-sections. EB cross-sections were treated with 
H&E stain to highlight cell nuclei. Squares measuring 50µm by 50µm were positioned 
equidistantly (where possible) on the stained cross-sections. Three squares were positioned at the 
surface and three more at the core. Individual cell nuclei within each square were counted and an 
average calculated representing cell density and the surface and core. Cell densities were taken 
from 3 separate EBs per sample. 
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carefully washed from the filter into a Falcon tube with PBS and centrifuged briefly 
at 1000rpm to pellet the EBs. PBS was subsequently aspirated and the pellet 
suspended in 2mL trypsin/EDTA. The suspension was pipetted carefully to 
dissociate intact EBs. 3mL SCM was added to inactivate the trypsin/EDTA and the 
suspension centrifuged at 1000rpm for 5mins. Supernatant was aspirated and the    Ȁ ?   Ǥ    
incubated for 30-60mins at 37°C and 5% CO2 in a humidified atmosphere. After 
incubation, suspensions were centrifuged and washed twice with PBS to remove the Ȁ ?Ǥ  ?mL PBS and a 10µl aliquot 
loaded onto an improved neubauer hemocytometer. A cell count was taken under 
fluorescence ȋ  Ȁ ?   hapter 2). All ES cells were counted 
under brightfield imaging. ES cells which fluoresced red were subsequently counted. 
All cells within 5 squares were counted and an average was calculated. Few ES cells 
were visible at 5 x 104 cells/mL. Therefore, all ES cells lying within the 25 square-
grid were counted. The number of ES cells which fluoresced red was calculated as a 
percentage of the whole EB suspension using the whole ES cell counts. 
Isolation of EBs without ES cell clusters and single ES cells was achieved by cell 
straining. This allowed analysis of EBs alone. Trypsinisation time was similar for all 
samples at a maximum of 5mins. Green fluorescence highlighted ES cells which were 
alive and thriving. Red fluorescence highlighted ES cells that were dead or necrotic. 
Tracking the number of dead ES cells within EBs allowed analysis of core necrosis 
within the EB structure over time. 
Chapter 4                         Results: EB Characterization 
 
141 
 
4.3. Results 
4.3.1. Embryoid Body Structure and Viability 
4.3.1.1. Internal Structure 
Both engineered and control EBs appeared to exhibit a layered internal structure 
(Fig 4.2). On closer analysis four different layers could be distinguished, each 
representing hypothetical stages of ES cell aggregation and EB formation. From the 
outermost layer towards the core the four distinguishable layers have been labelled 
as surface, outer and inner shells, and core. A distinct difference in ES cell density 
could be seen between the surface and the core. ES cells were less densely packed at 
the core than those near the surface due to the reduced number of cell nuclei 
observed in Fig 4.2C. This observation was conserved at both 5 x 104 and 1 x 106 
cells/mL. The core was sparsely populated with ES cell nuclei spaced apart 
randomly. The surface also appeared to consist of disorganised ES cell nuclei, but at a 
higher density. The inner and outer shells appeared to be transition stages between 
the surface and the core. The outer layer resembled a condensed version of surface 
ES cell nuclei. The inner shell resembled a dense version of core ES cell nuclei. The 
relative thickness of each layer appeared to decrease from the inner shell to the 
surface. 
4.3.1.2. Cell Viability 
The core and surface of EBs exhibited both red and green fluorescence respectively, 
indicating that cells within the EB core were dead or necrotic, and cells on the EB 
surface were alive and thriving. Similar observations were made in both
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Figure 4.2: EB structure and constituent cell viability. Engineered and control 1 ES cells were 
seeded at 1 x 10
6
 cells/mL into mass suspension, rotated at 15rpm for 6hrs prior to 9 days 
incubation at 37°C and 5% CO2 in a humidified atmosphere. After 9 days, cell viability within 
engineered (A) and control 1 (B) EBs was assessed by >ŝǀĞ ?ĞĂĚ ?assay. EBs were taken from 
duplicate samples after 9 days of aggregation and prepared for microtome-sectioning. EB cross-
sections were then stained with H&E. Fig C shows an H&E stained cross-section of an engineered 
EB and a diagrammatic representation of its structure. Cell nuclei within the core appeared 
swollen and enlarged indicating necrosis, rather than apoptosis where cell nuclei effectively 
shrink. Also, core cells did not show typical characteristics of apoptosis such as membrane 
blebbing. 
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engineered and control samples at 5 x 104 and 1 x 106 cells/mL (Figs 4.2A and B). 
Only EBs aggregated and cultured for 9 days were sampled due to structural 
instability of earlier stage EBs during repeat PBS washing to remove excess Ȁ ? stain. 
4.3.2. Embryoid Body Density and Necrosis 
4.3.2.1. Cell Density 
Engineered EBs appeared to exhibit dense populations of cells at both the surface 
and core (Figs 4.3A and B). Surface and core cell densities within engineered EBs 
were significantly ȋ  ?  ?Ǥ ? ?Ȍ greater than those in corresponding control EBs. Cell 
density showed minimal change over increasing seeding density in engineered and 
control EBs within the surface layer and the core (Fig 4.3). Both engineered and 
control EBs exhibited significantly ȋ  ?  ?Ǥ ? ?Ȍ denser cell populations within their 
surface layer in comparison to their core layer (Figs 4.3C and D). Surface to core cell 
density data for control 2 EB samples is not shown in Fig 4.3. However, results were 
not significantly different to those of control 1 EB samples (Fig 4.3D). 
4.3.2.2. Cell Death 
High seeding density of 1 x 106 cells/mL was reduced to 2.5 x 105 cells/mL for all 
subsequent experiments because 2.5 x 105 cells/mL was the maximum seeding 
density investigated that did not show measurable EB agglomeration (data not 
shown). EB agglomeration increases EB diameter and decreases constituent cell 
viability. The average proportion of dead cells within all EBs was not significantly 
different between engineered and control samples (Fig 4.4). There was no significant 
difference over seeding density from 5 x 104 cells/mL (Fig 4.4A) to 2.5 x 105 cells/mL 
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Figure 4.3: Effect of engineering on cell density within EBs. Engineered and control ES cells were 
seeded into mass suspension over a range of densities ranging 50, 100, 250, 500, 750 and 1000 x 
10
3
 cells/mL. Suspensions were rotated at 15rpm for 6hrs then cultured under stationary 
conditions for 9 days. After 9 days, EBs were fixed, sectioned and H&E stained. Labelled nuclei 
were counted and used to calculate representative cell densities at the EB surface (A) and core 
(B). Figs C and D directly compare the surface and core cell densities in engineered and control 1 
EBs, respectively. Three EBs were sampled for engineered and control samples and cell density 
measured in triplicate; n = 9.  ? ? ?WA?  ? ? ? ? ? ? ? ?WA䜀  ? ? ? ? ? ?WA䜀  ? ? ? ? ?ƌƌŽƌďĂƌƐA䄀 ^ ? ?D ? 
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Figure 4.4: Cell viability and EB core necrosis. Engineered and control ES cells were seeded into 
mass suspension at 5 x 10
4
 cells/mL (A) and 2.5 x 10
5
 cells/mL (B), rotated at 15rpm for 6hrs and 
incubated at 37°C and 5% CO2 in a humidified atmosphere for up to 9 days. After 1, 3, 5, 7 and 9 
days, EB suspensions were centrifuged and washed in PBS prior to trypsinization. Single cell 
suspensions were incubated with Live ?ĞĂĚ ? ƐŽůƵƚŝŽŶ ĂŶĚ ĚĞĂĚ ĐĞůůƐ ǁĞƌĞ ƋƵĂŶƚŝĨŝĞĚ ďǇ
hemocytometer cell count and calculated as a percentage of the whole. Experiments were 
conducted in triplicate; n = 3.  ? ? ?WA䜀  ? ? ? ? ? ? ? ?WA䜀  ? ? ? ? ? ?WA䜀  ? ? ? ? ?ƌƌŽƌďĂƌƐA䄀 ^ ? ?D ? 
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(Fig 4.4B) in all samples. Engineered and control samples showed a significant ȋ ?
0.001) increase in the proportion of dead cells constituting EBs after 5 days of 
aggregation and growth. The proportion of dead cells increased significantly ȋ  ?
0.001) from day 5 to day 9 in both engineered and control EBs. 
4.3.3. Cellular Morphology 
Both engineered and control EBs were cultured for 4 weeks in SCM under static 
conditions. EBs were allowed to spontaneously differentiate without the addition of 
exogenous cues. After 4 weeks EBs were processed for SEM imaging (refer to 
Chapter 2). A range of cellular morphologies were observed on the EB surface on 
both engineered and control samples. A representative selection of cellular 
morphologies was chosen and photographed (Fig 4.5). Morphologies resembled 
possible cell types such as endothelial (Fig 4.5A), neuronal (Fig 4.5B), ciliated (Fig 
4.5C), adipose (Fig 4.5D), and fibroblastic (Fig 4.5E). Loading processed EBs onto the 
imaging stubs caused some EBs to break apart. The advantage of this was 
accessibility to internal ES cell morphology (Fig 4.5F). Internal ES cells showed no 
change in morphology, remaining small, smooth and spherical. 
The surface of the EB appeared to compose of cells embedded in a fibrous mesh (Fig 
4.6A). During SEM processing, fragile EBs broke apart revealing cell morphology 
internally. The broken parts also allowed visualization of a cross section through the 
surface. Immediately below the surface layer is a mesh of fibrous material, most 
likely being ECM deposition. Internal cells were not apparent in the image, possibly 
due to having fallen apart during impact. ES cells in 2D culture prior to engineering 
and aggregation in suspension were labelled with Oct-4 antibody (Fig 4.6C). The 
bright green fluorescence illustrated that all cells were pluripotent and remained
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Figure 4.5: Cellular morphologies observed on the EB surface and internally. Engineered and 
control ES cells were seeded into suspension in SCM for 4 weeks. After 4 weeks, EB suspensions 
were washed and processed for SEM analysis. Images were taken of engineered samples. Similar 
morphologies were observed in control samples (data not shown). Morphologies appear to 
resemble cell types such as endothelial (A), neuronal (B), ciliated (C), adipose (D) and fibroblastic 
(E). Internal cells resembled undifferentiated ES cells with a small, smooth and spherical 
morphology (F). 
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Figure 4.6: ES cell pluripotency and differentiation within the EB. ES cells were seeded into mass 
suspension and rotated at 15rpm for 6hrs prior to 4 weeks culture at 37°C and 5% CO2 in a 
humidified atmosphere. After 4 weeks, EBs were processed for SEM analysis. During loading of 
SEM prepared EBs onto SEM stubs, the fragile EBs would sometimes break apart. Fig A shows a 
broken engineered EB. The EB surface can be visualized as cells embedded in a fibrous mesh. To 
ensure ES cells in continuous culture were pluripotent prior to EB experimentation, ES cell 
colonies in 2D culture (B) were immuno-labelled with a primary antibody against Oct-4 and FitC-
conjugated secondary antibody (C). A negative control was prepared by incubating ES cells with 
just the FitC-conjugated secondary antibody, not the Oct-4 primary antibody (D). 
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undifferentiated. Since the morphology of these cells was comparable to those within 
the EB structure, internal cells appeared undifferentiated. Therefore, the fact that 
surface cells were distinctly morphologically different to internal cells lends support 
to surface cells having undergone random differentiation. 
 4.3.4. Germ Layer Differentiation 
4.3.4.1. Embryoid Body Differentiation 
Both engineered and control ES cells were aggregated and cultured in SCM without 
the addition of exogenous growth factors for 9 days. EB sections were immuno-
labelled for the three germ layers, mesoderm, endoderm and ectoderm (Fig 4.7). 
Similar results were observed at 5 x 104 cells/mL and 2.5 x 105 cells/mL in both 
engineered and control samples. Engineered EBs exhibited mesoderm differentiation 
where both control EB samples did not (Figs 4.7A and J). In contrast, both control EB 
samples exhibited endoderm differentiation where engineered EBs did not (Figs 
4.7E, H, N and Q). Mesoderm differentiation appeared both internally and externally 
(Fig 4.7A). Endoderm differentiation appeared to be restricted to the section 
periphery indicating differentiation was located at the surface (Fig 4.7Q). Ectoderm 
differentiation was not observed in any samples, at least to a detectable level (Figs 
4.7C, F, I, L, O and R). 
4.3.4.2. Germ Layer Formation 
Engineered and control ES cells were aggregated for 3 and 9 days. RNA was 
extracted from the resultant EBs for PCR amplification. Fig 4.8 shows PCR results for 
undifferentiated cells (Oct-4) and the three germ layers, including mesoderm, 
endoderm and ectoderm (Brachyury, Gata-4, Nestin, respectively). Nestin expression 
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Figure 4.7: EB differentiation and germ layer formation. Engineered and control ES cells were 
seeded into mass suspension, rotated at 15rpm for 6hrs and aggregated for 9 days in SCM. After 9 
days, EBs were fixed, sectioned and fluorescence immuno-labelled for mesoderm (Brachyury), 
endoderm (Gata-4) and ectoderm (Nestin). Negative controls were prepared by skipping 
incubation with primary antibodies against the germ layers, and incubation with just 
fluorescence-conjugated secondary antibodies. DAPI was used as a counter-stain. Scale bars 
measure 100µm. 
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Figure 4.8: Effect of engineering on ES cell differentiation and germ layer formation during the EB 
stage. Engineered and control ES cells were seeded into suspension at 5 x 10
4
 cells/mL, rotated at 
15rpm for 6hrs and incubated under stationary conditions for between 3 and 9 days. After 3 and 9 
days, EBs were prepared for PCR analysis. EB lysates were analyzed for mesoderm (Brachyury), 
endoderm (Gata-4) and ectoderm (Nestin) expression. Lysates were also analyzed for 
pluripotency (Oct-4) to show the presence of undifferentiated ES cells. GAPDH was used as a 
quality control. Bands were scanned using densiometric analysis and equalized between samples 
using GAPDH expression levels. Day 9.5 mouse embryos were used as a positive control. Negative 
controls were prepared by not adding cDNA templates to the PCR mix before amplification. Error 
bars = standard deviation. 
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was absent in engineered samples and minimal in control samples. Brachyury and 
Gata-4 expression was observed in all samples. Brachyury expression appeared to be 
unaffected by engineering. However, both Gata-4 and Nestin expression appeared 
reduced within engineered samples in comparison control samples. This indicates an 
indirect enhancement of mesoderm formation via possible inhibition or 
downregulation of endoderm and ectoderm expression; possible increased 
mesoderm homogeneity. All samples exhibited high Oct-4 expression up to 9 days 
showing a high proportion of the cells within EBs remained undifferentiated. Day 9.5 
mouse embryos were used as positive controls and showed Oct-4, Brachyury, Gata-4 
and Nestin expression. Presence of bands showed that primer pairs were efficient for 
PCR amplification. Clear GAPDH expression within all samples showed reverse 
transcription efficiency. Negative controls revealed no sample contamination. 
4.3.5. Cadherin-11 Expression 
ES cells were seeded at 5 x 104 cells/mL and aggregated for 9 days in SCM. Fig 4.9 
shows fluorescence images of engineered and control EBs immuno-labelled for 
cadherin-11. All samples exhibited cadherin-11 expression. Engineered samples 
appeared to exhibit more cadherin-11 expression than control samples (Fig 4.9A). 
However, expression within engineered samples only appeared greater than control 
samples within small diameter engineered EBs. This indicated a potential correlation 
between EB diameter and cadherin-11 expression. Cadherin-11 expression within 
these small engineered EBs appeared below the EB surface. However, without 
fluorescence quantification from multiple EB sections, the conclusion is that all 
samples exhibited cadherin-11 expression. 
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Figure 4.9: Effect of engineering on cadherin-11 expression. Engineered (A), control 1 (B) and 
control 2 (C) ES cells were seeded into mass suspension at 5 x 10
4
 cells/mL rotated at 15rpm for 
6hrs and incubated at 37°C and 5% CO2 in a humidified atmosphere for 9 days. After 9 days, EBs 
were fixed, sectioned and immuno-labelled with primary antibody against cadherin-11 and 
phycoerytherin-conjugated secondary antibody. Fig D shows a negative control prepared by 
incubating the EB cross-section with only the secondary antibody, not the primary antibody. DAPI 
was used as a counter-stain. 
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4.4. Discussion 
Many individual studies have employed the use of EBs in their differentiation 
protocols as it provides a means of recapitulating natural 3D embryo growth and 
development in vitro (Conley et al., 2005). Specifically, EBs exhibit the ability to 
cause and potentially direct ES cell differentiation. Many methods are currently 
employed for efficient ES cell aggregation and EB formation. Each method of 
aggregation appears to enhance ES cell differentiation towards a specific cell type. 
However, minimal work is invested in the characterisation of these EBs (Koike et al., 
2007). Mostly, the aggregation method is altered to produce desired ES cell 
differentiation without adequate analysis of the transitional EB stage. Detailed 
analysis of the EB stage would provide a closer insight into the formation of 
differentiated cell types. Identification of trends in both EB structure and constituent 
cell viability and differentiation could pave the way for efficient production of 
desired cell types in potentially homogeneous populations. Understanding what 
properties EBs possess and how these relate to ES cell differentiation would enable 
standardisation of EB formation protocols. Here we show a detailed analysis of the 
EB structure and constituent cell viability and differentiation. Both engineered and 
control EBs were investigated at different seeding densities and over aggregation 
time. 
4.4.1. Embryoid Body Structure 
EB formation is extremely complex involving the interaction of many factors. Logic 
would dictate that EB formation begins with single ES cell-ES cell collisions and 
resultant adhesion. These interactions progress and eventually ES cell masses, 
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namely clusters, are generated. These grow in size through further aggregation and 
constituent cell proliferation. However, logic alone does not provide adequate 
explanation for how these events take place. The layered EB structure provided 
insight into EB formation which possibly arose through a build up of ES cell layers 
(Fig 4.2C). Importantly, this hypothesis implies two things, (1) ES cell proliferation 
has minimal bearing on overall EB structure and/or (2) cell mobility within the EB 
structure is extremely limited. If ES cell proliferation had a major effect on EB 
structure then constituent cells would increase the internal size of EBs exponentially 
in comparison to the surface. Consequently, the EB would exhibit a large core in 
comparison to the surface, a cell dense core and possibly surface traits like 
stretching. Stretching has been indicated by cellular morphology of surface cells in 
Chapter 3. However, Figs 4.2A and B clearly showed that the core of the EB was 
necrotic. Therefore ES cell proliferation could not be contributing to the increase in 
EB core size. As for limited cell mobility within the EB structure, constituent cells 
would be fixed in place once they became adhered. Additional ES cells would adhere 
to these in sequential layers hence generation of the observed layered internal EB 
structure. 
The above hypothesis is flawed in its explanation of the observed layered EB 
structure. The aforementioned hypothesis is based on the internal layered structure 
arising through physical ES cell-ES cell interaction and subsequent 3D orientation, 
which is spatially fixed within certain parameters. An alternative hypothesis, 
supported by ensuing data, describes the generation of layers within the structure as 
an artefact of cell viability and mobility. It is true that ES cells interacted and adhered 
to form clusters. These continued to acquire additional ES cells through aggregation, 
but also interaction with one another. Visual observations of cell clusters showed 
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them to be irregular in shape and consist of randomly orientated ES cells. Continual 
aggregation and EB growth resulted in dense spherical aggregates which exhibited a 
less chaotic organisation. This indicated that cells were more than capable of moving 
around within the EB structure. They could have potentially traversed the entire EB 
structure from one side to the other. Consequently, it was unlikely that the layered 
structure was a direct result of cell mobility. Even though ES cell adhesion would 
occur in layers, constituent cells within each layer had the ability to move between 
layers. Eventually, this movement would have blurred the boundaries between 
layers until they were no longer distinguishable. However, it was possible that the 9 
day period of aggregation investigated was insufficient time for this to occur. 
Therefore, layering as a consequence of cell mobility is not completely excluded. 
Constituent cell mobility raised another interesting point concerning core necrosis. It 
was possible that cells were mobile enough to enable restructuring of the entire EB 
mass into a less chaotic configuration. This restructuring may have involved 
internalisation and accumulation of damaged or dead cells within the EB core. Inter-
EB collisions or sensitivity to altering environmental conditions may have caused 
damage to surface cells which then became internalised. The core would have 
consequently become populated with dead cells. EB diameter would have been 
maintained but with a large proportion of dead cells, supporting observations in Figs 
3.9C and D where constituent cell numbers decreased whilst EB diameter increased. 
Accumulation of necrotic cells within the core was also exacerbated by hypoxia and 
starvation within the core. 
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4.4.2. Embryonic Stem Cell Viability 
The layered structure of the EB appeared to arise primarily from different levels of 
cell viability. Four layers could be distinguished including the surface, the outer and 
inner shells, and the core. The core was composed of dead or necrotic cells. The 
surface was composed cells which were alive and thriving but also disorganised as a 
result of rapid recent attachment. The inner and outer shells illustrated a transitional 
stage between alive and dead cells. The outer shell was composed of cells which 
were alive and resembled an condensed version of the surface. The inner shell was 
composed of cells which were necrotic and resembled the dead cells found at the 
core. Therefore, layering was simply a visualisation of cell death across the EB 
structure and not necessarily an artefact of ES cell aggregation. However, cell 
viability was acutely affected by properties such as cell density and organisation 
within the EB structure, and these properties were directly under the control of cell-
cell aggregation. Therefore, layering was an indirect consequence of ES cell 
aggregation. 
The difference in cell viability across the EB structure was most likely the result of 
hypoxia and/or starvation. Nutrient and gaseous exchange was made increasingly 
difficult as the distance between internal cells and the EB surface increased. It may 
have merely been that surface and outer shell cells had used all available nutrients 
and gases before they had chance to permeate towards the centre. Alternatively, 
permeation may have been severely restricted to the surface area due to constituent 
cell density. Another factor that may have had measurable effect is intercellular 
signalling which may have initiated apoptosis as a result of surrounding 
environmental cues (Lee et al., 2005). 
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Relative core to surface size could not be adequately calculated using the EB cross-
sections since it was impossible to tell whether the section was cut through the 
widest part of the EB. Sections could have been taken from the widest region of all 
EBs so as to enable calculation of relative core and surface size. However, this would 
have been immensely difficult and time consuming. Consequently, only core/inner 
shell and surface/outer shell ES cell densities could be adequately quantified from 
cross-section images. 
Engineered ES cells aggregated at an accelerated rate compared to control samples 
(Figs 3.7A and B). Logically, the rate of cell death should also have been accelerated. 
However, engineered EBs did not show signs of advanced necrosis or major 
structural differences. Therefore, engineering may not have detrimentally affected 
cell viability or altered the mode of EB formation. Similar results were observed at 5 
x 104 and 2.5 x 105 cells/mL. This showed that increased cell number had no direct 
effect on cell viability. High numbers of cells in suspension meant increased chance 
collisions and rapid EB formation. Accelerated EB formation should therefore have 
conferred increased core necrosis, yet this was not the case. Consequently, seeding 
density had minimal to no effect on both EB structure and constituent cell viability, 
at least not directly. However, without knowing the relative sizes of the core and 
surface, it remains unclear as to what extent, if any, both engineering and seeding 
density had on cell viability within the EB structure. Core necrosis within engineered 
EBs may have been more or less advanced compared to that in control samples. The 
maximum seeding density employed was reduced from 1 x 106 to 2.5 x 105 cells/mL, 
to minimize the occurrence of EB agglomeration and ensure the results reflected 
individual EB dynamics. 
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4.4.3. Cell Density 
As stated previously, ES cells aggregated to form EBs which exhibited a necrotic core 
and a thriving surface. Structural differences between the core and surface 
emphasized this distinction. Analysis of constituent cell densities provided insight 
concerning the discrepancy between surface and core cell viability. Surface density 
was calculated from the combined surface and outer shell layers, and core density 
was calculated from the combined core and inner shell layers. This was due to 
difficulty in definitively distinguishing between all four layers in most EB cross-
sections. Both engineered and control EBs were significantly (P A? 0.001) denser at 
the surface compared to the core (Figs 4.3C and D). The higher the density the more 
difficult it became for efficient nutrient permeation and gaseous exchange between 
internal cells and the surrounding environment. Consequently, core cells became 
starved and hypoxic, supporting the idea that the inner and outer shells represented 
a transitional stage between alive cells and eventual necrosis (Jiang et al., 2005). 
Thriving cells at the surface would also have been depositing large amounts of ECM. 
Layer upon layer of ECM would have trapped constituent cells and eventually 
prevented adequate penetration of nutrients into the EB structure. 
Engineered EBs exhibited significantly (P A? 0.001) greater cell density at both their 
core and surface compared to control EBs (Figs 4.3A and B). This showed that 
engineering had a direct effect on EB composition and overall structure. Engineered 
EBs did not show signs of advanced necrosis, which would have been expected with 
increased cell density. It is also possible that the increased density was simply not 
high enough to restrict permeability to a measurable level. Cell density did not 
significantly change over seeding density in both engineered and control EBs (Fig 
4.3). ES cell aggregation kinetics were simply accelerated by high initial cell 
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numbers, but EB structure and density remained unaltered. In summary, engineered 
EBs composed of significantly ȋ  ?  ?Ǥ ? ? ?Ȍdenser ES cell populations compared to 
control EBs, but without detrimental effect on constituent ES cell viability. 
Analysis of necrosis within the EB core via direct diameter measurement was 
difficult and prone to error. Instead, the degree of necrosis within the core was 
estimated as a percentage of the whole (Fig 4.4). The downside of this method was 
that it assumed all necrotic ES cells were positioned within the core. However, since     Ȁ ?        
were within the core, the assumption was accepted. Even though ES cells within  ǡ Ȁ ? Ǥ
This may have been because the fluorescence from live ES cells masked that from 
necrotic ES cells. Alternatively, ES cell mobility and reorganisation within the EB 
structure could have caused accumulation of necrotic ES cells within the core. Fig 4.4 
shows no significant difference between engineered and control EBs, indicating that 
even though engineered EBs are denser than their control counterparts this did not 
affect constituent cell viability. In fact, it suggested that engineering may have 
enhanced cell viability. Engineered ES cells aggregated rapidly to form large EBs 
which one would expect to exhibit signs of advanced necrosis compared to slower 
aggregating control EBs. However, the percentage of dead cells within engineered 
EBs equalled that in control EBs. Therefore, engineering allowed for the formation of 
larger EBs without elevated cell death. It is therefore plausible that if engineering 
was fine tuned to form EBs of equal size to control samples, engineered EBs may 
resolve the problem of necrosis within the core completely. Engineering had clearly Ǯǯo in a favourable manner, possibly through 
enhanced nutrient and gaseous exchange. This was emphasized by the fact that 
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engineered EBs did not show a significant increase in core necrosis until after 5 days, 
identical to control EBs. If engineering did not improve cell viability we would expect 
to see the observed increase in core necrosis at an earlier time point. However, the 
methodology used to calculate the percentage of core necrosis may not have been 
sensitive enough to highlight small but significant differences between engineered 
and control EBs. The cell count on a haemocytometer measures a minimum of 5 x 104 
cells/mL. This meant that core necrosis was measurable only after the core reached a   ?  ?  ? ?4 cells. Due to this, the true point at 
which necrosis began within the core remains unclear. Alternatively, time intervals 
between measurements may not have been sufficiently close together to highlight 
any differences. For example, engineered EBs may have exhibited a significant 
increase in core necrosis after 4 days, but the time points investigated in Fig 4.4 infer 
that it took 5 days. 
The significant (P  ? 0.001) increase in core necrosis after 5 days illustrated that core 
necrosis was both time and size dependent. After 5 days of aggregation and growth, 
engineered EBs were  ? 200µm in diameter and control EBs were  ? ? ? ? ?ȋ	 ?Ǥ ?ȌǤ
This demonstrated that engineering enhanced cell viability in larger EBs. However, 
dependency on size may not have been an issue with constituent cell viability. There 
was no significant increase in size from 3 to 5 days in either engineered or control 
EBs at 5 x 104 and 1 x 106 cells/mL to correlate with the significant ȋ  ?  ?Ǥ ? ? ?Ȍ
increase in core necrosis. The explanation may be that for a linear increase in 3D 
spherical size the number of constituent cells has to increase non-linearly. It is 
possible that after 5 days of aggregation the number of core cells had increased 
massively and consequently become necrotic. The observed cell death prior to day 5 
may not have been a sign of core necrosis, but merely damaged cells during the 
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aggregation procedure. This was indicated by the fact that there was no significant 
increase in necrosis between 1 and 3 days. If it were true core necrosis then 
accumulation at the core would have shown an increase. There was a significant (P  ? 
0.001) increase between 5 and 9 days of aggregation, illustrating that core necrosis 
increased over time. The percentage of core necrosis increased rapidly because of 
hypoxic conditions and starvation within the EB structure, but also, further cell 
damage on the surface and reorganisation towards the centre. Up to 80% of the EB 
became necrotic by day 9 highlighting a serious problem with extended EB culture 
(Fig 4.4B). It appeared that 3 days of EB culture was the maximum time allowed to 
avoid core necrosis. A variety of avenues could be explored to resolve this problem 
including vascularization of the EB structure (Gerecht-Nir et al., 2005, Goodwin, 
2007, Feraud et al., 2001). 
4.4.4. Embryoid Body Differentiation 
ES cells within the thriving EB surface showed signs of differentiation towards 
numerous cell types (Fig 4.5). Both engineered and control samples exhibited a 
similar range of cell morphologies after 4 weeks culture in SCM, indicating that 
engineering did not detrimentally affect ES cell differentiation potential. Cell 
morphologies included possible endothelial (Fig 4.5A) and fibroblastic cells (Fig 
4.5E) amongst others. Previous studies have shown that primitive endoderm cells 
are a primary cell type to differentiate during the EB stage (Hamazaki et al., 2004, 
Capo-Chichi et al., 2005). Concurrent with these findings, the morphology of the most 
abundant cell type observed on the EB surface matched that of cell derivatives from 
primitive endoderm (Lee and Anderson, 2008). However, it may simply have been 
that these primitive endoderm-like cells proliferated more rapidly than other cell 
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types and therefore spread over the surface quickly. Primitive endoderm cells 
inherently migrate towards the surface and therefore would be expected to coat the 
EB (Yang et al., 2007, Plusa et al., 2008, Rula et al., 2007, Chazaud et al., 2006). If this 
cell type was primitive endoderm cells it would provide some explanation for 
necrosis within the core. Effectively, they would have acted as a protective skin 
surrounding the EB and provided a barrier against unregulated nutrient and gaseous 
diffusion (Hamazaki et al., 2004, Sachlos and Auguste, 2008). This implies that core 
necrosis may not have been solely dependent on EB size and aggregation time, but 
on ES cell differentiation. However, since the purpose of EB formation is ES cell 
differentiation this can not be avoided, albeit directing differentiation during EB 
formation may have advantageous effects on constituent ES cell viability. As for 
heart/muscle cell differentiation, cultures of beating cells were observed in EB 
samples allowed to settle, adhere and spread on tissue culture plastic and grown for 
~14 days. Other studies have also demonstrated differentiation of heart cells from 
EBs (Ng et al., 2005). These have found that factors such as constituent ES cell 
number have a direct effect on downstream differentiation. As engineering directly 
affected the number of ES cells involved in EB formation in a controlled manner, it 
may provide a practical means of differentiation manipulation. Internal ES cells 
within the core exhibited a small spherical morphology similar to that of 
undifferentiated ES cells in continuous culture (Figs 4.5E, 4.6B and C). This is simply 
because core ES cells would have become necrotic and died before having the chance 
to differentiate. Another indication that ES cells within the core were 
undifferentiated and necrotic or dead is the distinct lack of ECM deposition. Cells 
within the surface exhibited extensive ECM deposition as observed by a thick fibrous 
mesh binding adjacent cells together (Fig 4.6A). This dense layer of ECM deposition 
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most probably contributed to the decrease in surface permeability for nutrient and 
gaseous exchange. 
The observations above were taken from 4 week old EBs exhibiting advanced stages 
in formation and differentiation. Analysis of early stage EBs was primarily via 
immuno-labelling of EB cross-sections after 9 days of aggregation (Fig 4.7). Attempts 
to investigate EBs from earlier time points were made, however, these EBs were 
either too small or simply too fragile to withstand processing and/or retrieve high-
grade sections. Engineered EBs at both 5 x 104 and 2.5 x 105 cells/mL exhibited 
mesoderm differentiation at the surface and within the core (Figs 4.7A and J) 
supporting the presence of heart/muscle cells discussed earlier. Differentiation 
observed within the core supports the earlier hypothesis that engineering enhanced 
cell viability within the core. However, it is unclear whether these cells differentiated 
within the core or simply migrated there after differentiating at the surface as a 
consequence of primitive endoderm migrating to the surface (Rula et al., 2007). 
Control EBs at both 5 x 104 and 1 x 106 cells/mL did not show positive labelling for 
Brachyury, indicating that engineered EBs exhibited a greater propensity for 
mesoderm differentiation. Control EBs exhibited endoderm differentiation where 
engineered EBs did not (Figs 4.7E, H, N and O). Endoderm may therefore be the 
preferred lineage during initial EB differentiation, supporting previous findings 
(Rust et al., 2006, Yang et al., 2002, Morrisey et al., 2000). Differentiation was 
potentially isolated at the surface unlike mesoderm differentiation in engineered 
samples. This may be that cells within control EBs were less mobile than their 
engineered counterparts, or that engineered EBs were at a more advanced stage of 
structural reorganisation than control EBs. Neither engineered nor control EBs 
exhibited ectoderm differentiation at either seeding density. This may be due natural 
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ectoderm differentiation within the EB taking longer than 9 days of aggregation 
without exogenous cues such as retinoic acid (Bain et al., 1995). Other reasons 
include, presence of unknown inhibitory factors or simply that any positive labelling 
was not at a detectable level (Murashov et al., 2004). 
PCR was employed to amplify the same germ layer markers as those labelled for 
immuno-fluorescence images (Fig 4.8). PCR data at first supported the observations 
made in Fig 4.7. However, there were a few discrepancies, such as the expression of 
Brachyury and Nestin in control EBs, and expression of Gata-4 in engineered EBs. 
Immuno-fluorescence images exhibited no expression of these markers in 
corresponding EB sections. This could be due to the fact that ES cell differentiation 
spontaneously occurred in patches rather than a continuous sheet encompassing the 
EB surface. Cross-sections in Fig 4.7 not exhibiting fluorescence may simply have 
been cut through regions of the EB where there were no differentiated ES cells. If we 
hypothesise that an EB is a perfect sphere measuring 100µm in diameter, then a 4µm 
thick cross-section views ~4% of the entire EB surface area. The surface area of a  ?ǤɎǤ2, where r is radius. The circumference of the circular cross-section is ɎǤǡǤ-section is calculated 
by multiplying the circumference by the thickness. The surface area of the cross-
section is then converted to a percentage of the whole EB surface. This percentage 
falls as the EB increases in size. It is therefore highly possible that differentiated 
areas were not included within the cross-sections. Alternatively, discrepancies could 
be due to the higher sensitivity of PCR. Where fluorescence was too weak to be 
visible, there were adequate amounts of mRNA for PCR amplification.  
Unlike control EBs, PCR revealed that engineered EBs exhibited no ectoderm 
expression during the 9 day aggregation period. This indicated that engineering may 
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have had a direct or indirect negative effect on Nestin expression. Both engineered 
and control samples exhibited mesoderm and endoderm differentiation. This is 
consistent with the natural sequence of differentiation events in which 
mesendoderm is primarily and possibly preferentially generated (Vallier et al., 2004, 
Hamazaki et al., 2004, Izumi et al., 2007, Smith et al., 2008). Interestingly, engineered 
samples showed reduced levels of endoderm and ectoderm expression compared to 
control samples. Consequently, mesoderm formation appeared indirectly enhanced, 
indicating potential for increased homogeneity of mesoderm derived cell types. 
Strong Oct-4 expression appeared in both engineered and control samples, 
suggesting that the majority of constituent cells remained undifferentiated (Fig 4.8). 
This is consistent with only surface ES cells undergoing differentiation. 
The potentially enhanced mesoderm differentiation within engineered samples was 
investigated further by immuno-labelling for cadherin-11 expression (Fig 4.9). It has 
previously been shown that cadherin-11 mediated ES cell-ES cell interaction has an 
important role to play in MS cell differentiation towards the osteogenic and 
chondrogenic lineages (Kii et al., 2004). Osteoblasts have also been successfully 
isolated by purification of cadherin-11 positive cells via magnetically activated cell 
sorting (Bourne et al., 2004). Therefore, the potential strong presence of cadherin-11 
expression within engineered EBs (Fig 4.9A) indicated that engineering may also 
exhibit enhanced differentiation of osteogenic lineages compared to control EBs. 
However, lack of fluorescence quantification meant that difference in cadherin-11 
expression between engineered and control samples remained unclear. 
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4.5. Conclusions 
In summary, engineering appeared to enhance cell viability within the EB structure 
even though they were larger in diameter and exhibited greater cell density at both 
their core and surface. EBs exhibited a layered structure which could be broken into 
four sections including the surface, outer shell, inner shell and core. The core 
composed of dead or necrotic cells possibly resulting from a lack of efficient nutrient 
and gaseous exchange, whilst the surface composed of thriving cells. Necrosis was 
indicated by swollen cell nuclei, lack of membrane blebbing and cell debris. The 
inner and outer shells illustrate transitional stages between surface and core states. 
The fact that internal cells were necrotic meant that only the EB surface underwent 
differentiation. A multitude of cell morphologies showed that engineering did not 
detrimentally affect ES cell differentiation. In fact, engineered EBs showed indirect 
enhancement of mesoderm formation through possible inhibition or downregulation 
of ectoderm and endoderm formation. It is possible that increased cell number and 
density within the engineered EB caused enhanced mesoderm differentiation. 
However, further analysis would be required to elucidate any direct link. Excitingly, 
engineering of the ES cell surface has demonstrated a distinct ability to influence 
aggregation and therefore provides ideal means to investigate these variables 
further. Mesoderm enhancement has important ramifications for engineered driven 
differentiation of ES cells towards the osteogenic lineage, such as increasing 
homogeneity of resultant osteogenic cultures (Mateizel et al., 2008). Positive 
immuno-labelling for osteoblast cadherin (cadherin-11) within engineered EBs 
indeed marked potential osteogenic differentiation. 
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Chapter 5  
5. Results 
Embryoid Body Osteogenic Potential 
5.1. Introduction 
Previous studies have demonstrated selective differentiation of osteoblasts from ES 
cells via EB culture with osteo-inductive factors including Asc, BGP and the 
glucocorticoid Dex (Bourne et al., 2004, Bielby et al., 2004, Handschel et al., 2008a). 
In vitro cultured osteoblasts hold great promise for tissue repair and regeneration of 
bone, damaged as a result of disease and trauma (Grayson et al., 2008, Heng et al., 
2004). Generating transplantable from ES cells bypasses many problems associated 
with existing bone repair strategies, such as genetic abnormalities within auto- and 
allografts, disease transmission from xenografts, micromechanical mismatch and 
biocompatibility of prosthetic implants, and cell availability (Vaccaro et al., 2002, 
Marquis et al., 2009, Pappalardo et al., 2007, Patil et al., 2009). Other exciting 
applications of osteoblast generation include in vitro analysis of early bone 
development and investigative tool for pharmacological and cytotoxic testing of 
bone-related drugs and biomaterials (Wdziekonski et al., 2006, Cao et al., 2005). 
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Analysis of cell-cell interaction revealed cadherin-11 expression within engineered 
EBs, a surface cell-adhesion molecule important in osteogenic differentiation 
(Kawaguchi et al., 2001, Bourne et al., 2004, Kii et al., 2004). Hypothesizing that 
surface engineering may induce differentiation towards osteogenic precursors, 
engineered EBs were cultured in, osteo-inductive (Asc, BGP and Dex) and control 
(Asc) media. Here is shown that engineered EBs exhibit enhanced osteoblastic 
differentiation assessed by bone nodule formation, ALP activity and expression of 
osteogenic markers Runx2 and OPN (Sottile et al., 2003, Chaudhry et al., 2004, 
Morris et al., 1992, Karner et al., 2007, Garreta et al., 2006). Evidently, engineered 
cell-cell interactions during EB formation have subsequent effects on ES cell 
differentiation, apparently influencing intercellular and possibly intracellular 
signalling pathways in favour of osteogenic differentiation.  
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5.2. Methods and Materials 
5.2.1. Osteogenic Differentiation without the Embryoid Body Formation 
Engineered and control ES cells were taken from continuous culture (Chapter 2) and 
seeded directly into gelatin-coated tissue culture plates in osteo-inductive and 
control media for 4 weeks. Comparative samples were set up in which ES cells had 
been allowed to form EBs before culture in osteo-inductive or control media. ES cells 
were seeded into mass suspension over a range of densities (5 x 104 to 2.5 x 105 
cells/mL), rotated for 6hrs at 15rpm and cultured for 3 days. Osteogenic 
differentiation was quantified after 4 weeks by bone nodule counts and ALP activity 
(Chapter 2). 
5.2.2. Bone Nodule Quantification 
Both engineered and control ES cells were cultured in mass suspension at a seeding 
density ranging from 5 x 104 cells/mL to 2.5 x 105 cells/mL. Resulting EBs were 
cultured for 1 to 9 days before transfer to tissue-culture treated plates and incubated 
in either osteo-inductive or control media for a period of 4 weeks. Alizarin Red stain 
was employed to highlight bone nodules within these cultures after 4 weeks 
(Chapter 2). Quantification of bone nodules was assessed by colorimetric assay and 
direct counting.  
5.2.2.1. Colorimetric Assay 
Once cell cultures were stained with Alizarin Red they were imaged at 10x 
magnification using a stereomicroscope (Nikon Eclipse TS100). Cultures were 
covered in 10% cetyl-pyridinium chloride (CPC) and gently rotated at room 
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temperature for a maximum of 10mins (Gregory et al., 2004, Srouji et al., 2005). Once 
the red stain had leached from the culture, 300µl aliquots were transferred to a 
96well plate. Absorbance was measured at 595nm using a KC4 plate reader. A blank 
measurement of 10% CPC solution was deducted from all sample readings. An 
average of three individual readings was taken. 
5.2.2.2. Bone Nodule Count 
Alizarin Red positively stained calcium deposits also known as bone nodules. Bone 
nodules within cultures were viewed and counted using a stereomicroscope (Nikon 
SMZ1500) set between 1x and 4x magnification. All bone nodules were counted in 
cultures containing minimal stained areas which could be easily distinguished from 
one another. Cultures that contained many bone nodules made counting very 
difficult as numbers were 100 to 1000x higher than those with minimal bone 
nodules. Consequently, a representative area of the whole culture was analyzed to 
minimize the number of bone nodules counted (Fig 5.1). The entire well was divided 
into 8 sections and all bone nodules within one section were counted and multiplied 
by 8. Three individual wells for each sample were quantified and an average taken. 
Duplicate cultures of all samples were quantified by Hoescht assay for total DNA 
content (Chapter 2). All readings were subsequently equalized for DNA content of 1 x 
106 cells. 
CPC is a cationic quaternary ammonium compound which is often used as a 
surfactant. It can cause disruption of the calcium phosphate crystals within bone 
nodules through solid/liquid phase adsorption (Dutour-Sikiric and Furedi-Milhofer, 
2006). Adsorption affects further growth and causes morphological aberrations 
through competition with Ca2+ ions for available phosphate ions 
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Figure 5.1: Quantification of Alizarin Red stained calcium deposits. Where cultures showed 
minimal bone nodule formation, the whole sample was analyzed. Where cultures exhibited large 
numbers of bone nodules, wells were divided into 8 equal sections. All calcium deposits within 3 
sections were counted and an average calculated. Values were then multiplied by 8 to represent 
the total bone nodule number. 
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(Horvath et al., 2000). The lattice structure of the calcium phosphate crystals can 
become unstable and eventually end in dissolution. These changes in the structural 
integrity of calcium phosphate crystals causes precipitation of intercalated Alizarin 
Red stain into suspension. 
5.2.3. Plate Coating 
To investigate the interaction between EBs and ECM components, plates in which EB 
suspensions were cultured for 4 weeks were pre-coated. Plates were removed from 
packaging and washed briefly with PBS. Four plates were set up for each coating 
included gelatin, fibronectin and collagen (BD Biosciences) and control uncoated 
plates. Each coating was applied within the recommended concentration limits 
quoted by the supplier (50µg/mL in PBS). Wells were covered in 1mL of the 
appropriate coating suspension for 30mins at room temperature. Excess solution 
was aspirated and EB suspensions were then directly transferred to the wells. It was 
found that gelatin-coated plates provided inexpensive enhancement of EB adhesion 
compared to both fibronectin and collagen-coated plates. All subsequent 
experiments employed gelatin-coated plates. 
5.2.4. Osteogenic Differentiation in Settled and Dissociated Embryoid Bodies  
ES cells were seeded into suspension and cultured for up to 9 days before resulting 
EBs were transferred into either osteo-inductive or control media (Chapter 2). EB 
suspensions were seeded into new wells pre-coated with 0.1% gelatin for 20mins at 
room temperature (Bielby et al., 2004, Randle et al., 2007). Suspensions were 
cultured for 4 weeks in stationary conditions to allow EBs to settle and adhere. 
Duplicate samples were aggregated for up to 9 days then transferred to a 15mL 
Falcon tube and centrifuged at 1000rpm for 5mins. Supernatant was aspirated and 
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the pellet washed in PBS before being suspended in 37°C trypsin/EDTA solution for 
a maximum of 5mins. The suspension was pipetted gently until EBs were fully 
dissociated. SCM was added and the suspension centrifuged. Dissociation was 
checked under a microscope for any large cell clumps. The whole single cell 
suspension was transferred to a gelatin-coated well in either osteo-inductive or 
control media and cultured for 4 weeks. 
5.2.5. Embryoid Body Differentiation and Osteogenic Differentiation 
5.2.5.1. Embryoid Body Stage 
To investigate the effect of EB stage on osteogenic differentiation, both engineered 
and control ES cells were seeded into mass suspension, rotated for 6hrs at 15rpm 
and cultured between 1 and 9 days. EBs were transferred on days 1, 3, 5, 7 and 9 into 
gelatin-coated plates in either osteo-inductive or control media and cultured for a 
further 4 weeks. Osteogenic differentiation was subsequently quantified by bone 
nodule counts and analysis of OPN and Runx2 expression via PCR amplification 
(Chapter 2) (Sottile et al., 2003). 
5.2.5.2. Osteogenic Differentiation over Time 
To investigate osteogenic differentiation over time, engineered and control ES cells 
were seeded at 5 x 104 cells/mL into mass suspension, rotated at 15rpm for 6hrs and 
cultured for 3 days. All EBs were transferred to gelatin-coated plates in either osteo-
inductive or control media and cultured for a further 4 weeks. Duplicate cultures 
prepared alongside to be analyzed by Hoescht assay. After 1, 2, 3 and 4 weeks, 
osteogenic differentiation was quantified by bone nodule counts. After 2 and 4 
weeks, OPN and Runx2 expression were analyzed by PCR amplification (Chapter 2). 
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5.2.5.3. Bone Extraction 
PCR amplification experiments for osteogenic markers OPN and Runx2 required 
validation via amplification from positive control samples. Adult mouse femurs were 
used as positive control samples. The hind legs of an adult mouse were amputated 
and mechanically stripped of skin and muscle with forceps and a scalpel blade in a 
PBS bath. Extracted bones were washed thoroughly in PBS and then chopped into 
smaller sections. Sections were allowed to settle and excess PBS was aspirated. Bone 
fragments were suspended in enzyme digestion solution (0.14% collagenase 1A and 
0.05% trypsin II-S in DMEM), rotated and incubated at 37°C and 5% CO2 in a 
humidified atmosphere for 20 to 30mins (Fuller and Chambers, 1995, Sakaguchi et 
al., 2004, Chambers et al., 1985). Suspensions were rotated until solution appeared 
cloudy and turbid. Once digested, the suspensions were washed through a 100µm 
sieve with PBS to remove the bone fragments. Samples were subsequently 
centrifuged for 5mins at 1000rpm and supernatant was aspirated. Pellets were 
suspended and washed in PBS. Where samples did not contain adequate amounts of 
extracted cellular material, bone fragments were incubated a second time with fresh 
enzyme digestion solution. Large cell pellets were lysed in RLT buffer in preparation 
for PCR amplification (Chapter 2). 
Chapter 5                 Results: EB Osteogenic Potential 
 
176 
 
5.3. Results 
5.3.1. Embryoid Body Adhesion 
To investigate osteogenic differentiation within both engineered and control samples 
over time, EBs had to first be attached to the wells of cell culture plastic plates. To 
enhance the adhesive properties of the plastic, wells were pre-coated with ECM 
components. Components were selected for their cell adhesion properties, cost and 
availability. Figs 5.2 and 5.3 show images taken of EB adhesion over 28 days of 
culture on uncoated, fibronectin, gelatin and collagen-coated plates in engineered 
and control samples, respectively. EBs adhered more rapidly when cultured in osteo-
inductive media compared to control media. This is illustrated in Fig 5.2 where EBs 
had adhered after just 7 days when cultured in osteo-inductive media on fibronectin 
and gelatin-coated plates. Equivalent EBs cultured in control media had not adhered 
to fibronectin and gelatin-coated plates until after 14 days. However, control EBs 
adhered to fibronectin and gelatin-coated plates after 14 days regardless of whether 
they were cultured in osteo-inductive or control media (Fig 5.3). Another 
discrepancy between engineered and control samples was observed in EBs seeded 
onto uncoated plates. Engineered EBs did not adhere to uncoated plates after 28 
days in either osteo-inductive or control media. Control EBs had adhered to uncoated 
plates 7 days after initial seeding when cultured in osteo-inductive media, but had 
not adhered when cultured in control media up to 28 days later. One clear similarity 
between engineered and control samples was observed in EBs seeded onto collagen-
coated plates. EBs did not adhere to collagen-coated plates up to 28 days after initial 
seeding whether cultured in osteo-inductive or control media. Both engineered and 
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Figure 5.2: EB adhesion and spreading in engineered samples. Engineered ES cells were seeded 
into mass suspension at 5 x 10
4
 cells/mL rotated at 15rpm for 6hrs and cultured for 3 days at 37°C 
and 5% CO2 in a humidified atmosphere. After 3 days, EBs were transferred to uncoated, 
fibronectin, gelatin and collagen-coated plates and cultured in either osteo-inductive or control 
media for 4 weeks. Cultures were imaged every week during the 4 week incubation. Scale bars 
measure 100µm. 
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Figure 5.3: EB adhesion and spreading in control 1 samples. Control 1 ES cells were seeded into 
mass suspension at 5 x 10
4
 cells/mL rotated at 15rpm for 6hrs and cultured for 3 days at 37°C and 
5% CO2 in a humidified atmosphere. After 3 days, EBs were transferred to uncoated, fibronectin, 
gelatin and collagen-coated plates and cultured in either osteo-inductive or control media for 4 
weeks. Cultures were imaged every week during the 4 week incubation. Scale bars measure 
100µm. 
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control EBs exhibited a lightly coloured and translucent appearance 1 day after 
transfer to either osteo-inductive or control media. However, as early as 7 days later, 
non-adhered EBs began to show a darkened appearance. EBs which had adhered and 
spread outwards also exhibited darkened areas. 
Fig 5.4 shows the individual stages of EB adhesion and spreading in control 1 and 
engineered samples on gelatin-coated plates. In control 1 samples, free-floating EBs 
were observed after initial seeding which appeared as translucent spherical cell 
aggregates. After 3 days in culture, control 1 EBs had made contact with the well 
surface and had loosely attached whilst maintaining their stereotypical spherical 
shape (Fig 5.4B). Once attached, control 1 EBs began to flatten and spread outwards. 
Cells that were morphologically different to initial ES cells, migrated outwards from 
the central EB mass to form a fringe after 7 days (Fig 5.4D). The cell mass of these 
flattened control 1 EBs continued to proliferate and spread outwards across this 
fringe of cells. By day 12 control 1 EBs had spread out completely and formed a thick 
continuous layer which continued to grow until the well surface was covered (Fig 
5.4F). Engineered EBs exhibited a more rapid, but similar attachment process (Figs 
5.4G to L). The site of initial attachment could still be distinguished throughout 
adhesion and spreading. 
 ? ? ? ? ? ?ŵďƌǇŽŶŝĐ^ƚĞŵĞůů ?ǀƐ ?ŵďƌǇŽŝĚŽĚǇŝĨĨĞƌĞŶƚŝĂƚŝŽŶ 
Osteogenic differentiation was quantified by ALP and Alizarin Red assay (Figs 5.5 
and 5.6, respectively). ALP activity is a standard marker for osteogenic 
differentiation however it is also a marker for ES cell pluripotency. Research has 
shown that ALP activity, whilst high in pluripotent ES cells, decreases at the start of 
differentiation and becomes elevated within particular differentiated cell types  
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Figure 5.4: EB adhesion and spreading on gelatin-coated plates in engineered and control 1 
samples. Control 1 (A to F) and engineered (G to L) ES cells were seeded into mass suspension at 1 
x 10
6
 cells/mL rotated at 15rpm for 6hrs and cultured for 3 days at 37°C and 5% CO2 in a 
humidified atmosphere. After 3 days, EBs were transferred to gelatin-coated plates and cultured 
for 12 days. Representative images were taken after 1, 3, 5, 7, 9 and 12 days. Scale bars measure 
100µm. 
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Figure 5.5:   ‘ǀƐ ? ^ ĐĞll differentiation and osteogenic differentiation; assessed by ALP assay 
(Chapter 2). Engineered and control ES cells were seeded directly into either osteo-inductive (A 
and B) or control (C and D) media directly from continuous culture at 5 x 10
4
 cells/mL (A and C) 
and 2.5 x 10
5
 cells/mL (B and D). Alternatively, ES cells were seeded into mass suspension rotated 
at 15rpm for 6hrs and cultured for 3 days at 37°C and 5% CO2 in a humidified atmosphere. After 3 
days, these EBs were transferred to either osteo-inductive or control media as appropriate. After 
transfer to osteogenic culture, all samples were cultured for 4 weeks. After 4 weeks, osteogenic 
differentiation was quantified by ALP activity assay. All experiments were repeated in triplicate 
and each experiment recorded ALP activity in triplicate; n = 9.  ? ? ?WA? ? ? ? ? ? ?  ? ?WA?  ? ? ? ? ?  ?WA?
0.05. Error bars = S.E.M. 
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Figure 5.6:  ‘ǀƐ ?^ĐĞůů differentiation and osteogenic differentiation; assessed by Alizarin Red 
assay. Engineered and control ES cells were seeded directly into either osteo-inductive (A and B) 
or control (C and D) media directly from continuous culture at 5 x 10
4
 cells/mL (A and C) and 2.5 x 
10
5
 cells/mL (B and D). Alternatively, ES cells were seeded into mass suspension rotated at 15rpm 
for 6hrs and cultured for 3 days at 37°C and 5% CO2 in a humidified atmosphere. After 3 days, 
these EBs were transferred to either osteo-inductive or control media as appropriate. After 
transfer to osteogenic culture, all samples were cultured for 4 weeks. After 4 weeks, osteogenic 
differentiation was quantified by Alizarin Red assay. All experiments were repeated in triplicate 
and each experiment recorded Alizarin Red staining in triplicate; n = 9.  ? ? ?WA? ? ? ? ? ? ? ? ?WA? ? ? ? ? ?
 ?WA䜀  ? ? ? ? ?ƌƌŽƌďĂƌƐA?^ ? ?D ? 
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(Berrill et al., 2004). EB samples cultured in osteo-inductive media showed 
significant ȋ  ?  ?Ǥ ? ? ?Ȍincrease in both ALP activity (Figs 5.5A and B) and bone 
nodule formation (Figs 5.6A and B) compared to ES cell samples. This was observed 
at both 5 x 104 and 2.5 x 105 cells/mL, respectively. Engineered EB samples exhibited 
significantly greater osteogenic differentiation than control EB samples when 
cultured in osteo-inductive media. Where ES cells were cultured in osteo-inductive 
media, no difference was observed between engineered and control samples. No 
difference was observed between engineered and control ES cell samples also 
cultured in control media, regardless of initial seeding density. At 2.5 x 105 cells/mL, 
EBs cultured in control media also showed no change in osteogenic differentiation 
between engineered and control samples. However, at 5 x 104 cells/mL engineered 
EB samples exhibited a significant ȋ ? ?Ǥ ? ? ?Ȍincrease in osteogenic differentiation 
when cultured in control media (Figs 5.5C and 5.6C). These results indicated that 
engineered ES cells significantly ȋ  ?  ?Ǥ ? ? ?Ȍincreased osteogenic differentiation 
when cultured through the EB stage. This was observed in both osteo-inductive and 
control media cultures. All samples cultured in osteo-inductive media exhibited 
greater levels of osteogenic differentiation than comparable samples cultured in 
control media. This indicated that osteo-inductive media alone, effectively directed 
ES cell differentiation towards the osteogenic lineage. All of the trends observed in 
Fig 5.5 were reflected in Fig 5.6 demonstrating a link between ALP activity and bone 
nodule formation. 
 ? ? ? ? ? ?^ĞƚƚůĞĚ ?ǀƐ ?ŝƐƐŽĐŝĂƚĞĚŵďƌǇŽŝĚŽĚǇŝĨĨĞƌĞŶƚŝĂƚŝŽŶ 
ES cells were aggregated in suspension for 3 days to form EBs before a 4 week 
incubation in either osteo-inductive or control media. Duplicate EB samples were 
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dissociated to single cell suspensions before the 4 week incubation. Figs 5.7 and 5.8 
show quantification of osteogenic differentiation within these samples through ALP 
activity and bone nodule formation, respectively. All samples cultured in osteo-
inductive media showed greater osteogenic differentiation than comparable samples 
cultured in control media (Figs 5.7A and C). This trend was observed in both settled 
and dissociated EB samples (Figs 5.8A and C). Settled EB samples exhibited 
significantly ȋ  ?  ?Ǥ ? ? ?Ȍincreased ALP activity and bone nodule formation in both 
engineered and control samples compared to dissociated EB samples (Figs 5.7B and 
5.8B). This was observed at both 5 x 104 and 2.5 x 105 cells/mL, but only when 
samples were cultured in osteo-inductive media. No difference was observed 
between settled and dissociated EB samples when cultured in control media (Figs 
5.7D and 5.8D). However, settled EBs from engineered samples did show a 
significant (P  ? ?Ǥ ? ? ?Ȍincrease in osteogenic differentiation when cultured in control 
media at 5 x 104 cells/mL, in comparison to dissociated EBs (Fig 5.7C). Both settled 
and dissociated EBs exhibited increased ALP activity and bone nodule formation in 
engineered samples compared to control samples. However, this was only observed 
in samples originally seeded at 5 x 104 cells/mL. At high initial seeding density in 
control media, engineered samples did not exhibit a marked increase in either ALP 
activity or bone nodule formation when compared to control samples (Figs 5.7D and 
5.8D). As previously mentioned, all trends observed in Fig 5.7 reflected those in Fig 
5.8, again highlighting a link between ALP activity and bone nodule formation. 
However, the relationship between them is more complicated than first appears. The 
relative changes in ALP activity were not matched by those in bone nodule formation 
between samples. For example, the relative decrease in ALP activity between 
engineered samples cultured in osteo-inductive and control media was greatly  
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Figure 5.7: ^ĞƚƚůĞĚ  ‘ǀƐ ?ĚŝƐƐŽĐŝĂƚĞĚEB differentiation and osteogenic differentiation; assessed by 
ALP assay. Engineered and control ES cells were seeded into mass suspension at 5 x 10
4
 cells/mL 
(A and C) and 2.5 x 10
5
 cells/mL (B and D), rotated at 15rpm for 6hrs and cultured for 3 days at 
37°C and 5% CO2 in a humidified atmosphere. After 3 days, these EBs were either transferred 
directly into osteo-inductive (A and B) or control (C and D) media, or dissociated via trypsinization 
prior to transfer. After transfer to osteogenic culture, all samples were cultured for 4 weeks. After 
4 weeks, osteogenic differentiation was quantified by ALP assay. All experiments were repeated in 
triplicate and each experiment recorded ALP activity in triplicate; n = 9.  ? ? ?WA? ? ? ? ? ? ? ? ?WA? ? ? ? ? ?
 ?WA䜀  ? ? ? ? ?ƌƌŽƌďĂƌƐA?^ ? ?D ? 
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Figure 5.8: ^ĞƚƚůĞĚ  ‘ǀƐ ?ĚŝƐƐŽĐŝĂƚĞĚĚŝĨĨĞƌĞŶƚŝĂƚŝŽŶĂŶĚosteogenic differentiation; assessed by 
Alizarin Red assay. Engineered and control ES cells were seeded into mass suspension at 5 x 10
4
 
cells/mL (A and C) and 2.5 x 10
5
 cells/mL (B and D), rotated at 15rpm for 6hrs and cultured for 3 
days at 37°C and 5% CO2 in a humidified atmosphere. After 3 days, these EBs were either 
transferred directly into osteo-inductive (A and B) or control (C and D) media, or dissociated via 
trypsinization prior to transfer. After transfer to osteogenic culture, all samples were cultured for 
4 weeks. After 4 weeks, osteogenic differentiation was quantified by Alizarin Red assay. All 
experiments were repeated in triplicate and each experiment recorded Alizarin Red staining in 
triplicate; n = 9.  ? ? ?WA? ? ? ? ? ? ? 踃?WA䜀  ? ? ? ? ? ?WA䜀  ? ? ? ? ?Error bars = S.E.M. 
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different to the relative decrease in their bone nodule formation. Overall, settled EBs 
from engineered samples exhibited the greatest increase in osteogenic 
differentiation compared to dissociated EBs from control samples. However, 
enhancement was lost at high initial seeding density when cultured in control media. 
5.3.4. Effect of Embryoid Body Stage on Osteogenic differentiation 
To investigate further the effect that differentiating ES cells through the EB stage had 
on downstream osteogenic differentiation, ES cells were aggregated for variable 
lengths of time prior to incubation with osteo-inductive or control media. EBs that 
were aggregated for only 1 day showed little or no osteogenic differentiation 
regardless of media and at both seeding densities. There was a significant ȋ ? ?Ǥ ? ? ?Ȍ
increase in bone nodule formation after 3 days of aggregation in both engineered 
and control samples (Figs 5.9A and C). However, this was only observed when 
samples were cultured in osteo-inductive media. Bone nodule formation decreased 
significantly ȋ ? ?Ǥ ? ? ?Ȍwith longer aggregation time up to 9 days. Engineered EBs 
exhibited significantly ȋ ? ?Ǥ ? ? ?Ȍgreater bone nodule formation than control EBs at 
both 5 x 104 and 2.5 x 105 cells/mL when cultured in osteo-inductive media. This 
enhancement was observed primarily in samples aggregated for 3 days and then 
slowly diminished with longer aggregation time. When cultured in control media, 
only engineered samples seeded at 5 x 104 cells/mL and aggregated for 3 days 
showed significant ȋ  ?  ?Ǥ ? ? ?Ȍbone nodule formation to a detectable level (Fig 
5.9B). ǡ     ȋ  ?  ?Ǥ ? ? ?Ȍ 
constituting only 6% of that when cultured in osteo-inductive media. Overall, it 
appeared that ES cells aggregated for 3 days showed the greatest increase in bone 
nodule formation, and that engineering enhanced this osteogenic differentiation 
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Figure 5.9: Effect of EB stage on ES cell differentiation and osteogenic differentiation: assessed by 
bone nodule counts. Engineered and control ES cells were seeded into mass suspension at 5 x 10
4
 
cells/mL (A and B) and 2.5 x 10
5
 cells/mL (C and D) rotated at 15rpm for 6hrs and cultured for 1 to 
9 days at 37°C and 5% CO2 in a humidified atmosphere. After 1, 3, 5, 7 and 9 days, EBs were 
transferred to gelatin-coated plates in either osteo-inductive (A and C) or control (B and D) media 
and cultured for 4 weeks. After 4 weeks, osteogenic differentiation was assessed via Alizarin Red 
stained bone nodule counts. Bone nodule numbers were equalized between samples using 
Hoescht data taken from duplicate samples, and expressed as bone nodules per 1 x 10
6
 cells. 
Important to note is the different y axis scale between Figs A/C and B/D. Experiments were 
repeated in triplicate and each experiment recorded bone nodules in triplicate; n = 9.  ? ? ? W A?
 ? ? ? ? ? ? ? ?WA䜀  ? ? ? ? ? ?WA䜀  ? ? ? ? ?ƌƌŽƌďĂƌƐA䄀 ^ ? ?D ? 
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further. However, enhancement was dependent on both initial seeding density of 
constituent ES cells and culture media composition. 
Fig 5.10 shows images of Alizarin Red stained bone nodules with engineered and 
control samples originally cultured from EBs aggregated for 3 days. All samples 
cultured in osteo-inductive media consequently formed bone nodules. However, it 
was clear that when cultured in control media, only engineered samples seeded at 5 
x 104 cells/mL exhibited bone nodule formation (Fig 5.10B). It was also clear to see 
that much of the sample around bone nodules highlighted in red was stained 
pink/purple. Bone nodules were variable is size and shape between samples. 
5.3.5. Aggregation Time and Osteogenic differentiation 
Due to osteogenic differentiation results in Fig 5.9, aggregation time for all 
subsequent experiments was set at 3 days. Osteogenic differentiation within 
engineered and control EBs was assessed over the 4 week incubation period in 
either osteo-inductive or control media. Only samples originally seeded at 5 x 104 
cells/mL were investigated. Osteogenic differentiation was again quantified through 
Alizarin Red stained bone nodule counts (Fig 5.11). Neither engineered nor control 
EBs exhibited bone nodule formation after 1 week in culture. Bone nodules were first 
observed after 2 weeks culture. However, only engineered samples exhibited bone 
nodule formation after 2 weeks. Control samples first exhibited bone nodule 
formation after 3 weeks, but only when cultured in osteo-inductive media (Figs 
5.12K and O). No bone nodules were observed in control samples cultured in control 
media over the whole 4 week period investigated (Figs 5.11B, 5.12L and P). After 
initial occurrence, the number of bone nodules increased significantly ȋ  ?  ?Ǥ ? ? ?Ȍǡ
then slowed as indicated by a plateau in Fig 5.11A. No difference was observed 
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Figure 5.10: Osteogenic differentiation within samples originally aggregated for 3 days; assessed 
by Alizarin Red stained bone nodules. ES cells were seeded into mass suspension rotated at 
15rpm for 6hrs and cultured for 3 days. After 3 days, EBs were transferred to osteogenic culture in 
either osteo-inductive or control media and cultured for 4 weeks. After 4 weeks, all cultures were 
stained with Alizarin Red solution to highlight bone nodule formation. 
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Figure 5.11: Effect of engineering on osteogenic differentiation over time. Engineered and control 
ES cells were seeded into mass suspension 5 x 10
4
 cells/mL rotated at 16rpm for 6hrs and cultured 
for 3 days at 37°C and 5% CO2 in a humidified atmosphere. After 3 days, EBs were transferred to 
gelatin-coated plates and cultured in either osteo-inductive (A) or control (B) media for 4 weeks. 
After 1, 2, 3 and 4 weeks, osteogenic differentiation was quantified via Alizarin Red stained bone 
nodule counts. Bone nodule numbers were equalized between samples using Hoescht data taken 
from duplicate samples, and expressed as bone nodules per 1 x 10
6
 cells. Experiments were 
repeated in triplicate and each experiment recorded bone nodules in triplicate; n = 9.  ? ? ? W A?
 ? ? ? ? ? ? ? ?WA䜀  ? ? ? ? ? ?WA䜀  ? ? ? ? ?ƌƌŽƌďĂƌƐA䄀 ^ ? ?D ? 
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Figure 5.12: Osteogenic differentiation over time; assessed by Alizarin Red stained bone nodules. 
Engineered and control ES cells were seeded into mass suspension at 5 x 10
4
 cells/mL rotated at 
16rpm for 6hrs and cultured for 3 days at 37°C and 5% CO2 in a humidified atmosphere. After 3 
days, EBs were transferred to gelatin-coated plates and cultured in either osteo-inductive or 
control media for 4 weeks. After 1, 2, 3 and 4 weeks, osteogenic differentiation was identified by 
Alizarin Red stained bone nodules. 
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between control samples cultured in osteo-inductive media (Fig 5.11A). Samples 
cultured in osteo-inductive media generated significantly ȋ  ?  ?Ǥ ? ? ?Ȍgreater 
numbers of bone nodules than equivalent samples cultured in control media. Overall, 
engineered samples exhibited bone nodule formation earlier than control samples. 
When control samples exhibited bone nodule formation, it was significantly ȋ  ?
0.001) less than that in engineered samples. Bone nodules were irregular in shape 
and variable in size (Fig 5.12). Areas around bone nodules appeared pink/purple as a 
result of background stain. Bone nodules were observed both within and at the 
periphery of EBs which had either completely or partially spread out. They also 
increased in size over time. This occasionally caused the boundaries between 
individual nodules to become blurred. 
Fig 5.13 shows photographs taken of engineered and control cultures at 1x 
magnification. Bone nodules within engineered and control samples cultured in 
osteo-inductive media were clearly visible. However, after 4 weeks of culture many 
nodules had increased in size so much that they had begun to overlap and could have 
been mistaken as one during quantification. Higher magnification helped resolve 
bone nodule boundaries. However, some were still indistinguishable. Another 
problem shown in Figs 5.13A and C was the occurrence of many tiny and positively 
stained specks located around any large bone nodules. These occurred in both 
engineered and control samples mainly after 3 weeks incubation in osteo-inductive 
media.  
PCR amplification of osteogenic markers supported bone nodule observations (Fig 
5.14). Since bone nodule formation was not observed after just 1 week in culture, 
samples were taken after a minimum of 2 weeks. Cultures were tested again after the 
full 4 weeks for comparison to assess osteogenic differentiation over time. Both 
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Figure 5.13: Effect of extended bone nodule formation. Engineered (A and B) and control 1 (C and 
D) ES cells were seeded into mass suspension at 5 x 10
4
 cells/mL rotated at 16rpm for 6hrs and 
cultured for 3 days at 37°C and 5% CO2 in a humidified atmosphere. After 3 days, EBs were 
transferred to gelatin-coated plates and cultured in either osteo-inductive (A and C) or control (B 
and D) media for 4 weeks. After 4 weeks, osteogenic differentiation was identified by Alizarin Red 
stained bone nodules. 
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Figure 5.14: Osteogenic differentiation over time; assessed by PCR amplification. Engineered and 
control ES cells were seeded into mass suspension at 5 x 10
4
 cells/mL rotated at 16rpm for 6hrs 
and cultured for 3 days at 37°C and 5% CO2 in a humidified atmosphere. After 3 days, EBs were 
transferred to gelatin-coated plates and cultured in either osteo-inductive or control media for 4 
weeks. After 2 and 4 weeks, EBs were incubated in papain buffer and whole lysates were analyzed 
by PCR amplification for osteogenic markers Runx2 and OPN. GAPDH was used as a quality 
control. Bands were scanned using densiometric analysis and equalized between samples using 
GAPDH expression levels. Cell extracts from adult mouse femurs were used as a positive control. 
Negative controls were prepared by not adding cDNA templates to the PCR mix before 
amplification. Error bars = standard deviation. 
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engineered and control samples exhibited OPN expression after 2 and 4 weeks in 
either osteo-inductive or control media. Both engineered and control samples 
exhibited Runx2 expression after 2 weeks which decreased after 4 weeks, in both 
osteo-inductive and control media. GAPDH expression and positive controls showed 
that the primer pairs and reverse transcription had worked efficiently. Duplicate 
engineered and control ES cell cultures seeded at 5 x 104 cells/mL and aggregated for 
3 days, were stained with Alcian Blue solution after 4 weeks incubation in osteo-
inductive or control media (Fig 5.15). Positive stain was observed in both engineered 
and control samples cultured in both osteo-inductive and control media. Staining 
appeared speckled and widespread throughout all cultures (Fig 5.15D). However, 
concentrated regions of positive staining were located at sites of initial attachment 
and within thick accumulations of cells (Figs 5.15A and B). 
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Figure 5.15: EB differentiation and chondrogenesis; assessed by Alcian Blue stain. Engineered and 
control ES cells were seeded into mass suspension at 5 x 10
4
 cells/mL rotated at 16rpm for 6hrs 
and cultured for 3 days at 37°C and 5% CO2 in a humidified atmosphere. After 3 days, EBs were 
transferred to gelatin-coated plates and cultured in either osteo-inductive or control media for 4 
weeks. After 4 weeks, cultures were stained with Alcian Blue solution to label GAGs and 
mucopolysaccharides within deposited collagen matrix, an indicator of chondrogenic 
differentiation. 
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5.4. Discussion 
Many studies have investigated osteogenic differentiation and the events involved in 
bone development with the intention of understanding the underlying mechanisms 
(Buttery et al., 2001). ES cell differentiation has been effectively directed towards the 
osteogenic lineage through the combination of EB formation and exogenously added 
growth factors (Bellows et al., 1990). However, due to a lack of understanding 
concerning mechanisms occurring within the EB and their effect on ES cell 
differentiation, it is difficult to decipher essential parameters which affect osteogenic 
differentiation. Controlled ES cell aggregation and formation of EBs exhibiting 
specified properties, afforded by the previously described surface engineering, could 
provide a means to understanding early events in osteogenic differentiation. Here it 
is shown that engineered EBs significantly ȋ  ?  ?Ǥ ? ? ?Ȍincreased osteogenic 
differentiation in comparison to control samples. Characterization of the EB stage 
and investigation of ALP activity, bone nodule formation and osteogenic markers 
indicated susceptibility to osteo-induction within engineered samples. This may have 
been the consequence of increased cell number, accelerated EB formation, altered ES 
cell-ES cell interaction, and/or altered ES cell-ECM interaction. Although these 
results do not definitively identify parameters of EB formation which affect 
osteogenic differentiation and their mode of action, they do warrant further 
investigation of engineered ES cell aggregation.  
5.4.1. Embryoid Body Adhesion and Growth 
One major similarity between engineered and control samples was that neither had 
adhered to collagen-coated wells whether cultured in osteo-inductive or control-
Chapter 5                 Results: EB Osteogenic Potential 
 
199 
 
media. EBs appeared inhibited or unable to interact with the collagen even though 
both medias contained Asc to aid ECM production and adhesion. It may be that the 
differentiated surface cells did not express the required surface integrins. It may also 
be possible that there was interaction with the type I collagen which caused 
differentiation towards non-adherent cell types. However, previous studies have 
shown that interaction with type I collagen does not induce differentiation of mouse 
ES cells (Hayashi et al., 2007). 
Control EBs appeared to dissociate over time forming single cell suspensions by day 
28 when cultured on collagen-coated plates, suggestive of cell death. Engineered 
samples however, exhibited intact EBs by day 28 due to the increased structural 
integrity afforded by engineered intercellular interaction. Although EBs were intact 
they exhibited a darkened appearance, far different from that of their initial 
translucent appearance. This darkening/blackening effect may have been an artefact 
of cell death within the core. Alternatively, it may simply have been due to refraction 
of the light as a result of cell proliferation and changing density, or differentiation 
towards perhaps pigmented cells. The fact that darkened areas also appeared in EBs 
which had adhered and thrived lends support to the idea that cell density and/or 
differentiation explains their presence and not cell death. The collagen employed 
was acid-soluble and therefore required an acidic environment to be solubilized and 
coat the wells. It may have been that the acid solvent was not sufficiently washed 
away before EBs were seeded into suspension. This would have altered local pH 
levels affecting cell adhesion.  
Similar observations were made in samples seeded onto uncoated plates. Engineered 
EBs cultured in osteo-inductive and control media, and control EBs cultured in 
control media all remained free-floating after 28 days. They also exhibited the 
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characteristic darkened appearance as few as 7 days after initial seeding. Some EBs 
were intact after 28 days, but large quantities had dissociated into single cell 
suspensions. This may be a consequence of EBs remaining in suspension. Free-
floating EBs would have undergone extensive cell death within their cores over 28 
days of culture due to decreased nutrient and gaseous exchange. Therefore, lack of 
adhesion would indirectly cause advanced ES cell death within the EB samples at 
large. Control EBs cultured on uncoated plates in osteo-inductive media had adhered 
and spread out during 28 days of culture. This may be due to a number of reasons 
including increased ECM deposition when cultured in osteo-inductive media or 
affected natural adhesion by engineering. However, the reason may be more 
complicated and remains unclear. Ultimately, it was concluded that both uncoated 
and collagen-coated plates were not sufficient for EB adhesion and growth. 
Both engineered and control EBs had adhered to fibronectin and gelatin-coated 
plates after 7 days in osteo-inductive media, and 14 days in control media. Osteo-
inductive media had therefore accelerated ES cell-matrix interaction and adhesion. 
EBs maintained a translucent appearance throughout, although some darkened 
patches were observed. This was most likely due to extensive ECM deposition 
causing refraction of the light. By day 28, EBs had adhered and spread outwards. It 
appeared that integrins expressed on the EB surface were specific for both 
fibronectin and gelatin (Critchley et al., 1999). Gelatin was chosen to coat plates for 
all subsequent experiments. 
EB adhesion and spreading occurred in stages depicted in Fig 5.4. EBs were seeded 
into suspension and were heavy enough to sink to the bottom. Once in contact with 
the gelatin-coated surface the EBs made initial attachment. This attachment was 
weak and could easily be broken by vigorous shaking of the whole suspension. After 
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initial attachment EBs became adhered to the well surface (Fig 5.4B). Prior to 
adherence, EBs exhibited a ringed structure around their core (Fig 5.4A). The core 
appeared dense and spherical, but the surface appeared random and uneven. 
However, smaller EBs did not exhibit this ring structure. They were simply ES cell 
accumulations resembling the surface of larger EBs. The ringed appearance 
illustrated the structural differences within EBs discussed in Chapter 4. The fact that 
smaller EBs did not exhibit structural differences showed that EB reorganisation was 
associated with size. After adherence, EBs began to flatten and spread outwards. 
Expansion from the site of initial attachment was also due to cell proliferation and 
highly mobile cells. Differentiating cells from the EB surface would have been the 
first to migrate outwards since undifferentiated ES cells exhibit characteristic 
nucleated growth (Stewart et al., 2008, Stojkovic et al., 2004, Imreh et al., 2004, Heng 
et al., 2005). These migrating cells had a flattened and stretched appearance similar 
to that of cultured fibroblasts (Fig 5.4D). These initial outgrowing cells provided a 
platform for further spreading and proliferation of the EB mass. After 7 days in 
culture, the central EB mass had spread out and begun to form a thick fringe of newly 
proliferated and/or differentiated cells (Fig 5.4E). However, the original mass of the 
EB was not completely lost and could still be distinguished by eye (Fig 5.4F). 
Differentiating cells within the EB may not have been mobile enough to migrate 
further away and therefore remained at the site of attachment. Alternatively, 
extensive ECM deposition between ES cells during the EB stage and initial adhesion 
could have trapped constituent cells and inhibited their migration. This also 
indicated that remodelling of ECM was either not occurring or not occurring fast 
enough to have been observed over 28 days. Engineered EBs appeared to exhibit 
accelerated adhesion as depicted in Figs 5.4G to L. 
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5.4.2. Embryoid Body Differentiation 
 ? ? ? ? ? ? ? ?ŵďƌǇŽŶŝĐ^ƚĞŵĞůů ?ǀƐ ?ŵďƌǇŽŝĚŽĚǇOsteogenic Differentiation 
Previous studies have shown that ES cells differentiate towards the osteogenic 
lineage without prior EB formation (Hwang et al., 2008b, Karp et al., 2006). However, 
these studies employed EBs aggregated for the standard 5 days and therefore were 
subject to any inhibitory effects of core necrosis on osteogenic differentiation. This 
may have accounted for the difference observed between samples with and without 
prior EB formation. To investigate whether EB formation was an essential step, both 
ES cells without an aggregation step and EBs were investigated for osteogenic 
differentiation. Both engineered and control samples with prior EB formation ȋ ? 0.001) increased osteogenic differentiation (Figs 5.5A and 
B). However, osteogenic differentiation was still observed in ES cell samples without 
prior EB formation (Figs 5.6A and B). Consequently, EB formation enhanced 
osteogenic differentiation but was not essential. However, this enhancement was 
only observed in samples cultured in osteo-inductive media. EB formation may 
therefore have made ES cells more sensitive to osteo-induction rather than actually 
driving or stimulating osteogenic differentiation. If engineering drove osteogenic 
differentiation then enhancement would have been expected in all engineered 
samples regardless of exogenous cues. Osteogenic differentiation in control samples 
with and without prior EB formation and cultured in control media was not 
significantly different (Figs 5.5C and D). Engineered samples with prior EB formation 
exhibited significantly ȋ ? 0.001) increased ALP activity and bone nodule formation 
than those without prior EB formation. This suggested engineered EBs may drive 
osteogenic differentiation of constituent ES cells whereas control EBs simply 
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increase sensitivity or responsiveness to exogenous osteo-inductive cues. A major 
difference between engineered and control EBs was their constituent ES cell 
densities. It may be that tighter adhesion between ES cells and mechanical stresses 
emanating from being in a high density environment drove osteogenic 
differentiation. In vivo osteogenesis involves environmental cues such as compaction 
and condensation which may occur from high density mechanical stress (Hall and 
Miyake, 1992, Titushkin and Cho, 2007). Therefore, engineered EBs may to some 
extent replicate this environment in vitro. 
At higher seeding densities (above 2.5 x 105 cells/mL) engineered EBs did not exhibit 
significantly increased osteogenic differentiation compared to control EB samples. 
ES cell suspensions at high density have previously been shown to generate larger 
EBs comprising more ES cells than those at 5 x 104 cells/mL (Chapter 4: Fig 4.4). No 
significant difference was observed between the ES cell densities of engineered EBs 
at both 5 x 104 and 2.5 x 105 cells/mL. The only difference observed was in 
constituent ES cell number. Therefore, osteogenic differentiation may be directly 
linked to ES cell number. Greater ES cell numbers may have had a negative effect on 
osteogenic differentiation. The increased number of EBs at high initial seeding 
density may have caused increased inter-EB signalling. This may have had a negative 
effect on osteogenic differentiation. Alternatively, larger EBs from engineered 
samples at 2.5 x 105 cells/mL would have taken longer to spread out after adhesion 
or shown restricted spreading. Lateral migration, monolayer formation and minimal 
3D interaction involved in spreading after the EB stage may therefore have been 
important in osteogenic differentiation. Previous studies have highlighted the 
importance of cell shape on cell function and therefore on cell differentiation (Chen 
et al., 1998). The change from EB to monolayer culture (3D to 2D) would have had 
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considerable effect on ES cell shape. In summary, engineered EBs may have provided 
internal dynamics that had a positive effect on osteogenic differentiation, but were 
sensitive to initial seeding density. 
 ? ? ? ? ? ? ? ?^ĞƚƚůĞĚ ?ǀƐ ?ŝƐƐŽĐŝĂƚĞĚŵďƌǇŽŝĚŽĚǇOsteogenic Differentiation 
Previous studies have shown that dissociating EBs prior to osteo-induction aids 
osteogenic differentiation (Woll et al., 2006). Both intact and dissociated EBs were 
consequently investigated for their effects on osteogenic differentiation (Figs 5.7 and 
5.8). Settled EBs exhibited significantly ȋ  ? 0.001) increased osteogenic 
differentiation compared to dissociated EBs in both engineered and control samples 
when cultured in osteo-inductive media at both 5 x 104 and 2.5 x 105 cells/mL (Figs 
5.7A and B). Clearly, enhancement provided by the EB stage was detrimentally 
affected by dissociation. However, dissociated samples still exhibited greater 
osteogenic differentiation than samples without prior EB formation, indicating that 
enhancement during the EB stage was not completely lost as a consequence of 
dissociation. Continued 3D interaction between ES cells within the EB structure may 
be beneficial to osteogenic differentiation (Tian et al., 2008, Purpura et al., 2004). 
However, it was previously shown that a transition from 3D to 2D culture 
demonstrated increased osteogenic differentiation (Bourne et al., 2004, Buttery et 
al., 2001). Dissociation would inevitably cause the formation of a 2D culture. 
Therefore, an alternative explanation is required for the difference between settled 
and dissociated EBs. Dissociation not only destroys 3D interaction between ES cells 
but also removes any ECM made during the EB stage. ECM acts as a scaffold and 
provides the basis for shape and structure of constituent proliferating and 
differentiating ES cells (Sachlos and Auguste, 2008, Prestwich, 2008, Prestwich, 
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2007). As stated previously, the shape and morphology of cells affects their function 
and differentiation (Thomas et al., 2002). It is possible that the continued ES cell-
ECM interaction afforded by settled EB culture helped in promoting cell-cell 
signalling for osteo-induction. When the same samples were cultured in control 
media there was no observed difference between settled and dissociated EBs. 
Therefore, it is unlikely that continued ES cell-ECM interaction alone efficiently 
induces osteogenic differentiation. Instead, it could cause responsiveness to 
exogenous osteo-inductive cues. However, settled EBs within engineered samples at 
5 x 104 cells/mL did exhibit significantly (P  ? 0.001) increased osteogenic 
differentiation compared to equivalent dissociated EBs when cultured in control 
media (Figs 5.7C and 5.8C). These dissociated EBs also showed significant (P  ? 
0.001) increase in osteogenic differentiation compared to equivalent control samples 
demonstrating that engineered samples enhanced osteogenic differentiation with or 
without exogenous osteo-induction. Engineering increased the interaction between 
ES cells and accelerated EB formation. It is possible that accelerated ES cell-ECM 
interaction was more advanced than that in control samples. The lack of increased 
osteogenic differentiation between settled and dissociated EBs in control samples 
cultured in control media may have therefore been due to a lack of advanced ES cell-
ECM interaction. Three days of aggregation appeared to have been insufficient for 
control samples to reach the advanced stage of ES cell-ECM interaction which was 
observed in engineered EBs over the same time period.  
The lack of enhancement in engineered samples at 2.5 x 105 cells/mL could have 
been the effect of exceeding a critical cell number within the EB beyond which had a 
negative effect on osteogenic differentiation. Cell number can affect many properties 
including density (Carpenedo et al., 2007), cell-cell interaction (Chen et al., 2008), 
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cell-matrix interaction (Giancotti and Ruoslahti, 1999), viability (Cormier et al., 
2006) and differentiation (Kurosawa, 2007, Kim et al., 2007a, Koike et al., 2007). 
Altering of any or all of these properties may have had drastic effects on ES cell 
differentiation (Ng et al., 2005). Overall, engineered samples exhibited advanced ES 
cell-ES cell and ES cell-ECM interactions which may have caused increased 
sensitivity to exogenous osteo-induction. 
Bone nodule formation is strictly a function of osteoblasts and is therefore a 
relatively accurate measurement for osteogenic differentiation quantification (Cao et 
al., 2005, Buttery et al., 2001). On the other hand, other cell types including the liver, 
kidney and intestinal epithelium have been shown to exhibit ALP activity (Fernandez 
and Kidney, 2007, Martins et al., 2001, Wood et al., 2003). ALP activity is also a 
standard pluripotency marker for undifferentiated ES cells (Berrill et al., 2004). 
Therefore, ALP activity must not accurately represent the true level of osteogenic 
differentiation. A new study has proven that ALP activity is in fact not proportional 
to mineralization (Hoemann et al., 2008). However, the study investigated adult bone 
cells and bone marrow stromal cells. Therefore it is only suggestive that ALP activity 
is not proportional to bone nodule formation within ES cell samples. Osteogenic 
differentiation within all investigated samples was far from homogeneous. 
Therefore, the ALP assays conducted may have measured ALP activity from these 
contaminating ALP-positive cells in addition to that from osteoblasts. Bone nodules 
were chosen for osteogenic differentiation quantification over ALP activity for all 
ensuing investigations. 
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5.4.3. Embryoid Body Development and Osteogenic Differentiation 
To investigate the effect of EB stage on osteogenic differentiation, ES cells were 
aggregated between 1 and 9 days prior to 4 weeks incubation in osteo-inductive or 
control media (Fig 5.9). All samples exhibited purple background staining which may 
have interfered with absorbance readings after chemical leaching (Fig 5.10). 
Consequently, bone nodules were photographed and counted, rather than assayed to 
maintain accurate quantification of osteogenic differentiation. Both engineered and 
control EBs aggregated for 1 day exhibited significantly (P  ? ?Ǥ ? ? ?Ȍ
formation than those aggregated for longer time periods (Figs 5.9A and C). Samples 
aggregated for 3 days exhibited a significant (P  ? 0.001) increase in bone nodule 
formation. Clearly, enhancement of osteogenic differentiation via the formation of 
EBs was dependent on aggregation time. It was possible that 1 day was insufficient 
time for EBs to accumulate an appropriate number of ES cells, undergo spontaneous 
differentiation and/or produce suitable quantities of ECM. It has previously been 
mentioned that ES cell-ECM interaction has an important role to play in ES cell 
differentiation (Ilic, 2006). It appeared that 3 days of aggregation was sufficient time 
for the EB stage to affect constituent ES cell differentiation and cause significant (P  ? 
0.001) increase in osteogenic differentiation. However, the trend between EB stage 
and osteogenic differentiation was not linear. After 3 days of aggregation all samples 
showed significant (P  ? 0.001) decrease in osteogenic differentiation up to 9 days. It 
has been shown that EBs aggregated for longer than 3 days begin to suffer core 
necrosis (Chapter 4). Cell death is an important event in embryogenesis and is 
involved in the differentiation of specific cell types (Hurle et al., 1995). Necrosis may 
therefore have triggered complex signalling for the differentiation of non-osteogenic 
cells (Yamashita et al., 2009, Trouillas et al., 2008). Longer aggregation periods have 
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also been shown to reduce osteogenic differentiation and increase cardiomyogenesis 
within resultant EBs (Hwang et al., 2006b). It is therefore possible that 3 days was 
optimum time for initiation of osteogenic differentiation prior to 2D culture, and that  ?  ?    ntiation of constituent ES cells towards alternative 
cell lineages. The observation of beating cardiomyocytes within all samples supports 
this assumption (data not shown). Engineered samples exhibited significantly (P  ?
0.001) increased bone nodule formation compared to control samples when cultured 
in osteo-inductive media (Figs 5.10A and B). The increase in osteogenic 
differentiation in engineered EBs after 3 days may have been due to the increased 
number of ES cells which remained viable and the advanced ES cell-ECM interaction. 
However, this enhancement became gradually diminished beyond 3 days of 
aggregation. Again, this may have been due to the occurrence of core necrosis 
beyond 3 days.  
An interesting observation was made when samples were cultured in control media 
(Figs 5.9B and D). At 2.5 x 105 cells/mL engineered EBs formed bone nodules (Fig 
5.10D), whereas control EBs did not form bone nodules in samples cultured for more 
than 1 day (Fig 5.10H). However, control samples only exhibited one or two bone 
nodules in the whole sample and therefore may simply have been due to chance 
differentiation, rather than optimised parameters for osteogenic differentiation. The 
lack of bone nodule formation in all samples indicated that any enhancement was 
oriented towards sensitivity to osteo-induction rather than directed osteogenic 
differentiation. The lack of bone nodules also indicated that Alizarin Red absorbance 
readings in Figs 5.6 and 5.8 were potentially inaccurate. The absorbance readings 
may have been of background stain rather than positive stain. However, if we 
considered this to be true and subtracted the values for samples cultured at 2.5 x 105 
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cells/mL in control media from all others as a blank (background stain), the same 
trends would still be observed. It is also possible that bone nodules were too small to 
see within the samples since data in Fig 5.9 represented bone nodules counted by 
eye. Another interesting observation was made when samples were cultured at 5 x 
104 cells/mL in control media (Fig 5.9B). Only engineered EBs exhibited bone nodule 
formation after the optimum 3 days of aggregation (Fig 5.10B). Clearly, engineered 
samples show directed osteogenic differentiation without exogenous osteo-
induction. However, the increase was only 6% of that found in osteo-inductive 
media. Therefore, engineered samples could simply have directed differentiation of a 
progenitor cell toward the osteogenic lineage. The 6% observed in control media 
may therefore have been chance osteoblast differentiation after enhancement of 
progenitor cells. Overall, engineered samples exhibited significantly (P  ? 0.001) 
increased osteogenic differentiation compared to control samples after an optimum 
aggregation period of 3 days. However, enhancement was significantly (P  ? 0.001) 
reduced in control media at 5 x 104 cells/mL and completely lost in control media at 
2.5 x 105 cells/mL. 
5.4.4. Engineered Osteogenic Differentiation over Time 
To investigate osteogenic differentiation within engineered and control samples over 
the 4 week incubation period, osteogenic differentiation was quantified every week 
during incubation (Fig 5.11). The number of bone nodules increased significantly (P  ? 0.001) over time, indicating that new ES cells were differentiating towards the 
osteogenic lineage. However, the same osteoblasts could simply have migrated and 
produced a second or third bone nodule. Migration was indicated by irregular 
shaped bone nodules (Fig 5.12E and K). If osteoblasts were stationary then nodules 
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would logically appear perfectly circular. Alternatively, if osteoblasts were mobile 
and migrating across the culture whilst mineralising, then nodules would logically 
become irregular and elongated in the direction of migration. Bone nodules also 
increased in size over time which may have caused overestimation of osteogenic 
differentiation when quantified by assay (Figs 5.12F, J and N). A more accurate 
method of quantification would have involved taking diameter measurements of 
individual bone nodules within a representative area and calculation of average bone 
nodule number against surface area coverage. Highly functional osteoblasts would 
mineralize more matrix generating larger bone nodules. Therefore, measurement of 
bone nodule size would provide indirect measurement of differentiated osteoblast 
function within engineered and control samples. Bone nodule counts give good 
estimation of individual occurrences of osteoblastic differentiation and bone nodule 
size measurements would illustrate continued function of these osteoblasts. 
Migration of osteoblasts to a second deposition site and continued mineralization at 
established sites caused merging of individual bone nodules. Visualisation of bone 
nodules by eye was inadequate to distinguish between individual nodules at 2.5 x 
105 cells/mL (Figs 5.13A and C). Samples were consequently viewed at 10x 
magnification. This helped resolve boundaries between separate bone nodules. 
However, some overlap remained and quantification was therefore subject to human 
error when attempting to visualise separate nodules. 
When cultured in control media, only engineered samples formed bone nodules 
which again equated to ~5-6% of that when the same engineered samples were 
cultured in osteo-inductive media. Control samples did not exhibit any obvious bone 
nodules (Figs 5.12D, H, L and P). Engineered samples interestingly exhibited bone 
nodule formation after only 2 weeks in culture in either osteo-inductive or control 
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media compared to control samples taking 3 weeks (Fig 5.11A and B). This 
emphasized the idea that enhancement within engineered samples was partly due to 
accelerated ES cell aggregation, EB formation and ES cell-ECM interaction. The 
increase in bone nodule formation between weeks 2 and 3 was greater than the 
difference between weeks 3 and 4. This may have been due to limited space within 
the wells or complete differentiation of the sample. If the whole culture had 
differentiated then there would be no more spontaneous occurrence of osteoblasts 
and therefore a possible reduction in the number of new bone nodules. Alternatively, 
continued deposition and formation of new nodules may have filled available space 
by week 4 and caused the quantification trend to plateau. The increase in bone 
nodule formation in samples cultured in control media was linear, possibly due to 
less osteoblasts having more space in which to form new bone nodules, and more 
space for existing nodules to increase in size due to the inherent lower levels of 
osteogenic differentiation. At 2.5 x 105 cells/mL, there was a notable decrease in 
osteogenic differentiation as a result of decreased space between EBs and 
differentiated osteoblasts. 
Limitations to the efficacy of both Alizarin Red assay and bone nodule count 
regarding osteogenic differentiation quantification have been identified.  Therefore, 
samples were assessed for osteogenic differentiation by PCR amplification of the 
transcription factor related gene, Runx2 and the bone related gene, OPN (Valenti et 
al., 2008, Randle et al., 2007). Samples were taken after 2 weeks when osteogenic 
differentiation was first observed and then again after 4 weeks at the end of the 
incubation period (Fig 5.14). Engineered samples exhibited OPN expression after 2 
and 4 weeks of culture in both osteo-inductive and control media. Runx2 expression 
was also observed, but reduced after 4 weeks. Control samples also exhibited both 
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OPN and Runx2 expression when cultured in osteo-inductive media which correlates 
with observations of bone nodule formation in Fig 5.11A. However, control samples 
also exhibited OPN and Runx2 expression when cultured in control media. This is 
inconsistent with observations made in Fig 5.11B. This may have been due to the 
increased sensitivity of PCR amplification compared to Alizarin Red stained bone 
nodules. Strong expression of OPN was observed after 2 and 4 weeks which was 
consistent with the presence of functional osteoblasts. Runx2 expression was 
present after 2 weeks but not as strongly as corresponding OPN expression. Runx2 
has been shown to induce OPN expression (Valenti et al., 2008, Lee et al., 2008b). 
Runx2 may therefore have been present in samples between 1 and 2 weeks inducing 
strong OPN expression by week 2. However, continued Runx2 expression after 
osteoblast differentiation has an inhibitory effect on osteoblast function (Kanatani et 
al., 2006). Runx2 is auto-regulated by the production of OPN (Takahashi et al., 2005). 
As OPN expression increases, Runx2 expression is down-regulated. Down-regulation 
of Runx2 is critical to the maturation of osteoblasts and transition to osteocytes 
(Maruyama et al., 2007). Therefore, the observed decrease in Runx2 expression after 
4 weeks in culture could have been the direct result of the observed strong OPN 
expression. Consequently, findings in Fig 5.14 were in agreement with current 
understanding of OPN and Runx2 function in bone development. In summary, Runx2 
was possibly expressed between 1 and 2 weeks of culture. This induced osteoblast 
differentiation and OPN expression. Runx2 expression was down-regulated by the 
increased OPN expression. Down-regulation of Runx2 allowed maturation of the 
osteoblasts. Mature osteoblasts were fully functional and began to mineralize 
surrounding matrix. 
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Expression of Runx2 was arguably absent in control samples after 4 weeks of culture 
compared to engineered samples. This would imply that osteoblasts may have been 
more mature in control samples. Advanced maturation may also mean advanced 
transition from osteoblasts to osteocytes. Osteocytes do not mineralize surrounding 
matrix. Therefore, osteoblasts may have formed and become quickly trapped within 
mineralized matrix which was not detectable by Alizarin Red stain. These osteoblasts 
may have subsequently formed osteocytes which ceased to form new bone nodules, 
or possibly increase the size of existing nodules. This could explain the absence of 
bone nodules in control samples cultured in control media (Fig 5.11B). However, 
similar results would have been expected in control samples cultured in osteo-
inductive media. The presence of bone nodules within these samples was most likely 
the result of Dex within the osteo-inductive media. Dex has been shown to cause 
osteoblast differentiation and up-regulation of type I collagen deposition (Jager and 
Krauspe, 2007). Osteo-inductive media would have caused differentiation of greater 
numbers of osteoblasts which would have mineralized substantial amounts of matrix 
to form bone nodules before becoming trapped and forming osteocytes. The strong 
expression of OPN after 4 weeks indicated that functional mineralizing osteoblasts 
were present in control samples cultured in control media. Consequently, the idea 
that osteoblasts became trapped and quickly formed osteocytes prior to detectable 
bone nodule formation must be incorrect. However, there are other explanations for 
the strong expression of OPN. Osteocytes have been shown to express OPN, 
especially when they are starved of oxygen or deprived of mechanical loading 
(Morinobu et al., 2003, Gross et al., 2005). The cultures were not placed under 
hypoxic conditions, but no mechanical loading was applied to the cultures either. 
Therefore, osteoblasts could have become trapped, formed osteocytes and ceased 
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forming a detectable level of bone nodule formation whilst OPN expression remained 
high. OPN has also been shown to up-regulate osteoclast function in bone 
remodelling (Terai et al., 1999). It is possible that control samples cultured in control 
media did not exhibit bone nodules because of strong OPN expression causing bone 
resorption through up-regulation of spontaneously differentiated osteoclasts. The 
presence of beating cardiac cells as contaminating cell types within all cultures 
provided evidence that HS cells were present. HS cells are progenitor cells of 
osteoclasts. It is also possible that greater numbers of progenitor cells within control 
samples cultured in control media differentiated to form chondrocytes instead of 
osteoblasts. Chondrocytes are closely related to osteoblasts and are essential to bone 
nodule formation. Without chondrocytes there would be no collagen matrix ready 
for mineralization. Alcian Blue stain revealed extensive collagen deposition 
throughout all cultures (Fig 5.15). This showed that cultures may have contained 
chondrocytes and that collagen matrix was not a limiting factor in bone nodule 
formation. Considerable matrix deposition was located at sites of initial EB 
attachment. Deposition was less dense further away from initial sites. This indicated 
that the initial migrating cells observed in Fig 5.4 may possibly have been 
chondrocytes depositing matrix as they migrated across the well surface. It is 
possible that chondrocytes within control samples did not produce enough matrix in 
which to be trapped and become hypertrophic when cultured in control media. 
Hypertrophic chondrocytes are essential in the differentiation of osteoblasts in vivo 
(Rich et al., 2008, Jukes et al., 2008). Dex within osteo-inductive media enhances 
collagen deposition (Jager and Krauspe, 2007, Tanaka et al., 2004). Therefore, 
samples cultured in osteo-inductive media may have exhibited an increase in 
trapped chondrocytes, which may have consequently become hypertrophic. 
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Increased ES cell-ECM interaction has been shown previously within engineered 
samples. Subsequently, there may also have been an increase in downstream 
trapped chondrocytes, hence the observed bone nodule formation (Fig 5.11B). 
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5.5. Conclusions 
In summary, gelatin-coated plates provided an inexpensive method of enhancing EB 
adhesion and spreading. EB culture exhibited significantly (P  ? 0.001) increased 
osteogenic differentiation when compared to ES cell culture. Settled EBs exhibited 
significantly (P  ? 0.001) increased osteogenic differentiation when compared to 
dissociated EBs. Settled EBs rapidly attached to gelatin-coated plates and began to 
flatten and spread outwards through both constituent ES cell proliferation and 
structural reorganization. Initial migrating cells which may have been chondrocytes 
moved outwards forming a fringe around the EBs. Deposited collagen matrix 
provided (1) support for lateral expansion of the EB and constituent ES cells, and (2) 
a basis for osteoblast driven mineralization and bone nodule formation. ES cell 
suspensions seeded at 5 x 104 cells/mL and aggregated for 3 days generated EBs 
exhibiting the greatest levels of osteogenic differentiation following osteogenic 
culture for 4 weeks. Engineered samples exhibited enhanced osteogenic 
differentiation in all samples, regardless of culture in osteo-inductive or control 
media. Enhancement in engineered samples may have been due to accelerated ES 
cell-ES cell and/or ES cell-ECM interaction and consequent differentiation. 
Accordingly, osteogenic differentiation appeared subject to variables such as ES cell 
number and 3D interaction which can all potentially be controlled and fine tuned 
through the proposed engineered culture system. 
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Chapter 6  
6. Results 
Microparticle Incorporation 
6.1. Introduction 
EBs are employed in many differentiation protocols and show control over ES cell 
differentiation (Carpenedo et al., 2007). Controlled alterations made to EB formation 
afforded by engineering, have had an important effect on resultant osteogenic 
differentiation. However, contaminating cells types were still observed illustrating 
how little is understood about the control the EB stage has over ES cell 
differentiation. It is hypothesized that these contaminating cell types arise from 
random differentiation of internal ES cells which are not exposed to exogenous 
osteo-inductive factors. Many studies have utilized biodegradable polymer 
microparticles as a delivery system for growth factors and proteins (Suciati et al., 
2006, Mantalaris et al., 1998, Sokolsky-Papkov et al., 2007). Here we show the 
delivery of internal osteo-induction to the EB via the release of Dex from 
incorporated PLGA/triblock microparticles. 
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6.2. Methods and Materials 
6.2.1. Microparticle Fabrication 
Microparticles were fabricated using a single emulsion system where polymer and 
Dex were dissolved and emulsified in dichloromethane (DCM, Fisher) (Xu et al., 
2008, Morita et al., 2000, Choi and Park, 2006). The polymer was a blend of triblock 
with PLGA (30:70). To fabricate microparticles with a theoretical content of 1% Dex, 
1g of polymer and 10mg of Dex were gently dissolved in 4mL DCM using a vortex 
mixer (VM20, Chiltern Scientific, Buckinghamshire U.K.) for 1min. Once dissolved, 
4mL of 0.3% polyvinyl acetate (PVA) in dH2O was carefully added to the 4mL 
DCM/polymer mix and emulsified using a vortex mixer for 1min. After emulsification 
the suspension was poured into a 100mL hardening bath of 0.3% PVA in dH2O that 
was continually stirred at 300rpm using a magnetic stirrer for 3hrs. Microparticles 
were subsequently vacuum filtered using appropriate pore size filter paper once 
hardened. Residual water was removed by freeze drying over 48hrs. Duplicate 
microparticles were fabricated without the addition of Dex to the suspension as a 
control. After microparticles were dried they were fractionated using a Retsch AS 
200 sieve set at 150 taps min-1 (1.6mm amplitude) and 280 horizontal oscillations 
min-1. Fractionation was carried out for 20mins consisting of 40sec cycles with a 3sec 
pause between each cycle. Filtered microparticle fraction had a 50-100µm diameter. 
Microparticles were vacuum-packed and stored at 4°C in the dark.  
DCM is an organic solvent which enables salvation of the polymer and Dex. Triblock 
is a polymer composed of three individual polymers joined together. The specific 
triblock used in the fabrication of these microparticles was PLGA-PEG-PLGA (Mw 
7,500). 
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6.2.2. Dexamethasone Incorporation 
6.2.2.1. Encapsulation Efficiency 
20mg of the Dex-encapsulated microparticles was dissolved in 2mL of acetonitrile. 
After further dilution to 10mL, Dex content was measured using reverse phase high 
pressure liquid chromatography with U.V. detector (HPLC-U.V.) set at 246nm. HPLC-
U.V. employed the use of a phenomenex C18 luna-column (4.6 x 150mm) on an 
Agilent 1090 machine. The mobile phase was 2mM acetate buffer (pH 4.8) and 
acetonitrile (58:42). Standards ranging from 0.2 to 100mg/mL Dex in acetonitrile 
were used to create a standard curve. Entrapment efficiency (%) was calculated 
through div Ǯmeasured Dex concentrationǯ by Ǯtheoretical Dex concentration ȋ ? ?Ȍǯ and multiplication by 100. Results were taken in triplicate and an average 
calculated. 
6.2.2.2. Controlled Release Assay 
20mg of Dex-loaded microparticles was placed inside a flow chamber and attached 
to a syringe pump driver machine (PHD2000, Harvard, Kent U.K.) which applied a 
constant force on the syringes. Syringes were filled with PBS and the whole setup 
was incubated at 37°C. PBS was pushed through the flow chamber and eluted into a 
collection chamber. At regular intervals the eluted PBS was analyzed by HPLC-U.V. 
for Dex content. Standards were made ranging from 0 to 20µg/mL to create a 
standard curve. Dex content was calculated by converting the fluorescence reading 
to µg/mL using the standard curve and multiplying by the volume of PBS eluted. The 
volume of PBS varied between samples. Samples were taken in triplicate and an 
average calculated. 
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6.2.3. Microparticle Quantification: Particle Sizing System 
The number of microparticles within each fractionated size range of microparticles 
was assessed using the PSS. 0 to 25mg of microparticles were suspended in 10mL of 
PBS containing 1% Tween 20. Weights increased with an increment of 5mg. 
Suspensions were gently inverted to ensure homogeneity prior to transfer into the 
glass holding vial of the PSS. The suspension volume was increased to 50mL with 
dH2O whilst under rotation with a magnetic stirrer. The suspension was allowed to 
drain until the last few millilitres so as to not allow air bubbles to enter the PSS. The 
glass holding vial was thoroughly washed with PBS and dH2O until the PSS measured  ? ?ȀǤ 
6.2.4. Microparticle Surface Analysis 
Microparticles were imaged using SEM to assess surface topography and visualize 
morphology (Chapter 2). Images were taken at 12kV and a working distance of 
38mm from the electron gun tungsten filament. Samples were gold sputtered once 
per sample for 4mins. 
6.2.5. Microparticle Coating  
Microparticles were coated in both ECM components and allylamine to improve ES 
cell attachment (Hamerli et al., 2003, Lu et al., 2008, Finke et al., 2007, Ren et al., 
2008). After coating, microparticles were seeded at high density in 2mL SCM and 
allowed to settle. ES cells were seeded on top at low density and the suspension was 
incubated overnight. The suspension was left stationary for the majority of the 
incubation with occasional gentle shaking to turn microparticles. After 24hrs, 
microparticles were stained with May-Grünwald and Giemsa and imaged. 
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6.2.5.1. Gelatin and Foetal Calf Serum 
Similar to the tissue culture plates for EB adhesion during osteo-induction, 
microparticles were pre-coated in gelatin and also FCS to enhance attachment of ES 
cells. PLGA is known to have high adsorption capacity for proteins such as gelatin 
and within FCS (Rouzes et al., 2000). Prior to coating, microparticles were sterilized 
by suspension in 5mL of dH2O and irradiation for 20mins in U.V. light (Shearer et al., 
2006, Moioli et al., 2006). Microparticles were subsequently transferred to an 
Eppendorf tube suspended in 1.5mL of PBS containing 1% gelatin or FCS. 
Suspensions were rotated for 1.5hrs at 37°C. FCS was employed to adsorb alternative 
adhesive proteins such as fibronectin and vitronectin to the microparticle surface 
(Garcia and Boettiger, 1999). 
6.2.5.2. Plasma 
Plasma coating can be used to modify surface chemistry by either etching or 
deposition of particular substances (Safinia et al., 2007). Microparticles were placed 
within a T-shaped borosilicate glass chamber and coated with plasma polymerized 
allylamine (ppAAm) for 4.5mins (Fig 6.1) (Barry et al., 2005). Plasma coating was 
repeated four times and degassed by one freeze-pump-thaw cycle after each coat. 
Between plasma coatings the chamber was cleaned by oxygen etching for 3mins. 
Both plasma polymerisation and oxygen etching were carried out at a power of 20W 
under a working pressure of 300mTorr. To prevent toxicity to the ES cells, plasma 
coated microparticles were left for 24hrs at room temperature. The process of 
plasma polymerisation sterilized the microparticles. 
Studies have shown that ppAAm-coating enhances cell attachment to surfaces 
previously found to have low affinity (Dehili et al., 2006). The coating provides a 
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Figure 6.1: Plasma-polymerised allylamine-deposition within a borosilicate glass chamber. 
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uniform thin film of reactive allylamine species including functional amine and 
amide groups (Griesser et al., 1994). Consequently, the surface becomes hydrophilic 
and nitrogen rich resulting in high affinity for proteins and cell attachment. 
Alternatively the surface is capable of immobilizing biologically reactive compounds 
for ES cell interaction through ECM components (Siow et al., 2006). 
6.2.6. Microparticle-Embryonic Stem Cell Aggregation 
Sterile gelatin and FCS-coated microparticles were seeded into 6-well tissue culture 
plates in 2mL of AM or SCM at high density. ES cells were seeded at 5 x 104 cells/mL. 
Seeding ratios ranged from 1:1 to 40:1 for ES cells to microparticles. Plates were 
either rotated at 15rpm for 6hrs or left stationary with a gentle shake after 3hrs. 
Plates were subsequently incubated at 37°C and 5% CO2 in a humidified atmosphere 
for 3 days in SCM to allow for aggregation and EB formation. Further optimization 
involved alteration of the initial step. Microparticles were seeded with ES cells into a 
1.5mL Eppendorf tube in 1mL SCM and rotated for 3hrs prior to transfer to tissue 
culture plates. Seeding ratios included 1:1, 2.5:1 and 5:1, ES cells to microparticles 
respectively. Suspensions were then incubated at 37°C and 5% CO2 in a humidified 
atmosphere for 3 days. EB suspensions were imaged at 10x magnification. 
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6.3. Results 
6.3.1. Fabricated Microparticles 
After fractionation both Dex-loaded and plain microparticles were analyzed by SEM 
for any differences in morphology and surface topography (Fig 6.2). Clearly, 
fractionation had been sufficient enough to separate out all microparticles with a 
d  ?  ? ? ? ? ȋ	  ?Ǥ ?  ). There were however, microparticles with a 
diameter < 50µm were found in both samples, present due to electrostatic 
interaction which fractionation did not overcome. The majority of microparticles in 
both samples had a spherical morphology with a smooth unblemished surface ideal 
for uniform degradation and release. No morphological differences were observed 
between Dex-loaded and plain microparticles. However, Dex-loading appeared to 
have a negative effect on microparticle size, with greater numbers at the lower end 
of the 50-100µm range compared to plain microparticles (Figs 6.2B and D). Dex-
loaded microparticles therefore exhibited a tighter size distribution than plain 
microparticles. Some microparticles did not exhibit a spherical morphology due to a 
fabrication defect, or that they simply collapsed before hardening in the 0.3% PVA 
solution (Figs 6.2E and F, respectively). Other defects included rippling across the ǡ ? 1µm, surface cracks and thick polymer 
deposits. Although, defects were at a low frequency in the whole samples there was 
no way to separate out affected microparticles. Consequently, a certain level of error 
within the following data was expected. 
Following the observation that Dex-loading appeared to have a negative effect on 
microparticle size, samples were analyzed by PSS to assess microparticle number in 
a given weight (Fig 6.3). This analysis was also performed for ensuing experiments 
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Figure 6.2: Surface morphology and size distribution of fabricated microparticles with a diameter 
range of 50-100µm. Once fabricated, both Dex-loaded (A and B) and plain (C and D) microparticles 
were analyzed by SEM (A and C) to assess surface morphology, and by PSS (B and D) to assess size 
distribution within the 50-100µm range. PSS analyzed all microparticles within 1mg of each 
sample. E and F show examples of deformed or collapsed microparticles. 
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Figure 6.3: Number of microparticles with increasing weight. Once fabricated, both Dex-loaded 
and plain microparticles from the fractionated 50-100µm range were analyzed by PSS over a 
range of weights including 1, 5, 10, 15 and 20mg. Experiments were repeated in triplicate and all 
EBs were counted per sample; n = 3. Error bars = S.E.M. 
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requiring exact ratios of microparticles to ES cells. Supporting previous observations, 
Dex-loaded samples generated significantly ȋ  ?  ?Ǥ ? ? ?Ȍgreater numbers of 
microparticles within the 50-100µm range. Both Dex-loaded and plain samples 
exhibited a linear trend in microparticle weight to number. However, plain 
microparticles showed considerable variability in number indicating that Dex-
loading may have had a positive effect on reproducibility concerning microparticle 
number during fabrication. 
6.3.2. Dexamethasone Entrapment 
Standard curves for Dex concentration in both acetonitrile and PBS are shown in Figs 
6.4A and B, respectively. Both show a linear relationship between increasing Dex 
concentration and peak area (detected by HPLC-U.V.). To calculate entrapment 
efficiency 20mg of Dex-loaded microparticles was dissolved in 2mL of acetonitrile 
which was diluted by 5 prior to HPLC-U.V. analysis. Average peak area was 185.9 
which was converted to 3.63µg/mL Dex using the standard curve in Fig 6.4A. 
Multiplication by the dilution factor of 10 equalled 36.3µg/mL Dex within 20mg of 
microparticles. Theoretical loading was 1% therefore 20mg of microparticles would 
have been expected to hold 200µg Dex. Entrapment efficiency was subsequently 
calculated to be 18.16%. 
The next step was to analyze the release profile of the microparticles (Fig 6.5). Peak 
area measurements were converted to Dex concentrations using the standard curve 
in Fig 6.4B. Concentrations were multiplied by a dilution factor and the PBS volume 
eluted to calculate Dex release over time. There was an initial burst release phase in 
the first 3 days releasing ~30% of the encapsulated Dex. Dex release was then linear 
and constant up to day 14 where ~80% had been released. Linear release between 
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Figure 6.4: Dex concentration standard curves. Dex was dissolved in both acetonitrile (A) and PBS 
(B) at varying concentrations including 0.2, 0.5, 1, 2, 5, 10, 20, 50 and 100µg/mL. Samples were 
analyzed by HPLC-U.V. set at 246nm. All samples were taken in triplicate and averages calculated; 
n =3. Error bars = S.E.M. 
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Figure 6.5: Release profile of Dex-loaded microparticles in PBS over time. Once fabricated, 
microparticles were placed within a flow chamber suspended in PBS and incubated for 30 days at 
37°C and 5% CO2 in a humidified atmosphere. The flow chamber was under continual PBS 
perfusion at 2µl/min. Flow through was collected and analyzed by HPLC-U.V. set at 246nm. 
Experiment was repeated in triplicate; n = 3. Error bars = S.E.M. 
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day 3 and 14 was ~1.3µg/mL every day. Beyond 14 days Dex release remained linear 
but at a reduced rate. 93% of the encapsulated Dex was released by day 30. 
Therefore, linear release between day 14 and 30 was ~0.3µg/mL every day. 
Consequently, Dex-loaded microparticles were capable of providing osteo-induction 
over the full 28 days of osteogenic culture. The release profile can be altered by 
mixing combinations of different sized microparticles. Small microparticles may limit 
the quantity of Dex delivered, but provide rapid release. Large microparticles would 
increase the quantity of Dex delivered, but release more slowly. Alternatively, the 
release profile can be altered by adjusting the degradation rate of the polymer. High 
molecular weight polymers would release slowly due to slow degradation, and low 
molecular weight polymers would release quickly due to rapid degradation. 
Degradation rate could also be controlled by blending of hydrophobic polymers with 
hydrophilic substances. 
6.3.3. Embryonic Stem Cell Adhesion 
Microparticles were coated in gelatin, FCS and ppAAm to enhance ES cell adhesion 
(Fig 6.6). Clearly, ES cells attached to microparticles with all 3 coatings. At sites of 
attachment ES cells subsequently became well spread out indicating a level of 
biocompatibility and support for colonization. ES cells showed a marked decrease in 
attachment to control uncoated microparticles (Fig 6.6D). Low level attachment was 
observed on few microparticles. However, this may be residual stain that was not 
sufficiently removed during washing. 
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Figure 6.6: Microparticle coating and ES cell attachment. Appropriate quantities of plain 
microparticles were suspended in 0.1% gelatin (A) or 10% FCS (B) and agitated at room 
temperature for 30mins. Suspensions were washed and suspended in PBS and sterilized by U.V. 
irradiation for 20mins at room temperature. An alternative microparticle coating was ppAAm (C). 
Once coated, microparticles were washed in PBS, seeded into SCM and allowed to settle before 
addition of ES cells at 5 x 10
4
 cells/mL. Cultures were incubated at 37°C and 5% CO2 in a 
humidified atmosphere for 24hrs. Control microparticles were left uncoated (D). After 24hrs, 
samples were carefully washed and ES cells were visualized with May-Grünwald and Giemsa stain. 
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6.3.4. Microparticle Incorporated Embryoid Bodies 
6.3.4.1. High Density Microparticles in Mass Suspension 
Microparticles were seeded into suspension with ES cells during aggregation to 
assess the efficiency of their incorporation within resultant EBs. Initially, 
microparticles were seeded over a wide range of ratios from 1:1 to 40:1 (Fig 6.7). At 
40:1 microparticle incorporation within EBs was not observed. Clearly, ratios above 
20:1 inhibited microparticle incorporation (Fig 6.7C). ES cells within these samples 
had adhered to the well surface and begun to proliferate outwards with free floating 
microparticles suspended above (Figs 6.7D). However, at low seeding densities of 1:1 
and 10:1, microparticles were incorporated within EBs (Figs 6.7A and B). 
Microparticles were visualized as opaque spheres embedded in translucent EBs. 
Microparticle incorporation occurred at low frequency, with the majority of EBs not 
containing any microparticles. The results indicate that microparticles coated with 
0.1% gelatin did lead to EB incorporation, but inefficiently. Observations also 
showed that microparticle incorporation was highly variable between EBs which 
would have affected localized concentrations of Dex during release. 
6.3.4.2. Low Density Microparticles in Mass Suspension 
To assess the efficiency of microparticle incorporation at low seeding ratio, 
suspensions were seeded at 1:1, 2.5:1 and 5:1 (Fig 6.8). Microparticles were coated 
in FCS, seeded with ES cells into SCM, rotated at 15rpm for 6hrs before 3 days 
incubation at 37°C and 5% CO2 in a humidified atmosphere. Microparticle 
incorporation was observed at all three densities. However, 2.5:1 exhibited a marked 
increase in microparticle incorporation and therefore chosen for all subsequent 
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Figure 6.7: ĨĨĞĐƚ ŽĨ  ‘ŵŝĐƌŽƉĂƌƚŝĐůĞ ƚŽ ^ ĐĞůů ? ƐĞĞĚŝŶŐ ƌĂƚŝŽ ŽŶ ĂŐŐƌĞŐĂƚŝŽŶ ?Plain microparticles 
were suspended in 0.1% gelatin solution and gently agitated for 20mins at room temperature. 
Microparticles were then washed and suspended in PBS and sterilized by U.V. irradiation for 
20mins at room temperature. Coated microparticles were transferred to mass suspension with 
control 1 ES cells seeded at 5 x 10
4
 cells/mL. Suspensions were rotated at 15rpm for 6hrs then 
cultured for 3 days in SCM at 37°C and 5% CO2 in a humidified atmosphere. Microparticles were 
seeded with ES cells over a range of ratios including 1:1 (A), 10:1 (B), 20:1 (C) and 40:1 (D) 
(microparticles to ES cells). Suspensions were imaged after 3 days of culture. 
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Figure 6.8: ĨĨĞĐƚŽĨ ůŽǁ  ‘ŵŝĐƌŽƉĂƌƚŝĐůĞ ƚŽ^ĐĞůů ? ƐĞĞĚŝng ratios on microparticle incorporation. 
Appropriate quantities of plain microparticles were suspended in 10% FCS and agitated for 
30mins at room temperature. Microparticles were then washed and suspended in PBS and 
sterilized by U.V. irradiation for 20mins at room temperature. Microparticles then were seeded 
with control 1 ES cells (5 x 10
4
 cells/mL) at 5:1 (A and B), 2.5:1 (C and D) and 1:1 (E and F) in SCM, 
rotated at 15rpm for 6hrs and cultured for 3 days at 37°C and 5% CO2 in a humidified atmosphere. 
Suspensions were imaged after 3 days. 
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experiments (Fig 6.8C). Many microparticles remained in suspension indicating that 
although incorporation efficiency had improved, it was still not optimal. At both 1:1 
and 5:1, microparticles were observed within EBs however, many EBs did not exhibit 
any microparticle incorporation (Figs 6.8A and E). Higher magnification showed that 
the number of incorporated microparticles between EBs was highly variable 
indicating a lack of control over incorporation. FCS-coating appeared to have little or 
no effect on incorporation efficiency in comparison to gelatin-coating. 
6.3.4.3. Eppendorf-Based Embryoid Body Formation 
The low frequency of microparticle incorporation may have been due to reduced 
interaction between ES cells and microparticles within culture wells and/or adhesive 
properties of gelatin and FCS. Microparticles were subsequently coated in ppAAm 
and seeded with ES cells into a 1mL volume of SCM in a 1.5mL Eppendorf tube (Fig 
6.9). Due to the Eppendorf tube being a sealed unit, the rotation time was reduced 
from 6hrs to 3hrs to avoid hypoxic conditions. The cap was removed from the 
Eppendorf tubes once every half to allow for fresh gaseous exchange and then 
resealed. The majority of EBs exhibited microparticle incorporation over all seeding 
ratios investigated observed as black spheres embedded within light and 
transparent aggregates. Clearly, a reduced suspension volume afforded by the 
Eppendorf method, appeared to enhance microparticle incorporation. Coating with 
ppAAm provided microparticles with sufficient adhesive properties for increased 
incorporation compared to both gelatin and FCS-coating. It therefore appears that 
the ability of ES cells to adhere to the microparticle surface did not directly correlate 
with microparticle incorporation. 2.5:1 was chosen as the optimum seeding ratio for 
all subsequent experiments. Microparticles were shown to be spread throughout the 
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Figure 6.9: Microparticle incorporation within Eppendorf derived EBs. Appropriate quantities of 
plain microparticles were coated with ppAAm and suspended in AM. Microparticles were then 
seeded with control 1 ES cells (5 x 10
4
 cells/mL) at 5:1 (A), 2.5:1 (B) and 1:1 (C) (microparticles to 
ES cells) into an Eppendorf tube suspended in AM. Suspensions were agitated at 15rpm for 6hrs 
(cap was opened and closed after 3hrs for exchange of gases as Eppendorf tube was a sealed unit) 
before transfer to mass suspension and culture in SCM for 24hrs before imaging. 
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EB structure in both engineered and control ES cell samples (Fig 6.10). The presence 
of DAPI stained cell nuclei covering the location of a microparticle indicated that the 
microparticle was embedded within the EB (Fig 6.10A). Other microparticle 
locations showed minimal or no cell nuclei coverage, indicating that the 
microparticle was at the surface of the EB (Fig 6.10B). 
6.3.5. Embryonic Stem Cell Viability 
Plain microparticles with ppAAm-coating were seeded in a 1.5mL Eppendorf tube 
with both engineered and control ES cells at a ratio of 2.5:1 (Fig 6.11). After 5 days of 
culture EBs were labelled  Ȁ ?   Ǥ  
fluorescence was observed in all samples illustrating the fact that the majority of ES 
cells were alive and thriving. Microparticle incorporation was therefore found to not 
have a detrimental effect on ES cell viability. However, there were areas of red 
fluorescence indicating the presence of dead or necrotic ES cells. Red fluorescence 
was mainly restricted to the centre of EBs as depicted by the overlay images in Fig 
6.11. Suspensions were incubated for 5 days instead of 3 days for increased EB Ȁ ?Ǥ
randomly spaced throughout the centre of the EB structure and not located in 
proximity to microparticles. No measurable difference was observed in ES cell 
viability between engineered and control samples. Microparticle incorporation 
appeared similar in all samples being randomly distributed both within an individual 
EB and between EBs. Microparticles were not auto-fluorescent. 
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Figure 6.10: Microparticle location within Eppendorf derived EBs. Appropriate quantities of plain 
microparticles were coated with ppAAm and suspended in AM. Microparticles were then seeded 
with engineered (A), control 1 (B) and control 2 ES cells (5 x 10
4
 cells/mL) (C) at an optimal ratio of 
2.5:1 (microparticles to ES cells) into an Eppendorf tube suspended in AM. Suspensions were 
agitated at 15rpm for 6hrs (cap was opened and closed after 3hrs for exchange of gases as 
Eppendorf tube was a sealed unit) before transfer to mass suspension and culture in SCM for 
24hrs. After 24hrs, microparticle incorporation was assessed by DAPI staining and fluorescence 
imaging at ex/em 358/461nm. 
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Figure 6.11: ES cell viability within microparticle-incorporated EBs. Appropriate quantities of Dex-
loaded microparticles were coated with ppAAm and suspended in AM. Microparticles were 
seeded with engineered (A), control 1 (B) and control 2 ES cells (5 x 10
4
 cells/mL) (C) at a ratio of 
2.5:1 (microparticles to ES cells) into an Eppendorf tube suspended in AM. Suspensions were 
agitated at 15rpm for 6hrs (cap was opened and closed after 3hrs for exchange of gases as 
Eppendorf tube was a sealed unit) before transfer to mass suspension and culture in SCM for 5 
days. After 5 days, ES cell viability within resultant EBs was assessed by >ŝǀĞ ?ĞĂĚ ? ƐƚĂŝŶ ? Žǆ
inserts were imaged at 20x magnification. 
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6.4. Discussion 
It has been shown that the aggregation step of EB formation has important 
ramifications on downstream differentiation of constituent ES cells. Alteration of the 
aggregation step afforded by the proposed engineered 3D culture system has been 
shown to increase osteogenic differentiation in differentiated ES cell cultures 
(Chapter 5). However, cultures were heterogeneous and contained contaminating 
cell types such as cardiomyocytes. This was due to random uncontrolled ES cell 
differentiation within the EBs prior to osteo-induction. One solution would be to 
aggregate ES cells in osteo-inductive media. However, this may only cause 
appropriate differentiation in ES cells located at the EB surface since the osteo-
inductive factors may not be able to permeate through the whole EB structure. 
Microparticles provide a means of delivering osteo-inductive factors such as Dex 
directly within the EB structure. By releasing Dex internally, it is hypothesized that 
most or all ES cells would be exposed during aggregation and EB formation (Fig 
6.12). This may aid osteogenic differentiation throughout the EB structure and 
minimize the occurrence of contaminating cell types in downstream cultures. 
However, microparticles had to be fabricated and assessed for both Dex 
encapsulation and release during degradation. Here is shown, efficient incorporation 
of Dex-loaded microparticles into the EB structure and evaluation of their effect on 
ES cell aggregation and constituent ES cell viability. 
6.4.1. Fabricated Microparticle Analysis 
Microparticles exhibited the stereotypical spherical shape expected in micelle 
formation during the oil/water phase (Fig 6.2). The polymer is hydrophobic and 
therefore orientates itself away from contact with surrounding water molecules. The 
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Figure 6.12: Dex-loaded microparticle incorporation and ES cell differentiation. Only ES cells 
located at the EB surface become differentiated when inductive factors are added exogenously 
within the surrounding media (A). These create a barrier against inductive factors and permeation 
internally is restricted. Dex-loaded microparticles can be incorporated within the EBs generating a 
mixed structure. The released Dex no longer needs to diffuse across the EB structure as it will be 
released from numerous locations throughout the EB. ES cells throughout the EB structure would 
become differentiated due to osteo-induction from these Dex-loaded microparticles (B). 
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least chaotic conformation to achieve this is a sphere where the pressure to move 
away from the water is equal between adjacent polymer molecules. Microparticles 
also exhibited a smooth and solid surface morphology from which a uniform release 
of Dex would be permitted. A smooth surface may also have reduced interaction 
between microparticles due to a lack of aberrations with which to link together. 
Interaction between microparticles was still possible through electrostatic attraction 
between hydrophilic surfaces. No major difference was observed between plain and 
Dex-loaded microparticles. However, Dex-loaded microparticles did exhibit a tighter 
size distribution compared to plain microparticles (Figs 6.2B and D, respectively). It 
was possible that solubilized Dex within the oil phase reduced chance interaction 
between polymer molecules when agitated using a vortex machine. Reduced chance 
interactions would lead to fewer polymer molecules within individual micelles and 
result in smaller microparticles. However, this was only an observation made during 
SEM imaging and would require verification by further analysis. Microparticles 
exhibited holes with a diameter measuring  ? 1µm in all samples. Holes are an 
artefact of the fabrication process. The DCM solvent requires an escape route in 
order to evaporate. Consequently, tiny channels are formed as the DCM evaporates 
and the microparticles harden. Microparticles are thought of as solid structures 
encapsulating a solid core of Dex, much like an egg (polymer = white, and Dex = 
yolk). However, DCM evaporation reveals microparticles are actually porous. This is 
beneficial to Dex release as it allows solution to enter the microparticles and aid both 
internal and external degradation. The majority of microparticles exhibited a 
spherical shape and smooth surface morphology (Figs 6.2A and C) however, a 
minority exhibited surface defects and imperfections. The larger proportion of these 
microparticles exhibited minor imperfections such as a rippled surface morphology. 
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The rippled effect was most likely due to uneven distribution of polymer. This would 
have effectively slowed Dex release since degradation time would have increased 
with polymer thickness. The smaller proportion of these microparticles exhibited 
large defects including partial to complete collapse (Figs 6.2E and F, respectively). 
This is suggestive of damage to the microparticle during fabrication. During 
hardening, the microparticles may have ruptured and become deflated whilst still 
supple. Complete evaporation of the solvent would therefore have left the 
microparticle in a hardened and permanently collapsed conformation. In all images, 
tiny microparticles with a diameter < 50µm were observed. Tiny microparticles were 
present even after fractionation to acquire a diameter range of 50-100µm. It appears 
that the force of gravity acting on these tiny microparticles was overcome by their 
electrostatic interaction with larger microparticles. Consequently, the 50-100µm 
fraction contained an unknown proportion of contaminating tiny microparticles. 
Their presence was unaccounted for and therefore so too was the amount of Dex 
they released. This would require further analysis for accurate quantification. 
However, since calculation of Dex encapsulation involved these tiny microparticles, 
the Dex they released was partly quantified as part of the whole fraction. 
Ensuing experiments required precise numbers of microparticles to ES cells. 
Therefore microparticle number within the 50-100µm fraction was quantified by PSS 
(Fig 6.3). Both plain and Dex-loaded samples exhibited a linear trend between 
microparticle number and weight showing a direct correlation. However, Dex-loaded 
samples exhibited an increased number of microparticles within a given weight. This 
supports the observation of smaller microparticles within Dex-loaded samples 
compared to plain samples in Fig 6.2. Since the amount of polymer was constant and 
the weight from the 50-100µm fraction was the same, then the only explanation for 
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increased microparticle number was that there must have been more microparticles 
at the low end (50µm) of the fraction than at the high end (100µm). Plain 
microparticles exhibited larger error in microparticle number which indicated a 
wider size distribution than Dex-loaded microparticles. 
6.4.2. Release Profile of Dexamethasone-Loaded Microparticles 
Entrapment efficiency was calculated as 18.16% which would mean that 1g of 
microparticles contained 1.8mg of Dex. This could possibly be increased by adding 
more Dex to the initial mixture. However, it has been suggested that the addition of 
Dex has an effect of microparticle size. Therefore, simply adding more Dex may 
hinder fabrication of microparticles with the required diameter range of 50-100µm. 
The 50-100µm range was chosen for practical reasons concerning fractionation and 
because of the need to avoid internalization within the ES cell. Subsequently, the 
release profile of Dex-loaded microparticles was assessed over a 30 day period (Fig 
6.5). There appeared to be an initial burst release phase followed by a steady release 
phase over 14 days which then decreased as encapsulated Dex became diminished. 
The initial burst release was mainly due to diffusion of Dex close to the surface and 
from evaporation channels (Yeo and Park, 2004). The rapid release could have 
caused a build up of Dex in the local vicinity that exceeded biologically acceptable 
levels, leading to toxicity and cell death. Many methods have been employed to 
reduce or stop this well recorded phenomenon (Allison, 2008). One such method 
involves cross-linking of the surface to reduce the dissolution of encapsulated drug 
(Thote et al., 2005). However, there are drawbacks with all attempts including a 
delayed steady release phase which is the most important part of drug release. 
Rather than altering parameters to reduce the initial burst release, microparticles 
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were simply incubated in PBS for 3 days prior to the addition of ES cells therefore 
bypassing the initial burst release. After the initial burst release, further Dex release 
slowed and exhibited a linear relationship with incubation time and therefore 
polymer degradation. This steady release phase lasted for 14 days and produced 
~1.3µg/mL/day Dex. The steady and slow release of Dex was ideal for sustained 
osteo-induction without exceeding non-toxic levels. Beyond 14 days, release 
decreased due to exhaustion of encapsulated Dex. However, release remained linear 
and persisted to 30 days providing osteo-induction for the full 4 week incubation 
period. Also, high but steady release of Dex would really only be required until 
terminal ES cell differentiation towards the osteoblastic lineage. Since osteoblast 
function in the form of bone nodules was observed within engineered samples after 
2 weeks, the release profile of Dex-loaded microparticles is ideal for osteo-induction 
without localized concentrations reaching cytotoxic levels. 
6.4.3. Microparticle Coating and Embryonic Stem Cell Attachment 
The next step was to investigate the adhesive properties of the microparticles 
concerning ES cell attachment. The hydrophobic properties of PLGA proved a 
hindrance towards ES cell attachment (Fig 6.6D). Therefore, different coatings that 
would bind to the hydrophobic surface and express adhesive molecules recognised 
by ES cells were investigated (Neff et al., 1998). The coatings included gelatin, FCS 
and ppAAm. Gelatin was used as it was found to improve EB adhesion to culture 
wells during previous osteogenic differentiation experiments and also to PLGA 
microparticles (Tsung and Burgess, 2001). FCS was used as it contains many 
components conducive to cell attachment such as fibronectin and vitronectin (Norris 
et al., 1990, Blanquet, 1982). Coating with ppAAm provides a synthetic method for 
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enhancing cell attachment (Hamerli et al., 2003). Initially, uncoated microparticles 
were assessed as a control for other coatings and showed minimal to no cell 
attachment after 24hrs incubation. All coatings enhanced cell attachment and 
spreading as observed by the presence of labelled cells on the microparticle surface 
(Figs 6.6A, B and C). No significant difference was observed between coatings 
however, results were qualitative not quantitative. Further analysis may have 
highlighted substantial differences. 
6.4.4. Microparticle and Embryonic Stem Cell Aggregation 
To determine the correct ratio of microparticles to ES cells for optimum 
microparticle incorporation within EBs a wide range was investigated from 1:1 to 
40:1, respectively (Fig 6.7). Microparticles were gelatin-coated and seeded into 
suspension with control ES cells in a volume of 2mL Ǥ      ?
20:1, microparticles were not incorporated within EBs. Microparticles remained free 
floating in suspension whereas ES cells attached to the culture well surface and 
proliferated to form colonies (Figs 6.7C and D). Due to the large number of 
microparticles in suspension the chance collisions between them would also have 
been high. These collisions could easily have damaged attached ES cells on the 
microparticle surface. Alternatively, ES cells may have attached to the microparticles 
but due to the high microparticle numbers it was difficult to find those that exhibited 
ES cell attachment. The lack of EB formation would therefore simply be due to the 
lack of interaction between microparticles exhibiting ES cell attachment. Previous 
experiments have shown that ES cells migrate and spread outwards once adhered to 
the well surface. This would explain the generation of 2D cell colonies observed in 	  ?Ǥ ?Ǥ ?  ? ?ǣ ?ǡ
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incorporated within the EB structure, as observed by opaque spheres embedded in 
translucent EBs (Figs 6.7A and B). The decreased number of microparticles would 
have lowered the chance of collisions between microparticles. Due to the lower 
number of microparticles, ES cell coverage would have been relatively higher than 
that with greater microparticle numbers. Consequently, chance collisions between 
ES cell attached microparticles would have been increased. As a result, ES cells 
coalesced and proliferated across the surface of the adhered microparticles 
generating microparticle embedded EBs. These observations warranted further 
analysis of low seeding ratios. However, the methodology was not optimal due to the 
low frequency of EB formation. Only two or three EBs were observed in whole 
samples. Many ES cells had attached to the well surface and microparticles were free 
floating. To address this problem, gelatin-coating was replaced with FCS-coating. 
Initial aggregation which was carried out in AM containing 1% FCS was subsequently 
carried out in SCM containing 10% FCS to both maintain coating on microparticles 
and also decrease possible stress from nutrient competition between ES cells. 
FCS-coated microparticles were seeded into suspension with control ES cells at low 
seeding ratios of 5:1, 2.5:1 and 1:1 (Fig 6.8). The most striking difference observed 
was that considerably more EBs formed at these low ratios. Evidently, high 
microparticle numbers hinder ES cell aggregation. However, the increased number of 
EBs did not exhibit increased microparticle incorporation. The majority of EBs 
comprised solely of ES cells with most microparticles free floating in suspension 
(Figs 6.8A and E). Consequently, low seeding ratio was essential for EB formation but 
had little or no effect on microparticle incorporation. The low number of 
microparticles allowed for increased ES cell-ES cell interaction and resultant EB 
formation. Another observation was that only large EBs contained microparticles 
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(Fig 6.8C). It was therefore possible that during rotation, ES cells attached to 
microparticles and formed EBs which continued to increase in size during stationary 
culture for 3 days. The presence of small EBs without microparticle incorporation 
developed from those ES cells that were not attached to microparticles during 
rotation. During stationary culture their chance of interaction with microparticles 
was reduced. These EBs may eventually have incorporated microparticles if given 
longer incubation periods. Alternatively, microparticles may not have been 
incorporated within EBs during initial aggregation. It is possible that EBs form from 
ES cells alone and proliferate until they reach a critical size. Once EBs reached a size 
which was larger than adjacent microparticles, microparticles became attached and Ǯǯ   Ǥ It has been shown that EBs are capable of structural 
reorganization and could therefore have reshaped and proliferated around the 
microparticle. This would explain why only larger EBs contained microparticles and 
why so many microparticles remained in suspension. However, further analysis of 
initial aggregation during rotation and immediately after would be required to 
vindicate this hypothesis.  
FCS-coated microparticles have been shown to enhance ES cell attachment however, 
this was within static culture. It was possible that rotation provided microparticles 
with too much kinetic energy so that interaction between microparticles and ES cells 
was not long enough for attachment. This supported the idea that microparticles Ǯǯ and provides explanation as to why minimal EB 
formation was observed in suspensions with gelatin-coated microparticles. Both 
gelatin and FCS notably enhance ES cell attachment, but only in static culture when 
ES cells and microparticles can be held in close proximity for long time periods. Both 
gelatin and FCS-coated microparticles were sterilized by U.V. irradiation for 20mins 
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prior to seeding into suspension with ES cells. It has been shown that U.V. exposure 
can increase the adsorption properties of gelatin and ECM components within FCS 
(Stevens et al., 1998). Therefore, ES cell attachment to U.V. irradiated gelatin and 
FCS-coated microparticles would have been greatly enhanced. It was therefore safe 
to assume that some attachment did occur. The absence of microparticle-
incorporated EBs therefore required alternative explanation. It was possible that the 
increased volume and decreased ES cell-ES cell interaction due to the addition of a 
microparticle suspension may have had a detrimental effect on EB formation. ES cell 
adhesion to the microparticles still occurred, but ES cell-ES cell attachment was 
reduced. 
Aggregation was transferred to an Eppendorf tube and microparticles were coated in 
ppAAm to enhance microparticle incorporation during the aggregation step (Dehili 
et al., 2006, Barry et al., 2005). Rotation speed remained at 15rpm but time was 
reduced to 3hrs to avoid hypoxia within the samples since the Eppendorf tubes were 
sealed. All samples generated microparticle-incorporated EBs as observed by black 
spheres within almost transparent ES cell aggregates (Fig 6.8). Coating with ppAAm 
enhanced microparticle incorporation. However, small EBs did not contain 
microparticles. This was due to proliferation of ES cells which had remained in 
suspension after the rotation period. The vessel shape also appeared to have had an 
effect on the efficiency of aggregation and EB formation. The culture well was 
cylindrical and rotation caused fluid movement such that a vortex was created. The 
vessel shape of an Eppendorf is also cylindrical however the tube was long and thin 
and placed on the rotating platform on its side. Consequently, fluid movement no 
longer formed a vortex but was rather reduced to a gentle unidirectional flow from 
one end of the tube to the other. The simple fluid movement may therefore have 
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been adequate to mobilize microparticles and ES cells enabling interaction without 
too much shear stress. Therefore, vessel shape was shown to control fluid flow which 
had a direct effect on EB formation. There was no observed difference between 
seeding ratios and therefore an arbitrary ratio of 2.5:1 was chosen for all subsequent 
experiments. Further analysis involved the use of both engineered and control ES 
cells (Fig 6.10). Microparticles were positioned within the EBs rather than adhered 
to the surface. The presence of DAPI stained ES cell nuclei in front of microparticles 
during imaging demonstrated the fact that they encased the microparticle. 
Microparticles that did not have ES cells in front were either embedded in the 
surface or not attached. Both engineered and control samples formed microparticle-
incorporated EBs. It was found that engineered ES cells no longer aggregated 
efficiently without the addition of avidin (Chapter 3). The advantage of ppAAm-
coating was that it would have adsorbed avidin protein to the microparticle surface 
which would therefore have enhanced direct adhesion of engineered ES cells. The 
presence of amine groups on the surface could also have caused direct adhesion to 
the reactive aldehyde groups on the engineered ES cell surface via reductive 
amination (Griesser et al., 1994, Myung and Choi, 2006). Gelatin and FCS-coating 
enhanced attachment of ES cells via recognition of natural adhesion molecules 
(Nagaoka et al., 2006, Pokutta and Weis, 2007, Muller et al., 2008). Engineered ES 
cells may have been temporarily unable to recognise these, until membrane renewal 
replaced the surface modification. 
6.4.5. Embryonic Stem Cell Viability 
ES cell viability was assessed within both engineered and control EBs containing 
microparticles (Fig 6.11). The majority of ES cells were alive and thriving. 
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Consequently, the Eppendorf-based method did not have a detrimental effect on ES 
cell viability. It was also suggestive that shear force and microparticle-microparticle 
collisions did not cause lethal damage to the ES cells during aggregation. ES cell 
viability also demonstrated the non-toxic effect of ppAAm. The most important 
finding was that the Dex release did not appear to build up to toxic levels. However, 
there were dead ES cells present within the EB, but their location did not correlate 
with that of the microparticles. It is possible that dead ES cells were simply 
reorganized to the core during EB restructuring. 
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6.5. Conclusions 
In summary, PLGA and triblock microparticles with a diameter of 50-100µm were 
fabricated using a single emulsion method. Dex was encapsulated within these 
microparticles with an efficiency of 18.16%, and release was linear and constant 
providing osteo-induction over 30 days after an initial burst release for 3 days. These 
microparticles were incorporated within both engineered and control EBs for the 
intention of delivering osteo-induction during EB formation. Ideal seeding ratio was 
found to be 2.5:1, microparticles to ES cells. However, mass suspension culture was 
found to be inadequate for microparticle incorporation. Introduction of an 
Eppendorf-based method increased the efficiency of microparticle incorporation and 
yielded high quantities of ES cell/microparticle EBs. Characterisation revealed that 
microparticles were randomly positioned throughout the EB structure and that 
neither their presence nor the potential released Dex caused noticeable cell death. 
However, the addition of microparticles resulted in the formation of larger EBs 
which in turn increased the surface to core distance. Consequently, efficient nutrient 
and gaseous exchange was decreased and microparticle incorporated EBs tended to 
suffer a higher frequency of core necrosis. However, control afforded by engineering 
provides the ability to alter aggregation kinetics and could therefore be employed to 
resolve this problem. Further analysis would be required to assess the impact of Dex-
loaded microparticle incorporation on osteogenic differentiation. 
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7. Conclusions 
 
To summarize, aggregation occurred via a rapid but weak initial attachment. These 
temporary connections were susceptible to breaking as a result of environmental 
stresses during initial rotation. However, once under stationary conditions ES cell 
clusters formed through further aggregation and structural reorganization to a less 
chaotic conformation. ES cell clusters developed into EBs through a complex 
interaction between ES cell aggregation, proliferation, death, cluster agglomeration 
and ECM deposition. Engineered EBs were significantly ȋ ? ?Ǥ ? ? ?Ȍlarger in size and 
exhibited improved constituent ES cell viability. 
Engineered EBs were both larger and denser than control EBs. However, ES cell 
viability remained unaffected demonstrating that engineering may have enhanced ES 
cell-ES cell adhesion in such a way to as improve nutrient and gaseous exchange 
across the entire EB structure. Extended culture beyond 3 days resulted in core 
necrosis. Core necrosis caused EBs to exhibit a layered structure where the 
innermost region composed of necrotic cells and the surface composed of alive and 
thriving ES cells. These surface ES cells were subject to environmental cues such as 
exogenous growth factors and began to spontaneously differentiate. A range of cell 
morphologies were observed on both engineered and control EBs illustrating the fact 
that chemical modification did not have a detrimental effect on ES cell differentiation 
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potential. This is extremely important if the proposed methodology were to be 
expanded to an industrial scale. All three germ layers were found to be present on 
the EB surface with a noticeable increase in mesoderm differentiation on engineered 
EBs. Cadherin-11 expression on the engineered EB surface indicated a potential for 
enhanced osteogenic differentiation. 
Further investigation revealed that cultures originating from engineered EBs 
exhibited enhanced levels of osteogenic differentiation, quantified by ALP activity, 
bone nodule counts and OPN/Runx2 expression. Osteogenic differentiation also 
appeared enhanced in ES cell cultures involving EB formation, and where EBs were 
not dispersed prior to osteo-induction. These observations indicated that ES cell-ES 
cell and ES cell-ECM interactions were highly prevalent in osteogenic differentiation. 
Surface cells were the first to migrate outwards from settled EBs and were thought 
to be chondrocytes. The ECM they deposited provided a platform for cell 
proliferation and eventual osteoblast-driven mineralization. Improved viability 
within engineered EBs also appeared to enhance osteogenic differentiation. It 
appeared that engineering simply enhanced mesoderm differentiation, which 
increased relative ES cell proportions susceptible to osteo-induction. 
Cultures exhibited contaminating cell types including beating cardiomyocytes. It was 
hypothesised that these arose from randomly differentiated internal progenitor cells 
within the EB during aggregation where there was no osteo-induction. Although 
engineering allowed for control of EB formation, it is believed that inductive signals 
may still be required for the generation of homogenously differentiated cell 
populations. The next step was to introduce osteo-inductive factors to the ES cells 
during the EB stage. Dex-loaded microparticles were chosen as a delivery system and 
their incorporation within the EB was investigated. The microparticles exhibited an 
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entrapment efficiency of 18.16% and a steady release of Dex over a 4 week period. 
Analysis revealed that microparticle incorporation was optimum when 
microparticles were ppAAm-coated and seeded at 2.5:1 with ES cells. The suspension 
volume and vessel shape were crucial to efficient microparticle incorporation, 
affecting parameters such as fluid motion, shear stress and field flow. Microparticles 
were randomly spaced throughout the EB structure resulting in uneven distribution 
of released Dex. However, levels were low enough to avoid cytotoxic effects. Further 
analysis would be required to assess control over spatial orientation of 
microparticles within the EB. The effect of microparticle incorporation on osteogenic 
differentiation was unfortunately not examined due to time restraints during the 
study. 
In conclusion, chemical modification of the ES cell surface has proven to exhibit a 
high degree of control over aggregation and EB formation. The proposed engineered 
3D culture system provided a reliable, reproducible and non-cytotoxic methodology 
for the controlled and enhanced production of EBs compared to control samples. The 
methodology also showed potential economic benefits via a reduction in the 
required incubation time due to accelerated ES cell aggregation. There will be many 
obstacles to overcome, but this novel aggregation method could be transferred to a 
human ES cell line (Ginis et al., 2004). These standardised EBs could provide a 
valuable tool in the field of tissue engineering and regenerative medicine (Griffith 
and Naughton, 2002, Rose and Oreffo, 2002). 
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Although the proposed 3D culture system holds great promise for the field of tissue 
engineering and regenerative medicine, many facets of the process still require 
investigation and resolution. Engineered EBs exhibited enhanced ES cell viability 
compared to control EBs. However, all EBs began to show signs of necrosis within 
their core after ~5 days in culture due to an ever increasing surface to core distance 
for efficient nutrient and gaseous exchange. Investigation revealed that EBs cultured 
for < 5 days exhibited the greatest levels of osteogenic differentiation providing a 
convenient solution to this problem. However, increased EB diameter via 
incorporation of microparticles appeared to accelerate core necrosis. Furthermore, 
the generation of other cell types may require extended culture during the EB stage 
beyond 3 days. Consequently, there is a distinct need for improved nutrient and 
gaseous exchange throughout the EB structure. One solution currently under 
investigation is vascularization of the EB structure. Many methods exist for effective 
vasculogenesis and angiogenesis within the EB involving addition of exogenous 
growth factors, co-culture and biodegradable scaffolds (Boyd et al., 2007, Wenger et 
al., 2005, Luong and Gerecht, 2008). It is hoped that vascularization will effectively 
generate an invasive network through which nutrients and growth factors can be 
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pumped into the EB structure maintaining ES cell viability and inducing 
differentiation. However, the obvious problem with this methodology is the 
generation of heterogeneous cell populations if the desired cell type is not 
endothelium. Engineered aggregation has shown influence over such EB properties 
that could aid in effective nutrient and gaseous exchange, including density and 
diameter. Therefore, fine tuning of affecting parameters, such as extent of 
biotinylation, exogenous avidin concentration and cell seeding density may provide 
control over EB structure and viability enabling longer incubation periods. 
In vivo embryogenesis involves countless intricately controlled interactions between 
numerous cell types. It is unknown how these interactions eventuate in the 
formation of specific cell types. Engineered EBs would provide an ideal means to 
investigate these interactions under controlled parameters. However, if 
heterogeneous populations are required for the efficient generation of desired cell 
types then these would require effective isolation in preparation for clinical 
application (Kim et al., 2007b, Kumashiro et al., 2005, Shamblott et al., 2001). 
Isolation techniques would also be required to extract desired cell types from 
cultures originating from vascularized EBs. 
Clinical application would require large quantities of biological material for 
transplantation. Consequently, the proposed 3D culture system would need to be 
scaled-up to an industrial level that is cost effective, whilst maintaining any observed 
enhancement to ES cell differentiation. One leading method of increasing production 
is the use of bioreactors (Dang et al., 2004, Botta et al., 2007, Come et al., 2008, Yin et 
al., 2007, Hwang et al., 2009). However, changing the aggregation method may have 
detrimental effects on the observed osteogenic differentiation enhancement within 
engineered samples. Further investigation would be required to assess bioreactors 
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as a viable option for increased production of desired biological material. 
Interestingly, bioreactor-based 3D models have been previously utilized to 
investigate cancer signalling (Mastro and Vogler, 2009). It may therefore be possible 
to use a similar model to investigate the signalling involved within engineered EB 
formation and how this affects observed osteogenic differentiation. 
Ultimately, the whole system would have to be transferred to a human ES cell line for 
the controlled investigation of early steps involved in human embryogenesis. 
Understanding the fundamental ES cell-ES cell and ES cell-ECM interactions involved 
in organogenesis is crucial to in vitro generation of potentially homogeneous cell 
populations for tissue regeneration, repair or replacement (Leahy et al., 1999). One 
drawback is that any biological material generated would inevitably lack in vivo 
architecture. To engineer tissues exhibiting in vivo architecture within the 
laboratory, ES cells can be cultured on biodegradable polymer scaffolds providing 
both chemical and spatial cues (Nichols and Cortiella, 2008, Fromstein et al., 2008, 
Lee et al., 2006). 
Since microparticles were successfully incorporated within the EB structure the next 
step would be to investigate their potential as a delivery system for internally 
released Dex and their consequent impact on downstream osteogenic differentiation. 
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